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Group A β-haemolytic Streptococcus (GAS), a gram-positive bacterium also known as Streptococcus 
pyogenes, is responsible for a wide range of invasive and non-invasive group A streptococcal 
diseases. These diseases range from mild infections such as impetigo and pharyngitis to serious 
diseases, such as streptococcal toxic shock syndrome and necrotising fasciitis. Moreover, GAS 
may trigger autoimmune diseases following repeated episodes of infection, such as acute rheumatic 
fever, rheumatic heart disease and acute post-streptococcal glomerulonephritis; these are 
important causes of mortality and morbidity in developing countries. Prevalence and incidence 
data on GAS infections from developing countries, which include South Africa, are largely lacking 
when compared with industrialised nations. In South Africa, GAS infections are not notifiable; 
thus no surveillance programme exists to capture such information.  
 
AIMS OF THE THESIS  
This thesis sought to (1) establish the South African arm of the AFROStrep biorepository and 
clinical database for patients with invasive and non-invasive GAS infection, (2) identify and 
summarise all published studies of laboratory-confirmed GAS infection in Africa, (3) describe, 
from national laboratory data, the incidence of invasive and non-invasive GAS isolates in South 
Africa and, (4) conduct a prospective, surveillance study in order to determine the molecular typing 




A systematic review was conducted on population-based studies reporting on the prevalence of 
laboratory-confirmed GAS infection among patients living in Africa (Study 1). A retrospective 
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study of the incidence of GAS infection was conducted on data obtained from the National Health 
Laboratory Service between 2003 – 2015 (Study 2). The AFROStrep registry and biorepository 
(based in Cape Town) was established and through passive surveillance, laboratory confirmed 
invasive and non-invasive GAS cases were collected over a 12-month period. The molecular 
analysis of invasive and non-invasive infection was determined using emm type sequencing to 
provide insight into vaccine development (Study 3). 
 
RESULTS AND DISCUSSION 
The pooled prevalence of GAS pharyngitis in Africa was determined to be 21% (95% CI, 13% to 
30%). Our pooled prevalence was lower than previous systematic review findings of Shaikh who 
reported figures of 37% (95% CI, 32% to 43%) in children of all ages, and 24% (95% CI, 21% to 
26%) among those younger than 5 years; nonetheless, GAS is still a significant infection amongst 
the people of Africa.  
 
The incidence rates of laboratory-confirmed non-invasive GAS infection in the South African 
public sector appear to have declined over the last 13 years. This observation was in contrast with 
studies conducted elsewhere since the 1980s, which reported increases in the incidence of GAS 
infection. Given the possibility that the lower incidence of invasive and non-invasive GAS 
infection found in our study is due to infrequent submission of specimens for microbiological 
culture by health practitioners (i.e., ascertainment bias), our findings may be an underestimate of 
the true burden of disease in South Africa.  
 
In our prospective surveillance study, Group A streptococcus were commonly isolated from pus 
swabs, blood, deep tissue and aspirates. Common clinical presentations included wound infections 
(20%), bacteraemia (15%), abscesses (9%) and septic arthritis (8%). Two-hundred and thirty-three 
isolates were available for emm typing, from which 46 different emm types were identified. The most 
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prevalent emm types were M76 (16% of isolates), M81 (10%), M80 (6%), M43 (6%), and M183 
(6%) and were almost evenly distributed between non-invasive and invasive GAS isolates. Non-
invasive and Invasive GAS infections were comparable in terms of prevalence and there was an 
association with M80 and patients presenting with non-invasive abscesses. When compared against 
the putative 30-valent vaccine under development, four of our most prevalent emm types are not 
included; vaccine coverage (i.e. vaccine type and non-vaccine type-killing) for non-invasive GAS 
and invasive GAS infection in our setting was 60% and 59% respectively, notably lower than 
coverage in developed countries.  
 
CONCLUSION 
This work provides evidence for a significantly high prevalence of GAS in Africa. While GAS 
surveillance in South Africa indicates a declining incidence of group A streptococcal disease in 
parts of the country over the last thirteen years, the findings may be an underestimate of the true 
burden of disease, demonstrating the need for accurate and comprehensive surveillance of GAS 
in South Africa. Finally, this research showed a low potential vaccine coverage in our setting and 
thus, emphasises the need for a reworking of the potential vaccine formulation to improve 




PhD Thesis: Dylan D Barth 12 
Table of Contents 
Plagiarism Declaration ........................................................................................................ 4 
Acknowledgements .............................................................................................................. 5 
Dedication............................................................................................................................ 7 
Publications arising from this thesis ................................................................................... 8 
Abstract ................................................................................................................................ 9 
List of Figures .................................................................................................................... 15 
List of Tables ..................................................................................................................... 17 
List of Abbreviations and Acronyms ................................................................................. 18 
1. CHAPTER ONE:  INTRODUCTION AND LITERATURE REVIEW ................ 20 
Introduction ................................................................................................................................21 
1.1 Streptococcus Pyogenes ........................................................................................................22 
1.1.1 History of group A streptococcus identification .......................................................................22 
1.1.2 Methods for identification and classification .......................................................................23 
1.1.3 M protein ..........................................................................................................................24 
1.2 Group A streptococcal infections and diseases .....................................................................25 
1.2.1 Non-invasive infections .....................................................................................................26 
1.2.2 Invasive infections .............................................................................................................30 
1.2.3 Mechanisms of invasion .....................................................................................................33 
1.2.4 Sequelae of GAS ...............................................................................................................35 
1.3 The epidemiology of GAS disease.........................................................................................39 
1.4 Emm type prevalence ............................................................................................................42 
1.5 Risk factors associated with group A streptococcus .............................................................44 
1.6 Primary prevention ................................................................................................................45 
1.6.1 Vaccines as a prevention strategy ........................................................................................45 
1.6.2 M protein vaccine ..............................................................................................................45 
1.6.3 Emm clusters .....................................................................................................................47 
1.7 Public health surveillance......................................................................................................48 
Objectives of this thesis: ............................................................................................................51 
2. CHAPTER TWO:  THE ESTABLISHMENT OF THE AFROStrep STUDY ....... 52 
2.1 Introduction...........................................................................................................................53 
2.2 Rationalé ...............................................................................................................................54 
2.3 Design of the study ...............................................................................................................55 
2.3.1 Study eligibility ..................................................................................................................56 
2.3.2 Data collection ..................................................................................................................56 
2.3.3 Governance ......................................................................................................................57 
2.3.4 Data analysis plan ..............................................................................................................57 
2.3.5 Ethics and dissemination ...................................................................................................58 
2.3.6 Status of the study and sites participation ............................................................................58 
2.3.7 Strengths and limitations ....................................................................................................59 
 
PhD Thesis: Dylan D Barth 13 
2.4 Discussion .............................................................................................................................59 
3. CHAPTER THREE:  METHODS ........................................................................... 61 
3.1 Systematic Review:  Prevalence of Group A streptococcal disease in Africa: .......................62 
3.1.1 Background.......................................................................................................................62 
3.1.2 Specific Objectives ............................................................................................................63 
3.1.3 Methods ...........................................................................................................................63 
3.2 Retrospective Study:  A review of invasive and non-invasive GAS infection in South Africa
 ....................................................................................................................................................70 
3.2.1 Background.......................................................................................................................70 
3.2.2 Specific Objectives ............................................................................................................70 
3.2.3 Methods ...........................................................................................................................71 
3.3 Prospective laboratory-based surveillance Study ..................................................................73 
3.3.1 Background.......................................................................................................................73 
3.3.2  Specific Objectives ...........................................................................................................73 
3.3.3 Methods ...........................................................................................................................74 
3.4 emm Typing ..........................................................................................................................77 
3.4.1 Culture and identification of Beta Haemolytic Streptococci ..................................................77 
3.4.2 Genomic DNA extraction .................................................................................................77 
3.4.3 Polymerase chain reaction ..................................................................................................77 
3.4.4 Agarose gel electrophoresis ................................................................................................78 
3.4.5 Sequencing and assigning emm types ..................................................................................79 
4. CHAPTER FOUR: ..................................................................................................... 80 
STUDY 1:  PREVALENCE OF GROUP A STREPTOCOCCAL DISEASE IN AFRICA:  
A SYSTEMATIC REVIEW ............................................................................................... 80 
4.1 Introduction...........................................................................................................................81 
4.2 Methods ................................................................................................................................82 
4.3 Results ...................................................................................................................................82 
4.4 Discussion ...........................................................................................................................102 
5. CHAPTER FIVE:..................................................................................................... 109 
STUDY 2:  INVASIVE AND NON-INVASIVE GROUP A Β-HAEMOLYTIC 
STREPTOCOCCAL INFECTIONS IN PATIENTS ATTENDING PUBLIC SECTOR 
FACILITIES IN SOUTH AFRICA: 2003 - 2015 ............................................................. 109 
5.1 Introduction.........................................................................................................................110 
5.2 Methods ..............................................................................................................................111 
5.3 Results .................................................................................................................................111 
5.4 Discussion ...........................................................................................................................121 
6. CHAPTER SIX: ........................................................................................................ 126 
STUDY 3: THE MOLECULAR TYPING OF NON-INVASIVE AND INVASIVE 
GROUP A STREPTOCOCCAL INFECTION AT GROOTE SCHUUR HOSPITAL IN 
CAPE TOWN .................................................................................................................. 126 
6.1 Introduction.........................................................................................................................127 
6.2 Methods ..............................................................................................................................128 
 
PhD Thesis: Dylan D Barth 14 
6.3 Results .................................................................................................................................131 
6.4 Discussion ...........................................................................................................................142 
7. CHAPTER SEVEN: CONCLUSIONS AND FUTURE DIRECTION ................ 147 
7.1 Originality / Novel Insight .................................................................................................147 
7.2 Implications for policy and practice ...................................................................................149 
7.3 Implications for future research ..........................................................................................149 
8. CHAPTER EIGHT: REFERENCES ..................................................................... 151 
9. CHAPTER NINE: APPENDICES ......................................................................... 163 
Appendix 9.1:  University of Cape Town IRB Ethics approval ................................................164 
Appendix 9.2: Systematic review data extraction form.............................................................167 
Appendix 9.3: AFROStrep Case Record Form .........................................................................176 
Appendix 9.4: Lab SOP: Culture procedure .............................................................................177 
Appendix 9.5: Lab SOP: DNA Extraction ................................................................................178 
Appendix 9.6: Lab SOP: Polymerase Chain Reaction ..............................................................180 
Appendix 9.7: OpenClinica database: Standard Operating Procedure ....................................181 
Appendix 9.8: AFROStrep Standard operating procedure .......................................................189 
Appendix 9.9: AFROStrep Assent form ....................................................................................204 





PhD Thesis: Dylan D Barth 15 
List of  Figures 
Figure 1.1 Blood agar plate with haemolysis surrounding streptococcus 
colonies 
23 
Figure 1.2 Electron micrograph of a chain of streptococci showing the surface 
M protein 
24 
Figure 1.3 Schematic illustration of M protein 25 
Figure 1.4 Patient with exudative GAS pharyngitis 27 
Figure 1.5 Skin structures and different GAS diseases 29 
Figure 1.6 Generation of a cross-reactive immune response in ARF 36 
Figure 1.7 The global prevalence of rheumatic heart disease 39 
Figure 1.8 Estimated global mortality from various pathogens 41 
Figure 1.9 Proportions of the 25 most common emm types in (A) high income 
countries, (B) Africa, and (C) the Pacific regions 
43 
Figure 1.10 Diagram of the four proteins and emm types comprising the 30-
valent M Protein-based vaccine.  
46 
Figure 1.11 Indirect bactericidal activity of the 30-valent GAS vaccine.  
A. Vaccine serotypes B. Non-vaccine serotypes 
47 
Figure 4.1 PRISMA flow diagram 83 
Figure 4.2 Risk of bias chart 90 
Figure 4.3 Prevalence of included studies 92 
Figure 4.4 Pooled prevalence of GAS Pharyngitis 94 
Figure 4.5 Countries contributing to this review 95 
Figure 4.6 Regional analysis: Pharyngitis 96 
Figure 4.7 Urban, peri-urban and rural analysis 97 
Figure 4.8 Age analysis: pharyngitis 98 
Figure 4.9 Sample size analysis: pharyngitis 99 
Figure 4.10 Quality of the studies: pharyngitis 100 
Figure 5.1 GAS isolation by province 113-114 
Figure 5.2 Annual incidence rates in the Eastern Cape 116 
Figure 5.3 Annual incidence rates of invasive and non-invasive GAS in the 
Eastern Cape 
121 
Figure 6.1 Distribution of emm types 135 
 
PhD Thesis: Dylan D Barth 16 
 
  
Figure 6.2 Frequency of emm types observed: VT, NVT-K, NVT-NK 137 
Figure 6.3 Frequency of non-invasive emm types: VT, NVT-K, NVT-NK 138 
Figure 6.4 Frequency of invasive emm types: VT, NVT-K, NVT-NK 139 
Figure 6.5 Seasonal variation 141 
 
PhD Thesis: Dylan D Barth 17 





Table 1.1 Superficial and invasive GAS diseases 26 
Table 1.2 WHO guidelines for primary and secondary prevention of ARF/RHD 37 
Table 1.3 WHO guidelines for period of dosage for secondary prevention 37 
Table 3.1 Search Strategy 64 
Table 3.2 Quality assessment criteria for prevalent studies with scoring 67 
Table 3.3 Primers used for emm typing 78 
Table 4.1  Characteristics of included studies 86-88 
Table 4.2 List of excluded studies 89 
Table 4.3 Summary of risk of bias evaluation 91 
Table 4.4  PRISMA Checklist 106-
108 
Table 5.1 Year of isolation, age and sex of GAS cases in South Africa 117 
Table 5.2 Source of isolation from patients with invasive and non-invasive GAS 
infection 
118 
Table 5.3 Age specific incidence rates of GAS  120 
Table 5.4 Mann-Kendall trend test for GAS in the Eastern Cape 121 
Table 6.1 Gender and age distribution of GAS cases 132 
Table 6.2 Clinical manifestations of invasive and non-invasive GAS infection 133 
Table 6.3 Sample types submitted for processing 134 
Table 6.4 Emm Cluster types 140 
 
PhD Thesis: Dylan D Barth 18 
List of  Abbreviations and Acronyms 
AFROStrep    The African group A streptococcal infection registry 
GAS    Group A β-haemolytic streptococcus  
iGAS     Invasive group A streptococcus  
non-iGAS    Non-invasive group A streptococcus 
ARF     Acute rheumatic fever 
RHD     Rheumatic heart disease 
NF     Necrotising fasciitis 
STSS     Streptococcal toxic shock syndrome 
APSGN Acute post-streptococcal glomerulonephritis 
Emm Type                   M protein gene 
MeSH    Medical subject heading 
VT    Vaccine type  
NVT-K    Nonvaccine type – killing  
NVT-NK    Nonvaccine type – no killing  
CI     Confidence interval 
IQR   Interquartile range 
ES     Effect size 
N     Number 
NS     Not stated 
CSF     Cerebral spinal fluid  
HIV   Human immunodeficiency virus 
YR     Years 
PY   Person-years 
IR   Incidence rate 
RD Rate difference 
 
PhD Thesis: Dylan D Barth 19 
HREC   Human Research Ethics Committee  
PRISMA-P   Preferred Reporting Items for Systematic Reviews and Meta-Analysis 
Protocols 
PROSPERO International prospective register of systematic reviews 
PRISMA    Preferred Reporting Items for Systematic Reviews and Meta-Analysis 
REMEDY   Global Rheumatic Heart Disease Registry 
ASAP    Awareness Advocacy Surveillance and Prevention Programme for 
Rheumatic Heart Disease 
NHLS             National Health Laboratory Service 
GSH             Groote Schuur Hospital 
DNA Deoxyribonucleic acid 
PCR Polymerase chain reaction 
WHO  World Health Organisation 









Chapter 1: Literature review 
PhD Thesis: Dylan D Barth 20 




Chapter 1: Literature review 
PhD Thesis: Dylan D Barth 21 
Introduction  
 
Group A β-haemolytic Streptococcus (GAS), also known as Streptococcus pyogenes, is a gram-positive 
bacterium. The complications of GAS infection have been described in more detail in Section 1.2. 
Briefly, GAS infection may cause skin, mucosal, systemic and autoimmune diseases (Cunningham, 
2000). Repeated GAS skin and pharyngeal infections may lead to serious autoimmune diseases, 
such as acute post-streptococcal glomerulonephritis, acute rheumatic fever (ARF) and rheumatic 
heart disease (RHD) (Cunningham 2012; Carapetis et al., 2005). 
 
Prevalence and incidence data on GAS from developing countries, which include South Africa, 
are largely deficient when compared with industrialised nations (Carapetis et al., 2005). In South 
Africa, GAS infections are not notifiable (to the Department of Health) and hence, no surveillance 
programme exists in South Africa to capture GAS infection information.  
 
This PhD project forms part of the Mayosi-led, Stop Rheumatic Heart Disease ASAP Programme 
(Robertson et al., 2006), which has as one of its aims, the documenting of the epidemiology of 
GAS-related diseases by collecting comprehensive clinical and microbiological data on GAS 
infections in South Africa.  
 
This thesis is nested within the AFROStrep study (Barth et al., 2016), which focuses on the 
establishment of a registry and biorepository for group A streptococcal infection in Africa. The 
pilot phase of AFROStrep will focus on South Africa. This thesis serves to establish the Cape Town 
arm describing the epidemiology from passive surveillance of laboratory data on GAS isolated 
from patients with invasive (iGAS) and non-invasive (non-iGAS) group A streptococcal diseases.  
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Here, I summarise the current knowledge related to disease estimates for GAS with a particular 
focus on South Africa. I also review the literature with regard to the natural history of GAS 
infection and the need for public health surveillance systems. Finally, I present the Cape Town 
model for collecting non-invasive and invasive clinical and epidemiological information on GAS.  
 
1.1 Streptococcus Pyogenes 
Group A β-haemolytic Streptococcus (GAS), also known as Streptococcus pyogenes, is a gram-positive 
bacterium. Gram-positive refers to the chemical and physical properties of the cell wall, 
characterised by a thick cell wall protein called peptidoglycan. Gram-positive bacteria retain the 
crystal violet dye and the cells stain purple under the microscope (Baron, 1996).  
 
1.1.1 History of group A streptococcus identification 
The first description of streptococcal infection was described by the Austrian surgeon, Theodor 
Billbroth, in 1874, in patients presenting with erysipelas and wound infections (Billroth, 1874, 
1877). He described the organism “kettenkokken” to be either isolated in pairs or in chains of four 
to twenty or more links The formal discovery of streptococci in history was recorded in 1879, 
when the organism was isolated from the uterus and blood of women with puerperal fever by 
Louis Pasteur (Alouf & Horaud 1997). He showed that streptococcus was responsible for the 
highest mortality rates of women and new-borns at the time. In 1884, Friedrich Julius Rosenbach, 
who studied bacteria isolated from suppurative lesions, further refined the name streptococcus to 
streptococcus pyogenes (pyo, pus and genes, forming) (Evans 1936). 
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1.1.2 Methods for identification and classification 
Streptococcus pyogenes, also referred to as Streptococcus haemolyticus, is so named due to the pattern of 
haemolysis (seen as a clear zone around colonies) observed on 5% sheep blood agar plates, 
incubated under anaerobic conditions (Figure 1.1).  
 
 
Dr Rebecca Lancefield, in 1933, subdivided the streptococci into groups based on differences in 
the surface antigen of the bacteria (Lancefield, 1933); Group A was classified by strains from 
human diseases; Group B by strains from bovine and dairy sources; Group C by various other 
animal sources etc. This was considered to be one of the most important advances in streptococci 
research since streptococcus pyogenes was identified as the organism responsible for streptococcal 
infections in humans and confirming the causative role in the development of Acute Rheumatic 
Fever (ARF) (Stollerman, 1975). These strains were then further classified based on the presence 
of a surface protein called the M protein (Figure 1.2).  
Figure 1.1 Blood agar plate with haemolysis 
surrounding streptococcus colonies. Photo: M 
Engel 2012 
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Lancefield was able to show more than 50 different GAS M types during her career (Lancefield, 
1933). Since then, M protein serological typing was replaced by sequence typing of the M protein 
(emm) gene and more than 200 emm types have subsequently been identified (Facklam et al., 1999).  
 
1.1.3 M protein  
The M protein consists of two polypeptide chains extending the cell wall of the bacteria, and 
composed of 4 blocks of amino acid residues (Fischetti, 1989). The N-terminus of the M protein 
(Figure 1.3) is hypervariable, thus allowing for the differentiation of GAS strains using specific M 
typing antisera (Cunningham, 2000). An emm type number is assigned to a sequence (e.g. “emm 2”). 
Where there are differences in the 5’ region of a particular type, this will determine the subtype 
e.g. emm2.1. Emm sequence typing is the preferred method to study the molecular epidemiology of 
GAS and has been widely applied in many regions of the world (Beall et al., 1996). 
Figure 1.2 Electron micrograph of a chain of 
streptococci showing the surface M protein 
(Fischetti, 2016). 
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1.2 Group A streptococcal infections and diseases  
GAS causes skin (pyoderma) and mucosal diseases (pharyngitis) (Cunningham, 2000). Pyoderma 
is characterised by infection of the epidermis, i.e. blisters and inflammation of the skin, while GAS 
pharyngitis causes symptoms that include tonsillar swelling and exudate, swollen cervical lymph 
nodes, etc. (Cunningham, 2000). GAS can also be invasive, causing Streptococcal Toxic Shock 
Syndrome (STSS), which can occur with an infection at any site in the body. The disease is 
characterized by the occurrence of shock and failure of organs, such as the kidneys, lungs, liver, 
and brain, early in the course of GAS infection. Repeated GAS pharyngeal and skin infections 
following the initial infection may lead to serious GAS-related illnesses, which include acute post-
Figure 1.3  Schematic illustration of M protein. Individual M proteins form coiled coils, which extend from the 
bacterial surface. Two coils wind around each other, forming a dimer that is stabilized by intermolecular 
interactions between amino acids in both strands. The hypervariable N-terminal region, lacking a helical structure, 
is followed by the A, B, C and D repeat regions (Smeesters et al., 2009). 
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streptococcal glomerulonephritis (APSGN), ARF and RHD (Carapetis, Steer, et al., 2005). RHD 
is associated with significant mortality and morbidity in children and young adults living in 
developing countries.  
 
GAS infections can be divided broadly into three categories, namely non-invasive, invasive and 




Invasive infections Autoimmune complications 
Pharyngitis Bacteraemia Acute Rheumatic Fever/ 
Rheumatic Heart Disease 
Scarlet fever* Cellulitis  




Streptococcal toxic shock 
syndrome* 
 
 Puerperal sepsis  
*Toxin mediated diseases 
 
1.2.1 Non-invasive infections 
Non-invasive skin infections are infections that occur in the outer layers of the skin, e.g. the 
epidermis.  
 
1.2.1.1 Pharyngitis and scarlet fever 
The most common cause of bacterial sore throat is caused by GAS; it mainly affects children 
between the ages of 5 and 15 years of age (Danchin et al., 2007; Olubodun 1994). Outbreaks of 
GAS pharyngitis can affect people across all ages, especially in places like schools, households and 
public spaces where there are crowds and close contact with people (Wessels, 2016). 
 
Table 1.1. Non-invasive, invasive and autoimmune complications of group A streptococcus 
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The clinical manifestation of streptococcal pharyngitis is characterised by a sudden onset of sore 
throat, fever and malaise (Wessels, 2016). Patients experience pain when swallowing, caused by 
the swollen and tender cervical lymph nodes. While most cases of sore throat are of viral etiology, 
symptoms of GAS pharyngitis may include fever, erythema and oedema of the posterior pharynx 
and tonsils which may be covered in yellowish or white exudate (Mandell, 2005) (Figure 1.4). If no 
treatment is administered, sore throat will usually self resolve within 3 – 6 days, however, throat 
cultures may remain positive for GAS for several weeks post the resolution of symptoms 
(Catanzaro et al., 1954).  
 
Although GAS is considered to be an extracellular pathogen, studies have shown the 
internalisation of GAS by human epithelial cells (LaPenta et al., 1994; Schrager et al., 1996). 
Complications of GAS pharyngitis include autoimmune diseases, such as APSGN. 
 
Emm types commonly associated with pharyngitis include emm types 1, 3, 5, 6, 12, 14, 17, 19, and 
24 (Cunningham 2000; Johnson et al., 1992; Wessels 2016). 
 
Scarlet fever is a clinical syndrome represented by a rash together with a group A streptococcal 
infection, commonly pharyngitis (Bisno et al., 2002). The rash appears almost immediately 
Figure 1.4. Patient with exudative GAS pharyngitis 
exudate (Mandell, 2005) 
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following infection and is characterised by minute papules, giving the skin a sandpaper-like feel. 
The rash last for 6 to 9 days. The tongue may also appear to look like a strawberry, characterised 
by its bright red colour and enlarged papillae on the surface of the tongue (Cunningham, 2000). 
Scarlet fever is thought to be caused by pyrogenic exotoxins; GAS strains containing the gene for 
one or more of 3 pyrogenic exotoxins A, B and C, cause scarlet fever (Bohach et al., 1990). These 
exotoxins, also known as streptococcal superantigens, are responsible for the strawberry tongue 
and rash that is clinically presented by scarlet fever. Emm types associated with scarlet fever are 
similar to those described in GAS pharyngitis (Cunningham, 2000; Shulman and Tanz, 2010).  
 
Treatment of pharyngitis/scarlet fever  
Penicillin VK (orally) or benzathine penicillin (intramuscularly) remain the first-line antibiotic of 
choice for the treatment of GAS pharyngitis in South Africa (Brink et al., 2004), given that GAS 
isolates remain susceptible to penicillin antibiotics globally. Amoxicillin is recommended as an 
alternative, given its similar effectivenes to penicillin (Bisno et al., 2002). The intramuscular 
administration of penicillin has been shown to be more effective than oral penicillin, by reducing 
the occurrence of ARF by as much as 91% (Manyemba 2003). For patients who are allergic to 
penicillin, alternatives such as clarithromycin, clindamycin, cephalexin, cefadroxil and 
azithromycin have been recommended (Shulman et al., 2012).  
 
1.2.1.2. Pyoderma and other skin infections 
It is important to understand the anatomy of the skin in order to differentiate skin disease caused 
by GAS. Figure 1.5 illustrates the different layers of the skin and deep tissues as these relate to the 
occurrence of different GAS conditions.  
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Impetigo is limited to the outer layer of the skin and does not invade the epidermis (Bisno and 
Stevens, 1996). Impetigo is highly contagious and clinically presents as pustules on the surface of 
the skin, often the extremities or the face. These pustules may rupture and thick honey-coloured 
crusts may develop (Cole and Gazewood, 2007). Systemic symptoms are not often present, 
although lymphadenitis may occur. Impetigo, if left untreated, self-resolves after a few weeks 
without scarring. Strains that cause pyoderma are different to those that cause pharyngitis and 
ARF (Shulman and Bisno, 2014). GAS may penetrate the skin though abrasions and other types 
of trauma. The global burden of impetigo infection is estimated to be approximately 111 million 
cases per annum (Carapetis et al., 2005). 
Figure 1.5. Skin structures and different GAS infections. (Source: Harrison’s Principles of 
Internal Medicine, 19th edition) (Stevens, 2015) 
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1.2.1.4 Erysipelas 
Erysipelas results from GAS penetrating the epidermis through abrasions and other skin traumas. 
Erysipelas affects the superficial epidermal layer of the skin, and the borders of infection are well 
distinguished from adjacent unaffected normal tissue. Furthermore, erysipelas is distinguished 
from other skin infections by its bright red appearance and raised lesions above the surrounding 
skin (Stevens and Bryant, 2016).  
 
 
Treatment of skin lesions  
The management of superficial GAS skin infections involves gentle cleansing of the wounds and 
honey-coloured scabs with a wash cloth and antibiotic soap in conjunction with antibiotic 
treatments, administered either orally and/or in the form of ointment (Walker et al., 2014).  
 
1.2.2 Invasive infections 
Invasive GAS infection is defined by the entry of GAS into the blood stream, deep tissues and 
other sites in the body that are usually considered to be sterile (Invasive Group A streptococcus 
Sub-Committee 2006; Sharkawy et al., 2002). Patients presenting with severe invasive GAS 
diseases, e.g. STSS, are associated with high rates of mortality.  
The global incidence for invasive GAS infections is estimated to be around 600,000 cases per year 
and responsible for 160,000 deaths per year (Carapetis et al., 2005). 
 
1.2.2.1 Cellulitis 
Cellulits occurs in the subcutaneous deep tissues of the skin (Bisno and Stevens, 1996). It results 
from infected burns, wounds or mild trauma. Clinical presentations include erythema (redness of 
the skin), tenderness, swelling and localised pain. Systemic manifestations include fever and 
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malaise. In addition, there may be associated bacteraemia and lymphangitis. The appearance, to a 
moderate extent, differs from erysipelas; lesions are not raised, the boundary between involved 
and uninvolved tissues is less defined, and lesions appear more pink than red in colour.  
 
1.2.2.2 Necrotising fasciitis 
Necrotising fasciitis (NF), also known as a “flesh-eating” disease, occurs when the deeper 
subcutaneous tissues and fascia are infected with GAS (Figure 1.5) (Stevens & Bryant 2016). NF 
is characteristed by the rapid spread of necrosis (also refered to as gangrene) of the skin and 
underlying organs. NF is initiated at the site of trauma or during a surgical incision. The lesion 
initially appears as mild erythema; however, 1 – 3 days later, the inflammation is more 
prounounced and the skin becomes purple in appearance. A large blister containing hemorrhagic 
or yellow fluid appears. Bacteraemia is often present and, following infection, an abscess may 
occur. By the fourth to fifth day, gangrene is evident in the affected skin and the spread is almost 
uncontainable.  
 
The mortality rate associated with patients presenting with NF is high, even when appropriate 
treatment is administered (Stevens and Bryant, 2016). The delay in the correct diagnosis may result 
from the absence of clinical clues; it may only be recognised when the patient presents with STSS. 
The successful management of patients with NF is dependant on early recognition. Furthermore, 
severe pain and fever are among the earliest clinical manifestations and are important clues that 
point towards NF (Stevens and Bryant, 2016).  
 
The emm types associated with NF are 1, 3 and 28 (Olsen and Musser, 2010).  
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1.2.2.3 Streptococcal toxic shock syndrome  
STSS is toxin mediated and may present with other invasive GAS diseases in response to the 
production of superantigens, characterised by a sudden onset of hypotension, fever, shock and 
multiple organ failure (Lappin and Ferguson, 2009). These GAS antigens engage T-cell receptors, 
activating large numbers of T-cells and resulting in a massive cytokine reponse by T-cells; antigen-
presenting cells cause tissue damage, intravascular thrombosis and organ failure (Lappin and 
Ferguson, 2009; O’Loughlin et al., 2007). 
 
The common sites of entry for GAS include the pharynx, mucosa, vagina and skin (Walker et al., 
2014). Surgical procedures have also provided entry points for GAS infection. An additional risk 
factor for STSS includes emm types 1 and 3 that have been associated with an increased incidence 
of STSS (Kiska et al., 1997).  
 
1.2.2.4 Bacteraemia  
Bacteraemia refers to the presence of GAS in the blood stream, characterised by a sudden onset 
of fever, chills, nausea and vomiting, resulting from the pro-inflammatory cytokine response. The 
direct pathway into the blood stream may occur as a result of childbirth (puerperal sepsis), injury 
or as a consequence of superficial infection or colonisation of the skin or throat (Johansson et al., 
2010; Walker et al., 2014).  
 
1.2.2.5 Septic Arthritis 
Septic arthritis refers to the presence of bacteria in the joint through direct inoculation or via the 
bloodstream. Patients with septic arthritis often present with hot, swollen or tender joints with a 
reduced range of movement (Gupta et al., 2001). 
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1.2.2.6 Puerperal sepsis 
Puerperal sepsis is an infection of the genital tract which occurs during labour or within 42 days 
of the postpartum period (Van Dillen et al., 2010). Puerperal sepsis often presents with fever, pelvic 
pain, vaginal discharge and a delayed reduction in the size of the uteris. Puerperal sepsis is 
responsible for at least 75,000 maternal deaths per year occurring in predominantly low-income 
countries (Maharaj, 2007). Risk factors for puerperal sepsis include home birth in non-sterile 
environments, poor nutrition, prolonged labour with multiple vaginal examinations and caesarean 
section births (Kramer et al., 2009; Maharaj 2007). 
 
 
1.2.3 Mechanisms of invasion 
Phagocytosis, the process by which a cell engulfs a solid particle (known as a phagosome), is one 
of the primary human defence mechanisms. GAS has many virulence factors; the four main 
mechanisms are adherence, antiphagocytosis, colonisation, and the production of pyrogenic 
exotoxins (Bisno et al., 2003). 
 
Prior to the colonisation and internalisation of GAS, adhesion to the host epithelial cells has been 
observed (Bisno et al., 2003). Adhesins present in GAS include: pili, M protein, fibronectin binding 
properties, and lipoteichoic acid (Courtney et al., 2002). Streptococcal pili have been shown to play 
a role in adhesins in GAS infections (Manetti et al., 2007). The M protein adheres to Hep-2 cells 
in tissue cultures and skin keratinocytes (Wang and Stinson, 1994). Fibronectic binding protein, 
e.g. F1, adheres to cutaneous Langerhans cells (Hanski and Caparon, 1992). Lipoteichoic acid 
adheres to fibronectin in human buccal epithelial cells. Furthermore, anti-lipoteichoic acid serum 
has been shown to block colonisation and infection of the upper respiratory tract in mice 
(Courtney et al., 2002). 
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GAS has the ability to avoid the natural defense mechanisms of the human body by means of an 
antiphagocytosis mechanism. Interference with opsonisation via the alternate complement 
pathway is achieved through the antiphagocytic properties of the M protein (Bisno, 1979). Control 
factors are further complemented by the binding of the M protein and other host proteins, 
preventing the activation of the alternate pathway and thus protecting the bacteria from host 
phagocytosis by polymorphonuclear leukocytes (Bisno et al., 2003). In addition, the M proteins 
also binds to the Fc region of IgG to invade host phagocytosis. In addition, a capsule comprising 
hyaluronic acid also achieves an antiphagocytic effect (Wessels et al., 1991). Encapsulated GAS are 
able to resist phagocytosis, while those lacking the capsule are susceptible to phagocytosis (Wessels 
et al., 1991).  
 
Colonisation of GAS is achieved by factors that evade immunoglobulins and the complementing 
cascade (Courtney et al., 2002). The production of cytolytic toxins may increase, depending on 
whether or not there is a good nutrient supply, thus resulting in dominance over normal flora. C5a 
peptidase, produced by GAS, inactivates C5a, a component of the complement pathway, thereby 
minimising the influx of neutrophils and increasing survival (Courtney et al., 2002; Walker et al., 
2014).  
 
Exotoxins, namely streptolysin O and streptolysin S, play an important role in the pathogenesis of 
GAS diseases (Sumby et al., 2005). Streptolysin O is ineffective in the presence of oxygen, and is 
thus lethal to erythrocytes and toxic to polymorphonuclear leukocytes, platelets, tissue-cultures 
and lysosomes. Similarly, Streptolysin S (which is not affected by oxygen) has a destructive effect 
on polymorphonuclear leukocytes, platelets, tissue-culture cells and lysosomes (Bisno et al., 2003).  
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Treatment of invasive disease 
Management of severe invasive GAS disease includes hemodynamic stabilisation and specific 
antimicrobial therapy (Wong and Stevens, 2013). If NF is suspected, prompt surgical intervention 
is required and fasciotomy or debridement may be necessary (Young et al., 2006). Furthermore, 
penicillin G should be administered intravenously (3 to 4 million units every 4 hours), together 
with intravenous clindamycin (600 to 900mg), every 6 to 8 hours, for 10 to 14 days (Allen and 
Moore, 2010).  
 
1.2.4 Sequelae of GAS  
 
1.2.4.1 Acute rheumatic fever/rheumatic heart disease 
Repeated GAS infections, such as pharyngitis, can give rise to auto-immune diseases, such as ARF 
and RHD. ARF/RHD is the most serious autoimmune sequela of GAS infection. The 
pathogenesis of RHD is thought to be initiated by molecular mimicry of the M protein to the 
human cardiac myocin, amongst others, resulting in permanent heart valve damage (Zabriskie, 
1967) (see Figure 1.6). Briefly, following a GAS adhesion and invasion of the pharyngeal epithelial 
cells, GAS antigens activate both B and T cells. Molecular mimicry between GAS carbohydrate or 
serotype-specific M protein and the host heart, joint or brain tissues can lead to an inappropriate 
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autoimmune response, which causes the major manifestations of ARF. Damaged cardiac tissue, as 
a result of repeated episodes of ARF, leads to the development of RHD.  
 
Prevention  
The early detection, diagnosis and treatment of GAS pharyngitis with penicillin prevents the first 
attack of ARF (referred to as primary prevention) (Marijon et al., 2012). If the first episode of ARF 
is not prevented, further episodes of a GAS pharyngitis may increase the chances of developing 
RHD. Secondary prevention refers to the prevention of episodes of ARF (Manyemba and Mayosi, 
2003). Penicillin is administered intramuscularly as prophylaxis to prevent further episodes of ARF 
and worsening of RHD. Table 1.2 details the guidelines of the World Health Organisation (WHO) 
for primary and secondary prevention strategies in the treatment of ARF/RHD. Table 1.3 lists the 
duration of secondary prevention relating to the severity of carditis. 
  
Figure 1.6. Generation of a cross-reactive immune response in 
ARF (Carapetis et al., 2016) 
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Table 1.2. WHO Guidelines for primary and secondary prevention of RF/RHD (World Health 
Organisation, 2004) 
Antibiotic Administration  Dose 
Primary Prevention 
Benzathine benzylpenicillin Single intramuscular injection 1200000 units 
600000 units <27kg 
Phenoxymethyl penicillin 
(Penicillin VK) 
Orally 2-4 times/day for 10 full 
days 
Children: 250mg bid or tid. Adolescents or adults: 250mg 
tid or qid, or 500mg bid 
Amoxicillin Orally 2-3 times/day for 10 full 
days 




Orally 2-3 times/day for 10 full 
days 
Varies with agent 
Erythromycin ethylsuccinate Orally 4 times/day for 10 full days Varies with formulation. Available as the stearate, 
ethylsuccinate, estolate or base 
Secondary Prevention 
Penicillin Intramuscular injection. Every 4 
weeks (28 days) 
Children: < 20kg: 600 000 U Children >20kg or adults: 
1,200 000U 
Penicillin VK Orally bid 250 mg bid 
Erythromycin  Orally 2-4 divided doses per day 40mg/kg per day; 400mg adolescents and adults bd. 
mg, milligrams kg, killograms; bid, twice daily; tid, three times daily; qid, four times daily  
Table 1.3. Period of dosage for secondary prevention (World Health Organisation, 2004) 
Category Duration of prophylaxis 
All persons with ARF with no or mild carditis Minimum of 10 years after most recent episode or age 21 
All persons with ARF and moderate carditis Minimum of 10 years after most recent episode or age 30 
All persons with ARF and severe carditis Minimum of 10 years after most recent episode or age 30 and then 
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1.2.4.2 Acute post-streptococcal glomerulonephritis  
APSGN is an immune disorder of the kidneys that is characterised by oedema, urinary 
abnormalities, hypertension and decreased levels of complement components in the serum 
(Shulman and Bisno, 2014). Risk factors for APSGN include poverty, poor hygiene and 
overcrowding (Shulman & Bisno 2014; Steer et al., 2007). The incidence of APSGN is estimated 
to be approximately 470,000 cases per year and the cause of approximately 5,000 deaths per year, 
globally (Carapetis et al., 2005). Finally, the emm types causing APSGN are different to the emm 
types causing ARF/RHD and they are associated with nephritogenic strains of GAS, e.g. 1,4, 12, 
49, 55, 57, and 60 ( Shulman & Bisno 2014; Shulman & Tanz 2010). 
 
Treatment of APSGN  
Antibiotic treatment of APSGN does not directly affect the clinical pathway; however, antibiotic 
therapy may eliminate GAS strains causing infection and reduce the risk of transmission. Penicillin 
is the antibiotic of choice, thus treatment is directed at the complications of the disease. Most 
children with APSGN will completely resolve symptoms of edema and kidney function following 
treatment. (Walker et al., 2014).  
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1.3 The epidemiology of GAS disease 
 Streptococcus pyogenes is responsible for a wide range of diseases that are prevalent worldwide (Bailie 
et al., 2005; Steer et al., 2007). In 2005, Carapetis et al., published a report, commissioned by the 
WHO, summarising the burden of GAS diseases in the world (Carapetis et al., 2005). In this report, 
the prevalence of severe GAS disease is estimated to be 18.1 million cases with an annual incidence 
of 1.78 million cases, and responsible for approximately 517,000 deaths each year, globally  
(Carapetis, Steer, et al., 2005).  
 
Together, ARF and RHD (comprising the greatest burden of GAS-related disease) affect around 
15.6 million people, with 282,000 new cases (Carapetis et al., 2005), and lead to the death of at least 
233,000 people worldwide per annum (Carapetis et al., 2005). Africa carries the highest burden of 
the disease compared with other regions (Figure 1.7). As a result of the failure to execute 
comprehensive prevention programmes, ARF and RHD are endemic in the developing countries 
of the world (Remenyi et al., 2013). Approximately 40 – 60% of ARF episodes result in RHD 
(Allen 1982;  Carapetis et al., 2000; Ralph & Carapetis 2013) . The burden of invasive GAS disease 
Figure 1.7. The global prevalence of rheumatic heart disease (Carapetis et al., 
2005). 
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was reported to be 663,000 new cases and 163,000 deaths per annum. Furthermore, the prevalence 
of GAS pyoderma was estimated to be 111 million cases and over 616 million incident cases of 
GAS pharyngitis per year (Carapetis, Steer, et al., 2005).  
 
In the developed world, the incidence of many diseases has steadily declined; however, in many 
developing countries, the burden of streptococcus pyogenes continues to linger, causing millions of 
deaths every year (Carapetis, Steer, et al., 2005), the majority of which are attributable to RHD. 
The epidemiology of GAS-related disease remains poorly understood, compared with other 
infectious diseases. Many countries have subsequently legislated iGAS infections as a notifiable 
condition, thus establishing iGAS surveillance.  
 
Increases in the incidence of GAS diseases, particularly iGAS diseases, have been observed globally 
since the 1980s (Hoge et al., 1993; Lynskey et al., Lawrenson and Sriskandan, 2011). Outbreaks of 
infection and GAS sequelae have been reported during this time (Efstratiou, 2000) with similar 
increases also observed elsewhere ( Darenberg et al., 2013; Lamagni et al., 2009; Report 2014). 
These increases in the incidence of iGAS infections have been associated with specific strains, 
leading to the possibility that these strains may represent more virulent properties, thus giving rise 
to the outbreak. Of interest, in most developing countries, the emm1 strain was found to be 
dominant among iGAS infections (O’Loughlin et al., 2007). The fluctuations in the incidence of 
iGAS infection vary by geographic region and time, and may be a reflection of the population’s 
susceptibility to particular strains or a variation in the predominant strains (O’Brien et al., 2002), 
which may also lead to fluctuations in the severity of infections and outcomes.  
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According to the WHO, GAS ranked as the ninth leading cause of human mortality on the global 
scale. The majority of deaths were attributed to invasive GAS infections and RHD (World Health 
Organisation, 2005) (Figure 1.8).  
 
In the developed world, a decline in the prevalence and incidence of ARF/RHD has been 
observed over the last 150 years as a result of improved living conditions and the extensive use of 
penicillin for the treatment of GAS pharyngitis (Carapetis, Mcdonald, et al., 2005). Conversely 
however, developing countries, which account for 80% of the world’s population, continue to 
experience high cases of ARF/RHD affecting some 2.4 million children aged five to fourteen years 
old, residing in developing countries (Carapetis et al., 2005). The prevalence of GAS infection is 
higher in children due to multiple exposures, e.g. at schools, and host immunity. Higher rates of 
infection have also been observed among the elderly.  
Figure 1.8. Estimated global mortality from 
various pathogens (Carapetis et al., 2005)  
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1.4 Emm type prevalence  
In a recent review, Steer et al., summarise the distribution of emm types in the world (Steer et al., 
2009). As previously mentioned (in Section 1.1.3), because of the diversity of the M protein, certain 
emm types have been associated with iGAS infections. In the developed world, emm1, emm3, emm12 
and emm28 have been associated with iGAS disease (Creti et al., 2007; O’Loughlin et al., 2007; Steer 
et al., 2009). Furthermore, emm1 has also been strongly associated with pharyngitis. 
 
Many developed countries have undertaken emm typing surveillance over the last decade. The 
results from the Steer review have highlighted differences in the molecular epidemiology of GAS 
between developing and developed countries (Steer et al., 2009). The emm types found to be 
circulating in developing regions were more diverse and did not have dominant emm types 
compared with those seen in developed regions. Figure 1.9 illustrates differences in emm type 
distribution between (A) developed countries, (B) Africa and (C) the Pacific region. The need for 
further studies looking at the molecular epidemiology of GAS is thus warranted in developing 
countries to understand the data better.  
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Figure 1.9. Proportions of the 25 most common emm types in (A) high income countries, 
(B) Africa, and (C) the Pacific regions (Steer et al., 2009).   
Chapter 1: Literature review 
PhD Thesis: Dylan D Barth 44 
1.5 Risk factors associated with group A streptococcus 
The highest prevalence rates for GAS have been observed among people in the lower socio-
economic status category. A few studies reported higher prevalence estimates in environments 
considered to be of lower socioeconomic status when compared with studies in areas with a higher 
socioeconomic status (Carapetis et al., 2005; Engel 2012).  
 
Seasonal peaks have also been observed in a few studies. In a prospective (Active Bacterial Core) 
surveillance study of iGAS, over an eight-year period, consistent peaks in winter and early spring 
were observed (Nelson et al., 2016). Similar peaks were also seen in European countries (Darenberg 
et al., 2013; Lamagni et al., 2008). GAS pharyngitis is seen to peak in autumn and winter 
(Cunningham 2000; Stollerman 1997). These seasonal variations are thought to be the result of a 
combination of concurrent viral infections, overcrowding, and exposure to children with 
pharyngitis (Factor et al., 2003). 
 
Studies on GAS and its sequelae, ARF and RHD, have observed higher rates of disease in females 
compared with males (Carapetis et al., 2005). The reasons for this observation are not clearly 
understood.   
 
Host factors associated with an increased risk of iGAS infections include HIV infection (Davies 
et al., 1996), history of injectable drug use (Passaro et al., 2002), diabetes, cardiac disease and cancer 
(Factor et al., 2003). Environmental factors with an increased risk of iGAS infection are related to 
the presence of a child with a sore throat as well as household size (Factor et al., 2003).  
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1.6 Primary prevention  
1.6.1 Vaccines as a prevention strategy  
 
Efforts to prevent and control GAS disease have been focussed on vaccine development, an 
important component of which requires an understanding of the burden and distribution of the 
emm types causing the disease. The current data are mostly informed by developed countries.  
 
GAS-related diseases are endemic in developing countries of the world due to the failure to apply 
comprehensive prevention programmes (Remenyi et al., 2013). Thus, the introduction of safe, 
effective and affordable vaccines to prevent GAS infections may be the most cost-effective 
method of primary prevention. A sequence based method, emm typing, of the N-terminal region 
of the M protein, widely used in many regions of the world, is the preferred method to study the 
molecular epidemiology of GAS strains (Beall et al., 1996). Potential vaccine coverage in different 
geographic regions, especially those with high rates of ARF/RHD, requires a detailed 
understanding of the molecular epidemiology of GAS infections and the prevalent emm types 
circulating in the community (Steer et al., 2009). Currently in the pre-clinical stage is a 30-valent 
vaccine (reformulated from a 26-valent vaccine) based on the variable N-terminal regions of the 
surface M protein of GAS (Dale et al., 2011). Furthermore, another vaccine (J8 vaccine), based on 
antigens from the conserved C-repeat portion of the M protein, is undergoing phase 1 clinical 
trials (Dale et al., 2013).  
 
1.6.2 M protein vaccine  
The target for vaccine development is based on the hypervariable N-terminus region of the M 
protein, which allows for the differentiating of GAS strains using specific M typing antisera 
(Cunningham, 2000). This region has been able to evoke antibodies with the greatest bactericidal 
properties, while showing no harmful cross-reaction with human tissue (Dale 2008; Dale et al., 
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2013). The latest formulation comprises a 30-valent M protein vaccine, reformulated from a 26-
valent M protein vaccine. This vaccine is informed by the epidemiology of GAS pharyngitis and 
invasive infections from the developed world. The 30 emm types and M proteins amino acid 
sequences can be seen in Figure 1.10.  
 
 
Of interest, the current 30-valent formulation evoked bactericidal antibodies against a number of 
non-vaccine serotypes of GAS (Figure 1.11). A bactericidal killing of >50% was observed with 
88% of isolates. Among non-vaccine types, 81% of isolates were killed (Dale et al., 2013). This 
cross-optimization of non-vaccine types of GAS evoked by the current 30-valent M Protein 
formulation is not clearly understood, but more research is underway to understand the 
mechanisms involved better.  
Figure 1.10. Diagram of the four proteins and emm types comprising the 30-valent M Protein-based 
vaccine. 
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1.6.3 Emm clusters  
The emm cluster system is a new typing system that classifies >200 emm-types into 48 emm clusters 
containing closely-related M proteins that share structural and binding properties (Sanderson-
Smith et al., 2014). Whilst this cluster system has not been applied widely to existing 
epidemiological data, data from which emm-clusters have been obtained indicate that emm-clusters 
associated with iGAS infection did not significantly change over time compared with emm-types. 
This system predicts the continent of the M protein vaccine antigen and is believed to serve as a 
framework to investigate the cross-protection phenomenon (currently not completely understood) 
and to provide a complementary hypothesis for the many variants from low-middle income 
countries (Sanderson-Smith et al., 2014a). Furthermore, this concept could lead to the formulation 
Figure 1.11. Indirect bactericidal activity of the 30-valent GAS vaccine.  
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of an M Protein vaccine that will provide broad coverage in both developing and developed 
nations.  
 
1.7 Public health surveillance  
1.7.1 Importance of public health surveillance systems  
Public health surveillance provides an essential platform to guide and inform prevention and 
control strategies to improve health outcomes of populations (Soucie, 2012). Public health 
surveillance is described as “the ongoing, systematic collection, analysis, and interpretation of 
health data, essential to the planning, implementation and evaluation of public health practice, 
closely integrated with the dissemination of these data to those who need to know and linked to 
prevention and control” (Thacker and Berkelman, 1988). The intention of surveillance is to 
empower decision-makers with effective, timely and useful evidence to lead a public health action 
plan. The design and implementation of surveillance systems are determined by their objectives 
and actions required from a particular intervention programme, with some requiring rapid 
interventions (infectious diseases), and others requiring timeous monitoring in order to plan 
interventions (chronic diseases) (Nsubuga et al., 2006).  
 
1.7.2 Laboratory surveillance  
Laboratory-based surveillance systems involve training, resources, and facilities. A reference 
laboratory is important for quality control and support. Laboratory-based surveillance systems 
usually involve the systematic referral of isolates from sentinel clinics or health centres. A 
systematic sampling approach provides reliable data and is a better representation of the burden 
of disease compared with an arbitrary attempt at reporting trends of infections. Furthermore, the 
regular communication between a public health laboratory and an epidemiologist is essential for 
the successful execution of disease control programmes.  
Chapter 1: Literature review 
PhD Thesis: Dylan D Barth 49 
The use of serotyping is being widely adopted in surveillance laboratories and provides data on 
the subtypes of certain infectious diseases. A good example of this is the monitoring of Salmonella: 
laboratories in 61 countries around the world make use of serotyping for public health surveillance 
(Herikstad et al., 2002). Molecular analysis empowers laboratory-based surveillance systems, 
allowing for the detection of prevalent or new strains that may be causing disease in populations. 
 
1.7.3 The need for adequate registries 
A patient disease registry is a powerful surveillance tool in epidemiology (McDonald et al., 2005). 
Surveillance of infectious diseases forms the foundation of prevention and control strategies by 
identifying any changes in disease patterns, which may warrant further investigation, and by 
planning the implementation of control measures.  
 
Disease registries are guided by research questions that are developed to serve multiple purposes. 
They provide platforms to study the natural history of disease, their clinical features, cost-effective 
treatment strategies and measures of improved quality of care (Glicklich and Dreyer, 2007).  
 
Registries for streptococcal surveillance have been established in many developed countries, 
including Canada, England and the USA, where invasive group A streptococcus (iGAS) are a 
notifiable disease (CDC 1997; GOV.UK 2014; Davies et al., 1996; Tyrrell et al., 2005;). In 2004, the 
Eurosurveillance program began to capture comprehensive information on all cases of iGAS 
infection in Europe (Martin et al., 2011; Meehan et al., 2013). This surveillance programme was 
successful in tracking trends in iGAS infection, monitoring clusters and outbreaks, and conducting 
molecular epidemiological emm sequence typing on all isolates. In the United Kingdom, routine 
surveillance data indicate a significant increase of iGAS isolates from December 2008 (n=143) 
compared to the same period in 2007 (n=86) (Lamagni et al., 2009). In Alberta, Canada, 
surveillance of iGAS infection collects information that informs vaccine development and 
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contributes to the implementation and evaluation of new intervention strategies for controlling 
GAS disease (Tyrrell et al., 2005).  
 
The size and severity of the burden of GAS-related diseases highlight the importance of 
epidemiologic surveillance to detect changes in disease distribution in various populations. 
 
The incidence and prevalence of GAS infections in developing countries are largely unknown due 
to the lack of studies and surveillance from these regions (Carapetis et al., 2005). Currently, iGAS 
infection is not notifiable in South Africa, thus there exists no registry for the documenting of 
GAS-related disease in the country (nor on the rest of the African continent), despite the 
importance of GAS infections in this region. Given that systematically collected data are essential 
for an effective disease-control programme (Nsubuga et al., 2006), measuring the incidence and 
temporal trends is an essential first step toward reducing the burden of GAS disease in developing 
countries (Robertson et al., 2006). 
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Objectives of this thesis:  
 
1. To establish the AFROStrep biorepository and clinical database composed of South 
African patients with a GAS-related diagnosis (both invasive and non-invasive). 
2. To identify and summarize all studies reporting on the molecular epidemiology of Group-
A streptococcal (GAS) isolates in Africa.  
3. To describe from national laboratory data, the incidence of invasive and non-invasive 
Groups A streptococcal isolates in South Africa, 2003 – 2015. 
4. To conduct a prospective, surveillance study in order to determine the burden of invasive 
disease associated with GAS in South Africa over a 12-month period.  
5. To describe the molecular (emm) typing of invasive GAS isolates in South Africa, 
particularly with respect to how they compare and contrast with the molecular types of 
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This section has been published in part in the following peer-reviewed journal: 
Barth DD, Engel ME, Whitelaw A, Alemseged A, Sadoh WE, Ali SKM, Sow SO, Dale J, Mayosi 
BM. Rationale and design of the African group A streptococcal infection registry:  the AFROStrep 
Study. BMJ Open, 2016. 
 
2.1 Introduction 
Group A β-haemolytic streptococcus (GAS), a gram-positive bacterium also known as Streptococcus 
pyogenes, causes skin, mucosal, systemic and autoimmune diseases (Cunningham, 2000). Repeated 
pharyngeal and skin infections with GAS may lead to serious autoimmune diseases such as acute 
post-streptococcal glomerulonephritis, acute rheumatic fever (ARF) and rheumatic heart disease 
(RHD) (Cunningham 2012; Carapetis, Steer, et al., 2005). Invasive GAS disease (iGAS) is 
associated with significant morbidity and mortality in children and young adults world-wide (Lees 
and Carrol, 2014). Increases in the number of cases of both invasive and non-invasive GAS 
diseases have been observed globally since the 1980s (Hoge et al., 1993; Lynskey et al., 2011). The 
reasons for these observations are not well understood and have subsequently, caused many 
countries to commence active surveillance systems for iGAS to closely document the 
epidemiology of the disease.  
 
A patient disease registry is a powerful surveillance tool in epidemiology (McDonald et al., 2005). 
Guided by research questions, registries are developed to serve multiple purposes and provide a 
platform to study the natural history of disease, clinical features, cost effectiveness of treatment 
strategies and care, to assess safety and harm, and to provide measures of improved quality of care 
(Glicklich and Dreyer, 2007). Registries for streptococcal surveillance have been established in 
some developed countries, for example Canada, England and USA, where iGAS is a notifiable 
disease (Tyrrell et al., 2005; CDC 1997; GOV.UK 2014; H. Dele Davies et al., 1996).  
In 2004, the Eurosurveillance program began to capture comprehensive information on all cases 
of iGAS infection in Europe (Martin et al., 2011; M. Meehan et al., 2013). This surveillance 
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programme was successful in tracking trends in iGAS infection, monitoring clusters and outbreaks, 
and conducting molecular epidemiological emm sequence typing on all isolates. In the United 
Kingdom, routine surveillance data indicate a significant increase of iGAS isolates from December 
2008 (n=143) compared to the same period in 2007 (n=86) (Lamagni et al., 2009). In Alberta, 
Canada, surveillance of iGAS infection collects information that informs vaccine development and 
contributes to the implementation and evaluation of new intervention strategies for controlling 
GAS disease (Tyrrell et al., 2005).  
Currently, there exists no registry for the documenting of GAS-related disease in Africa, despite 
the importance of GAS infections in this region. Given that systematically collected data are 
essential for an effective disease-control programme (Nsubuga et al., 2006), we have established 
the AFROStrep Registry as an essential first step towards understanding the prevalence of 
laboratory-confirmed GAS disease in African countries.  
 
2.2 Rationalé  
In a World Health Organisation (WHO) report, GAS was put in the top ten leading causes of 
mortality world-wide, with the majority of deaths attributed to rheumatic heart disease, a chronic 
sequel of GAS pharyngitis (World Health Organisation, 2005). Prevalence and incidence data on 
laboratory-confirmed GAS infection from African countries are lacking when compared with 
industrialised nations (Carapetis, Mcdonald, et al., 2005), although a number of studies in Africa 
have previously published data on GAS in a number of countries including Ethiopia, Mali, Nigeria, 
Sudan and Tunisia (Hraoui, Boutiba-Ben Boubaker,  a. Doloy, et al., 2011; Malik & Ali 2014; 
Mayosi 2006; Milagritos D. Tapia et al., 2015; Tesfaw et al., 2015b).  
 
The AFROStrep study is a collaborative study that aims to establish the first registry and 
biorepository of laboratory-confirmed GAS isolates in Africa, with one of its main objectives being 
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to collect comprehensive epidemiological, clinical, microbiological, and molecular data for GAS 
infections on the continent. AFROStrep will serve as a platform for further investigations including 
molecular characterisation of isolates in order to contribute to the growing body of knowledge 
informing vaccine development.  
 
The registry comprises two components;  
1. Active surveillance of GAS pharyngitis cases from whom GAS has been isolated at clinics 
and community health centres.  
2. Passive surveillance of laboratory data on GAS isolated from patients with invasive (iGAS) 
and non-invasive (non-iGAS) streptococcal disease.  
 
Objectives of the AFROStrep Registry 
1. To collect demographic and clinical information from patients with iGAS and non-iGAS 
laboratory-confirmed infection.  
2. To determine the molecular epidemiology of non-invasive and invasive GAS infection.  
3. To assess strategies for treatment, control and prevention of GAS infection. 
4. To conduct studies that contribute to the development of appropriate interventions such 
as vaccines.  
 
2.3 Design of the study 
AFROStrep is a prospective, regional, multicentre, clinic- and laboratory-based registry initiative 
involving centres in Africa, many of which are part of the Stop Rheumatic Heart Disease A.S.A.P. 
Programme (Robertson et al., 2006) and related studies such as the Global Rheumatic Heart 
Disease Registry (the REMEDY study) (Karthikeyan et al., 2012). AFROStrep seeks to document 
the prevalence, incidence, clinical and molecular characteristics of laboratory-confirmed GAS 
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infection in Africa. This thesis served to establish the Cape Town component, specifically 
focussing on the passive surveillance of laboratory data on GAS isolated from patients with iGAS 
and non-iGAS disease.  
 
2.3.1 Study eligibility 
All patients presenting with a sore throat (including tonsillitis) at participating clinics and 
community health centres regardless of age, and who have not had antibiotics in the previous 30 
days, are eligible to participate in the active surveillance arm of AFROStrep. For the passive 
surveillance component, all patients, irrespective of age, confirmed as having GAS disease, are 
eligible for inclusion.  
 
Inclusion criteria. Anyone presenting with a sore throat with microbiological laboratory confirmation 
of GAS, providing informed consent (Appendix 9.11) is eligible for enrolment. Exclusion criteria. 
Patients will be excluded if no informed consent was obtained. 
Clinical data and accompanying laboratory data will be entered into the AFROStrep database 
designed on the OpenClinica platform version 3.0 (https://www.openclinica.com). In addition, 
isolates will be subjected to cryo-preservation for long-term storage in the AFROStrep 
biorepository. This will enable further molecular investigations as part of the wider vaccine 
initiative spanning a number of sites worldwide. 
 
2.3.2 Data collection 
The study nurse in each site will seek participation in the study among eligible patients attending 
health care facilities for treatment of sore throat. Consenting patients will be examined clinically 
on a number of symptoms after which, a throat swab will be taken for microbiological culture. A 
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case report form will be used for recording data. Patient care will remain within the domain of the 
attending clinician or nurse. Antibiotics prescribed will also be documented. 
 
Sample size. Active surveillance:  To allow for comparison of prevalence across respective sites 
participating in AFROStrep, a minimum sample of 246 participants with pharyngitis needs to be 
enrolled at each site. This calculation was  based on existing prevalence estimates for GAS 
pharyngitis of around 21% (Engel et al., 2014); 95% confidence interval (CI) and a precision level 
of 5% (Altman, 1980). 
Passive surveillance. Eligible patients will be identified from positive GAS cultures isolated at 
participating laboratories. Clinical data will be obtained from hospital folders. 
 
2.3.3 Governance 
The institutions inputting data to the registry own their data.  The registry committee will meet on 
a regular basis to address requests for data sharing which will be subjected to satisfactory evidence 
regarding the intended use of the data, maintenance of confidentiality and benefit to the entire 
community of patients, including the individual.   
 
2.3.4 Data analysis plan 
The information to be collected will include (but not be limited to) date of birth, gender, date and 
duration of illness, presenting clinical features and, microbiological findings. To protect the privacy 
of patients, a file will be created that will have no specific identifiers. Analysis will be conducted 
using Stata 11.2 (StatCorp, College Station, TX). Descriptive statistics will be used to describe the 
clinical syndromes associated with invasive and non-iGAS disease. The number of positive 
samples obtained each month will be analysed to determine prevalence of GAS among pharyngitis 
cases treated at the health facilities. Geographical Information Systems (GIS) will be used to plot 
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the residences of participants. Molecular characterization will be reported using emm-typing as 
previously described (Beall et al., 1996). 
 
2.3.5 Ethics and dissemination 
Ethics approval for the AFROStrep registry has been obtained from the Human Research Ethics 
Committee of the University of Cape Town (HREC/REF: R006/2015) (Appendix 9.1). Each 
recruiting site will seek ethics approval from their local ethics committee. Using standardized case 
report forms tailored to local requirements, eligible patients will be informed about the AFROStrep 
registry, and their consent to participate will be recorded prior to enrolment. Children eight years 
of age and older will also be requested to provide assent (Appendix 9.10). Reports and publications 
emanating from the AFROStrep Registry will not include any information that identifies either the 
patient themselves, their parents or guardians. Participants will be identified throughout the study 
duration by the study number allocated to them at the time of enrolment. All data will be stored 
on a password-protected computer and handled in the strictest confidence. The establishment of 
the biorepository will follow prescribed guidelines and documentation will be drawn up to afford 
maximum protection for the participants, who will be requested to provide specific consent for 
the long-term storage of their isolates. Findings and updates will be disseminated to collaborators, 
researchers, health planners and colleagues through peer-reviewed journal articles, conference 
publications and proceedings. 
 
2.3.6 Status of the study and sites participation 
The active and passive surveillance arms of AFROStrep commenced in November 2015; initially, 
pilot sites in South Africa were anticipated to participate in the AFROStrep Registry, after which, 
enrolment will expand across centres from the rest of Africa. All participating sites will enrol 
patients for a minimum of two years. A similar study had previously been conducted in Cape Town 
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(Engel et al., 2014). A standard operating procedure for AFROStrep with more information is 
available (Appendix 9.8). 
 
2.3.7 Strengths and limitations 
Health facilities collaborating in this study have huge catchment areas; thus, we anticipate large 
numbers of enrolment which will provide an acceptable population from which to draw 
conclusions on the general and molecular epidemiology of GAS in patients. However, the 
AFROStrep study is a clinic- and laboratory-based registry and will not address the true burden of 
disease in the community. Furthermore, concerning the passive surveillance component, given the 
financial constraints facing many centres in Africa, it is conceivable that specimens submitted for 
laboratory evaluation will represent the more severe cases. Finally, in the light of the hypothesis 
that GAS impetigo plays a role in the pathogenesis of post-streptococcal diseases (Parks et al., 
2012), we acknowledge that the registry may be rendered incomplete by not including skin cultures, 
for reasons of the risk of mixed infections. But, given that many cases of iGAS begin on the skin, 
the molecular epidemiology of the most pathogenic GAS should be captured nevertheless. In 
addition, the physical examination will include notation of coexistent pyoderma.  Nevertheless, 
despite the limitations, AFROStrep will provide the first insights into the epidemiology of 
laboratory-confirmed GAS disease in African countries.  
 
2.4 Discussion  
To the best of our knowledge, the AFROStrep study is the first prospective study of clinical, 
epidemiological and microbiological characteristics of group A streptococcal disease in Africa. Our 
registry, which includes the documenting of non-invasive GAS such as pharyngitis, represents an 
improvement on current registries limited to iGAS information. We will collect detailed data on 
clinical features at the time of presentation which will be stored together with corresponding 
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detailed laboratory information including molecular characterisation of GAS strains. The 
AFROStrep study will also document current practices in treating group A streptococcal infection, 
with particular reference to prescription of penicillin antibiotics. Finally, AFROStrep, because of 
its multicentre nature, presents the scope for examining regional similarities and differences in 
clinical and molecular features and outcomes of GAS infection. 
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3. CHAPTER THREE:  METHODS 
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In this section, I will be describing the methods used in the inter-linked studies encompassed 
within this thesis. Firstly, I will provide a brief background followed by the detailed approaches 
used in each study.  
 
3.1 Systematic Review:  Prevalence of Group A streptococcal disease in Africa:   
 
This protocol for this systematic review has been published in part in the following peer-
reviewed journal: 
Barth D, Mayosi BM, Jabar A, Engel ME. Prevalence of Group A streptococcal disease in North 




The true burden of group A streptococcal (GAS) disease in Africa is not known. GAS is a 
significant cause of mortality and morbidity on the global scale and in developing countries. 
According to Carapetis et al, the prevalence of severe GAS disease is at least 18.1 million cases 
with an incidence of at least 1.78 million cases per year. Systematic reviews represent a scientific 
approach to the aggregation of individual studies, that fits pre-specified eligibility criteria, so as to 
present a summary of the best available evidence to answer a specific research question. Systematic 
review are different from traditional reviews in that it aims to reduce bias in the selection of articles 
by making use of predefined, explicit methods (Higgins and Green, 2011). We conducted a 
systematic review and meta-analysis to investigate the burden of GAS disease among children and 
adults in Africa. This systematic review was based on and reported according to the Preferred 




Chapter 3: Methods 
PhD Thesis: Dylan D Barth 63 
3.1.2 Specific Objectives 
 
The primary objective of this review was to provide a quantitative summary, from published 
studies, of the prevalence of laboratory-confirmed GAS among people living in African countries. 
Secondary outcomes included evaluating the quality of included studies and analysing demographic 
and other characteristics which include the distribution of GAS emm types in Africa. This review 
will complement the findings of an existing review published in 2009 (Andrew C Steer et al., 2009) 




The methods for this review follows those published previously (Mahmoud Werfalli et al., 2014). 
This systematic review’s protocol  has been published in the PROSPERO International 
Prospective Register of systematic reviews (http://www.crd.york.ac.uk/PROSPERO), 
registration number CRD42014012900, in a peer reviewed journal (Barth et al., 2015), and is 
prepared according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis 
Protocols (PRISMA-P) 2015 Statement (Moher et al., 2015).  
 
3.1.3.1  Search methods and identification of studies 
A broad search strategy was designed to maximise sensitivity (Table 3.1). The main search 
comprised individual searches using detailed medical subject heading (MeSH) terms for group A 
Streptococcal infection combined with terms relevant to Africa. In an attempt to maximise the 
likelihood of finding articles conducted in Africa, we applied an African search filter developed by 
Siegfried and colleagues (Pienaar et al., 2011; Eisinga et al., 2006).  
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Table 3.1. Search Strategy 
((((((GAS) OR Group A Streptococc*) OR streptococc*) OR pharyngitis) OR streptococc* 




((((‘‘Africa’’[MeSH] OR Africa*[tw] OR Algeria[tw] OR Angola[tw] OR Benin[tw] OR 
Botswana[tw] OR ‘‘Burkina Faso’’[tw] OR Burundi[tw] OR Cameroon[tw] OR ‘‘Canary 
Islands’’[tw] OR ‘‘Cape Verde’’[tw] OR ‘‘Central African Republic’’[ tw] OR Chad[tw] OR 
Comoros[tw] OR Congo[tw] OR ‘‘Democratic Republic of Congo’’[tw] OR Djibouti[tw] OR 
Egypt[tw] OR ‘‘Equatorial Guinea’’[tw] OR Eritrea[tw] OR Ethiopia[tw] OR Gabon[tw] OR 
Gambia[tw] OR Ghana[tw] OR Guinea[tw] OR ‘‘Guinea Bissau’’[tw] OR ‘‘Ivory Coast’’[tw] OR 
‘‘Cote d’Ivoire’’[tw] OR Jamahiriya[tw] OR Jamahiriya[tw] OR Kenya[tw] OR Lesotho[tw] OR 
Liberia[tw] OR Libya[tw] OR Libya[ tw] OR Madagascar[tw] OR Malawi[tw] OR Mali[tw] OR 
Mauritania[tw] OR Mauritius[tw] OR Mayotte[tw] OR Morocco[tw] OR Mozambique[tw] OR 
Mozambique[tw] OR Namibia[tw] OR Niger[tw] OR Nigeria[tw] OR Principe[tw] OR 
Reunion[tw] OR Rwanda[tw] OR ‘‘Sao Tome’’[tw] OR Senegal[tw] OR Seychelles[tw] OR 
‘‘Sierra Leone’’[tw] OR Somalia[tw] OR ‘‘South Africa’’[ tw] OR ‘‘St Helena’’[tw] OR Sudan[tw] 
OR Swaziland[tw] OR Tanzania[tw] OR Togo[tw] OR Tunisia[tw] OR Uganda[tw] OR 
‘‘Western Sahara’’[ tw] OR Zaire[tw] OR Zambia[tw] OR Zimbabwe[ tw] OR ‘‘Central 
Africa’’[tw] OR ‘‘Central African’’[tw] OR ‘‘West Africa’’[tw] OR ‘‘West African’’[tw] OR 
‘‘Western Africa’’[tw] OR ‘‘Western African’’[tw] OR ‘‘East Africa’’[tw] OR ‘‘East African’’[tw] 
OR ‘‘Eastern Africa’’[tw] OR ‘‘Eastern African’’[tw] OR ‘‘North Africa’’[tw] OR ‘‘North 
African’’[tw] OR ‘‘Northern Africa’’[tw] OR ‘‘Northern African’’[tw] OR ‘‘South African’’[ tw] 
OR ‘‘Southern Africa’’[tw] OR ‘‘Southern African’’[tw] OR ‘‘sub Saharan Africa’’[tw] OR ‘‘sub 
Saharan African’’[tw] OR ‘‘sub-Saharan Africa’’[tw] OR ‘‘sub-Saharan African’’[tw]) NOT 




The search strategy was conducted independently by two reviewers (DB; ME) among multiple 
databases which include Medline (accessed via PubMed), Web of Science (accessed via IST Web 
of Knowledge), and Scopus databases from the earliest inception to the latest published data.  
In addition, we searched through proceedings from the XIX Lancefield International Symposium 
on Streptococci and Streptococcal disease (http://www.lancefield2014.com) and complemented our 
results with searches in Google Scholar, conference proceedings, scanning reference list of 
included articles, and theses databases. The search strategy was modified to suit the vocabulary of 
individual database(s). Our search was not restricted by any time period cut-off nor by language.  
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3.1.3.2 Inclusion criteria 
We included studies describing the prevalence of GAS across all age groups, resident in countries 
belonging to the African continent, in the geographic regions of sub-Saharan and North Africa 
diagnosed with a laboratory-confirmed GAS isolate from all ethnicities, socioeconomic and 
educational backgrounds. All study designs were considered for inclusion. For the purpose of this 
review, the diagnosis of GAS was determined by culture and/or rapid antigen detection testing. 
The molecular characterisation of GAS was considered if the emm typing method was used to 
ascertain the strains. This technique is thought to be concurrent with the gold standard M-typing 
technique (Tewodros and Kronvall, 2005). We considered both published articles and unpublished 
studies. Articles published in other languages with full English abstracts were eligible for inclusion. 
 
3.1.3.3 Exclusion criteria 
We excluded narrative reviews, opinion pieces, letters and any other publications lacking primary 
data and/or explicit method descriptions. For publications of the same data, the most complete 
and recent versions were considered for inclusion. 
 
3.1.3.4 Data extraction and management 
Search results from all databases mentioned above and reference search results from published 
and unpublished data were managed with Mendeley referencing software (Copyright © 2009-2013 
Mendeley Ltd). Data were extracted using predefined criteria using a data extraction form 
(Appendix 9.2). 
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3.1.3.5 Selecting studies for inclusion 
Full text study articles were screened and scrutinised by title and abstract against predefined 
inclusion and exclusion criteria. Two reviewers (DB; ME) were assigned to evaluate and appraise 
the results of the searches based on the title and abstract. If the reviewer was uncertain, the study 
was marked as pending. Once all the studies were reviewed independently, the reviewers together 
compared their scripts; discrepancies were discussed and where necessary, a third reviewer (BM) 
was called upon to resolve any disagreements.  
 
3.1.3.6 Quality appraisal of included studies 
Internal, external validity and generalizability of the included study results were evaluated for risk 
of bias. An assessment of the risk of bias informed the evaluation of heterogeneity in the pooled 
analysis. A quality assessment tool for evaluating prevalence studies as suggested by Hoy and 
colleagues (and adapted by Werfalli and colleagues) were employed. The revised version allows for 
a composite score to assist with relative comparison between the studies, thereby reducing 
reviewers’ subjectivity (Hoy et al., 2012; Werfalli et al., 2014). In a nutshell, Werfalli and colleagues 
added a quantitative scoring system to the Risk of Bias table, allocating four points for external 
validly score and six points for internal validity. The scoring system tool categorizes high risk 
studies as those with an overall score of 0-5 points, moderate risk as 6-8 and low risk > 8 points 
(Table 3.2).  
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Table 3.2. Quality assessment criteria for prevalent studies with scoring (Hoy et al., 
2012; Werfalli et al., 2014) 
Items  Quality Score 
External Validity   
1. Was the study's target population a close representation of the national population in relation to 
relevant variables? 
(1 point) 
2. Was the sampling frame a true or close representation of the target population? (1 point) 
3. Was some form of random selection used to select the sample, OR was a census undertaken? (1 point) 
 4. Was the likelihood of nonresponse bias minimal? (1 point) 
 Total (4 points) 
Internal Validity   
1. Were data collected directly from the subjects (as opposed to a proxy)? (1 point) 
2. Was an acceptable case definition used in the study? (1 point) 
3. Was the study instrument that measured the parameter of interest shown to have validity and reliability? (1 point) 
4. Was the same mode of data collection used for all subjects? (1 point) 
5. Was the length of the shortest prevalence period for the parameter of interest appropriate? (1 point) 
6. Were the numerator(s) and denominator(s) for the parameter of interest appropriate? (1 point) 
 Total (6 points) 
Risk assessment    
Quality   Overall score 
High Risk: Further research is very likely to have an important impact on our confidence in the estimate 
and is likely to change the estimate. 
0- 5 points  
Moderate Risk: Further research is likely to have an important impact on our confidence in the estimate 
and may change the estimate. 
6 -8 points 
Low Risk:  Further research is very unlikely to change our confidence in the estimate > 8 points  
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3.1.3.7 Data synthesis  
To calculate the unadjusted prevalence estimates of symptomatic group A streptococcal infection 
in our study population, we individually recalculated the reported prevalence estimates to confirm 
numerators and denominators. We confirmed the prevalence estimates reported by the authors 
were correct; however, some studies had to be adjusted to obtain numerators and denominators 
relevant to our study population. Secondly, where sample populations included both symptomatic 
GAS and asymptomatic GAS (van Zyl et al., 1981; Bélard et al., 2015; O’Meara et al., 2015; Mzoughi 
et al., 2004; Tewodros et al., 1992), we only extracted information from symptomatic  GAS patients.  
 
Using Stata® (version 13.1) the Freeman-Tukey double arcsine transformation metaprop routine 
was used to calculate the combined prevalence estimate, with the standard error across the 
unadjusted estimates from the included studies. The Freeman-Turkey stabilises the variance of 
study-specific prevalence, minimizing the influence from studies with extremely small prevalence 
or extremely large prevalence estimates (Nyaga et al., 2014).  
 
We stratified the aggregated prevalence by region in order to confirm earlier reports of regional 
differences in GAS (Andrew C Steer et al., 2009), thus, we endeavoured to assess similarities and 
difference within the Africa continent. Our hypothesis was that GAS infection would differ 
regionally because of geographical and climatic differences. We also evaluated prevalence estimates 
according to study design so as to assess methodological influences on overall estimates. Our 
hypothesis was that GAS prevalence’s would not be statistically different across study designs. We 
intended to perform sub-analyses of GAS colonization risk factors including gender, crowding, 
and seasonality.  
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3.1.3.8 Sensitivity analysis  
Where heterogeneity was statistically significant, sub-group and sensitivity analysis was conducted 
to establish if the meta-analysis results are influenced by the effect of study designs as well as the 
geographical settings (low income versus middle income countries). Sensitivity analysis was 
performed to determine potential sources and explanations for the heterogeneity. These analyses 
included plotting studies of a high quality and comparing results to see how it differs from the 
overall result. Studies which were considerably heterogeneous and where pooling data was not 
possible, the findings were narratively explained together with tables and figures where applicable. 
Any discrepancies or disagreements were discussed by the reviewers and if necessary an 
independent reviewer was asked to provide clarification. 
 
3.1.3.9 Ethics and dissemination 
Systematic reviews draw on publicly available data and therefore do not require formal ethical 
review. The findings of this systematic review will be disseminated through peer-reviewed journal 
publications and conference proceedings.  
To our knowledge, there are no systematic reviews that have specifically looked at the burden of 
laboratory-confirmed GAS infection in Africa. We expect this review to compliment that of Steer 
and colleagues in 2009 which reported on the global emm type distribution of GAS. Finally, we 
believe that the results of this systematic review will have implications for policy, practice and 
vaccine development, informed by data solely from Africa where the burden of GAS disease is 
among the greatest. 
 
3.1.3.10 Funding 
No funding was received for this review. 
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The epidemiology of GAS infection has been discussed in detail in section 1.3. Briefly, increases 
in the annual number of cases for GAS disease, especially invasive GAS (iGAS) diseases have been 
observed globally since the 1980s. The incidence and prevalence of both iGAS and non-iGAS 
infections in developing countries, which includes South Africa, are largely unknown (Carapetis, 
Mcdonald, et al., 2005). Systematically collected data are essential for a functioning disease-control 
programme (Nsubuga et al., 2006) and thus, the measurement of incidence and temporal trends 
are an essential first step toward reducing the burden of GAS disease in developing countries 
(Robertson et al., 2006). We conducted a retrospective study of cases of iGAS and non-iGAS 
infection identified at the National Health Laboratory Services to determine the incidence of GAS 
infection in South Africa. 
 
3.2.2 Specific Objectives  
 
The aim of this study was to describe the epidemiology of iGAS and non-iGAS infection and 
associated clinical characteristics in the public sector of South Africa, over a recent 13-year period 
(2003 – 2015).  
  
Chapter 3: Methods 
PhD Thesis: Dylan D Barth 71 
3.2.3 Methods 
 
3.2.3.1 Study design and population  
This study was conducted under the auspices of the AFROStrep Study, an initiative aimed at 
documenting the epidemiology of GAS in Africa (Barth et al., 2016). We performed a retrospective 
analysis of iGAS and non-iGAS isolates cultured at National Health Laboratory Service (NHLS) 
centres from January 2003 to December 2015. The NHLS is the largest diagnostic pathology 
service in South Africa, supporting both national and provincial health departments in healthcare 
delivery in the nine provinces of South Africa (http://www.nhls.ac.za). Following for the 
application and approval for data use from the NHLS information systems, we were able to 
retrieve all recorded cases of GAS infection from January 2003 to December 2015, in a Microsoft 
excel spreadsheet. Data fields not relevant to the objectives and analysis of this review were 
removed.  
 
3.2.3.2 Case Definition 
iGAS was defined as GAS isolated in culture from a sterile site such as blood,  cerebrospinal fluid 
(CSF) and pleural fluid (Sharkawy et al., 2002; Invasive Group A streptococcus Sub-Committee 
2006). GAS isolated from a non-sterile site such as the skin and throat was considered to be non-
invasive (Su et al., 2009). In addition to microbiological data (including site of isolation), we also 
abstracted demographic information and clinical data, where available.  
 
3.2.3.3 Statistical analysis 
The overall and age-specific incidence rates of iGAS and non-iGAS infection were calculated using 
annual census population data for South Africa, reported per 105 person-years (py). A statistical 
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exploratory analysis was also conducted to identify changes in the trend of GAS infection 
(increasing, decreasing or remain unchanged) over the 13-year time interval. The change in GAS 
infection was not expected to be linear from year to year (with no correlation between 
measurements collected at different times), and therefore we employed the Mann–Kendall Test 
for Monotonic Trend (MK test)(Kendall, 1975), rather than parametric linear regression analysis 
which requires that the residuals from the fitted regression line be normally distributed; an 
assumption not required by the MK test. Linear trend (median drop per year in GAS infection 
rates) was assessed using the robust linear regression Theil–Sen estimator (Birkes and Dodge, 
1993);  this technique was shown to be significantly more accurate than simple linear regression 
for skewed and heteroskedastic data and compares well against no robust least squares even for 
normally distributed data in terms of statistical power. The strength of the trend was assessed using 
the MK test statistic. The test for significance was set at the 5% level. All statistical analyses were 
performed using STATA® version 13 (StataCorp, Texas, USA). 
 
3.2.3.4 Ethical approval 
Ethics approval has been obtained from the Human Research Ethics Committee at the University 
of Cape Town (HREC/REF: R006/2015) (Appendix 9.1). 
  
Chapter 3: Methods 
PhD Thesis: Dylan D Barth 73 




GAS is responsible for a wide range of non-iGAS and iGAS diseases (Bailie et al., 2005; Steer et al., 
2007). Primary prevention efforts for GAS infection include the development of a 30-valent 
serotype vaccine, reformulated from a 26-valent vaccine (Dale et al., 2011); the M serotypes of 
GAS  included in this reformulation were based on data from the developed world and cross 
coverage of certain emm types were observed. iGAS emm type data from sub-Saharan Africa is 
essential for assessing potential vaccine coverage. Three studies (Engel et al., 2014; Milagritos D 
Tapia et al., 2015; Tewodros & Kronvall 2005) reported on the molecular epidemiology of non-
iGAS and a single study (Seale et al., 2016b) reported on the molecular epidemiology of iGAS, in 
sub-Saharan Africa. By means of a one-year prospective laboratory study, under the auspices of 
AFROStrep, we determined the clinical characteristics and molecular epidemiology of non-iGAS 
and iGAS infection among South African patients attending Groot Schuur Hospital, a tertiary 
institution in Cape Town, so as to inform the development of M protein-based vaccines. 
 
3.3.2  Specific Objectives  
 
This surveillance study aims to describe the clinical and molecular emm type distribution of non-
iGAS and iGAS infections from the National Health Laboratory Services in Cape Town between 
February 2016 and March 2017.  
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3.3.3 Methods 
 
3.3.3.1 Clinical Surveillance and Case Definitions 
In order to determine the extent of GAS infections and the serotypes that cause disease in South 
Africa, we conducted a prospective laboratory surveillance study among samples from February 
2016 – March 2017 submitted to the National Health Laboratory Service (NHLS) for processing. 
The NHLS is the largest diagnostic pathology service in South Africa (http://www.nhls.ac.za). 
iGAS was defined as GAS isolated in culture from a sterile site including blood,  cerebrospinal 
fluid (CSF) and pleural fluid (Invasive Group A streptococcus Sub-Committee 2006; Sharkawy et 
al., 2002). GAS isolated from a non-sterile site such as the skin and throat was considered to be 
non-invasive (Su et al., 2009). We documented demographic data, clinical presentation, laboratory 
data and emm types that cause non-iGAS and iGAS infections. At the time of a laboratory-
confirmed GAS diagnosis, a standardized case report form (Appendix 9.3) was completed and 
clinical information were determined by patient folder review and medical notes by a 
microbiologist practitioner. Isolates were collected and stored at -80 degrees °C until transfer to 
the AFROStrep laboratory.  
 
3.3.3.2 Study eligibility 
All patients, irrespective of age, confirmed as having a positive GAS culture isolated from the 
NHLS laboratory at Groote Schuur Hospital, were eligible for inclusion. Inclusion into AFROStrep 
is subject to anyone with a microbiological laboratory confirmation of GAS and the availability of 
clinical data.  
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3.3.3.3 Data collection 
Clinical data and accompanying laboratory data were entered into the AFROStrep database 
designed on the OpenClinica platform version 3.0 (https://www.openclinica.com) (Appendix 9.7). 
In addition, isolates were subjected to cryo-preservation for long-term storage in the AFROStrep 
biorepository to enable further molecular investigations as part of the wider vaccine initiative 
spanning a number of sites worldwide.  
 
3.3.3.4 Study procedure 
GAS isolated from sterile or non-sterile sites in the human body were processed and stored on 
microbeads by the Microbiology Laboratory at the NHLS. GAS isolates were collected once a 
month from the NHLS and taken to the AFROStrep laboratory housed in the department of 
Medicine at the University of Cape Town. GAS isolates were stored in the AFROStrep laboratory 
at -80°C in cryopreservative microbeads until DNA extraction. Each isolate was inoculated onto 
5% sheep blood agar plates according to the standard protocol, inverted and incubated 
anaerobically at 37 °C for 24-48 hours (Appendix 9.4). All cultures of beta-haemolytic colonies 
were further identified by Gram stain, catalase, and serogrouping, as appropriate.  
 
The emm typing procedure was performed according to established protocols (Beall et al., 1996). 
Briefly, DNA was extracted from single colonies of GAS and subjected to PCR-amplification 
using primers targeting the N terminal of the emm gene. The PCR products are separated and 
visualized using agarose gel electrophoresis and purified (Appendix 9.6). DNA was extracted using 
the Wizard Genomic DNA Purification Kit (Appendix 9.5) and the DNA quality and quantity 
were determined using the NanoDrop technique. The amplified DNA product was sent to the 
University of Stellenbosch for sequencing according to guidelines by the Centres for Disease 
Control and Prevention (CDC) (https://www.cdc.gov/streplab/protocol-emm-type.html). The 
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BLAST programme (https://www2a.cdc.gov/ncidod/biotech/strepblast.asp) was used to 
compare the DNA sequences with published sequences in the CDC databases. More detailed 
methods are described below in section 3.4. In addition, we also recorded the cluster sequence 
types.  
 
3.3.3.5 Data analysis plan 
The information collected included; date of birth, gender, presenting clinical features, and 
microbiological findings. To protect the privacy of patients a separate database was created that 
contained no specific identifiers. Analysis was conducted using Stata 13 (StatCorp, College Station, 
TX). We evaluated the association between emm type and clinical symptoms by means of a Chi-
square or Fishers exact test. A p value of <0.05 was considered to be statistical significant. 
 
3.3.3.6 Ethics and dissemination 
Ethics approval for the AFROStrep registry was obtained from the Human Research Ethics 
Committee of the University of Cape Town (HREC/REF: R006/2015) (Appendix 9.1). Reports 
and publications emanating from the AFROStrep Registry will not include any information that 
identifies either the patient themselves, their parents or guardians. Participants were identified 
throughout the study duration by the study number allocated to them at the time of enrolment. 
All data are stored on a password-protected computer and handled in the strictest confidence. 
Findings and updates will be disseminated to collaborators, researchers, health planners and 
colleagues through peer-reviewed journal articles, conference publications and proceedings. 
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3.4 emm Typing 
3.4.1 Culture and identification of Beta Haemolytic Streptococci 
Group A streptococcal isolates were stored at -80°C in the AFROStrep laboratory upon receipt at 
the microbiology laboratory at the NHLS. GAS isolates were stored in storage media containing 
microbeads. GAS samples were inoculated on 5% sheep blood agar and incubated for 48 hours at 
37°C, in the presence of 5% CO2. Isolation of streptococcus pyogenes using culture remains the gold 
standard for identification (Murray et al., 1976). Contaminated specimens were sub-cultured on a 
fresh blood agar plate. Isolates confirmed as Lancefield group A were investigated further.  
 
3.4.2 Genomic DNA extraction  
The Wizard Genomic DNA Purification Kit,500 was used to extract DNA from the bacteria. 
Following incubation, single colonies were removed from the agar plate and suspended in 1ml 
nucleus free water, stored in Eppendorf tubes. The protocol for DNA extraction as per the 
instruction of the manufacturer was followed. For a detailed step-by-step guide, see appendix 9.6.  
 
3.4.3 Polymerase chain reaction  
Following the extracted DNA from the previous step in 3.4.2, the emm gene was amplified in 
accordance with the CDC protocol (Beall et al., 1996). This method amplifies a portion of the gene 
using sequence specific primers. These primers, in pairs, bind to either side of the double-stranded 
DNA. The primers used (Table 3.3), were synthesized at the Department of Molecular and Cell 
Biology at the University of Cape Town. Taq Polymerase, the enzyme responsible for the PCR 
amplification, is isolated from the bacterium thermas aquaticus (Saiki et al., 1988)  Taq Polymerase is 
able to survive high temperatures during PCR cycles. To ensure the successful amplification of the 
emm gene, the CDC recommends a combination of reagents at specific concentrations (CDC, 
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2011). PCR reagents comprised 1X buffer, 1.5 mM MgCl2, 0.2 mM dNTP, 70 picomol/Ql of the 
forward and reverse primers and 1.5U of SuperTherm Taq (JMR, Holdings, London UK), and 
then brought to a final volume of 50 Ql with DNAse-free water.  
 
Target gene Primer  Primer Sequence 
Emm gene Primer 1 (forward) TAT T(C/G) GCT TAG AAA ATT AA 
 Primer 2 (reverse) GCA AGT TCT TCA GCT TGT TT 
 Emmseq2 TAT TCG CTT AGA AAA TTA AAA 
ACA GG 
   
During PCR, cycling conditions for amplification of the emm gene involves three principle 
amplification steps; denaturation, annealing and elongation. The cycling conditions for emm typing, 
recommended by the CDC (CDC, 2011) begins with initial denaturation at 94°C for  60 seconds, 
followed by 30 cycles of denaturation at 94°C for 15 seconds, annealing at 46.5°C for 30 seconds 
and extension at 72°C for 75 seconds. An additional 20 cycles followed with denaturation at 94°C, 
annealing at 46.5°C for 30 seconds, extension at 72°C for 75 seconds with a 10 second increment 
in between each of the subsequent 19 cycles. The final extension was carried out at 72°C for 10 
minutes. 
 
3.4.4 Agarose gel electrophoresis 
The technique used to separate DNA fragments, based on their sizes (Stellwagen, 2009) when 
subjected to an electrical current is referred to as electrophoresis. DNA is negatively charged 
because of the phosphate groups on its sugar-phosphate backbone thus migrating to the positive 
end of the agarose gel when an electric current is passed through. The percentage of agarose within 
Table 3.3. Primers used for emm typing 
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the gel determines the pore size; hence different percentages of gels are prepared based on the size 
of DNA fragments to be separated. The larger the DNA fragments, the slower they migrate 
through the agarose gel compared with smaller fragments (Stellwagen, 2009). 
 
Agarose gel electrophoresis was used to separate the DNA fragments following PCR. As the 
expected sizes of emm amplicons range from 750 bp to 1400 bp, a 2% agarose gel was used to 
separate the PCR products. Agarose (SeaKem. LE Agarose, Lanza, USA) was dissolved in 1X 
TAE buffer and ethidium bromide (10 ng/Ql), which intercalates between base pairs of DNA and 
fluoresces under ultraviolet light. Eight microliters (µl) of the PCR product were loaded into each 
well, with 2 Ql of loading dye. The fragments were separated by passing an electric current through 
the agarose for 3 hours of 60V to allow the negatively charged DNA fragments to migrate towards 
the positive electrode. The rate of migration is inversely proportional to the size of the fragments. 
A molecular marker (HyperLadder IV, Bioline, UK) was included to enable estimation of emm 
amplicon sizes.  
 
 
3.4.5 Sequencing and assigning emm types  
DNA purification and sequencing were conducted at the University of Stellenbosch. Sequencing 
of purified DNA was done using the ABI Prism. BigDyeTM Terminator Cycle Sequencing kit 
(Applied Biosystems, USA) at Stellenbosch University, South Africa. The DNA concentration was 
adjusted to 10 ng/Ql for amplicon less than 1000-bp and 20 ng/Ql for amplicons more than 1000-
bp as recommended by the sequencing facility at Stellenbosch University, South Africa. Primer 
emmseq2 (Table 1.1), recommended by the CDC, was prepared to 1.1 ng/Ql and used for 
sequencing reaction (CDC, 2011). Sequences generated were analysed using BioEdit v7.0.9 (Ibis 
Biosciences, USA). The sequences were submitted electronically to the streptococcus pyogenes emm 
sequence database centre at the CDC which assigned all the emm types and subtypes 
(https://www2a.cdc.gov/ncidod/biotech/strepblast.asp). 
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4. CHAPTER FOUR: 
 
STUDY 1:  PREVALENCE OF GROUP A STREPTOCOCCAL 
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4.1 Introduction 
 
The prevalence of severe group A streptococcal (GAS) disease is estimated to be 18.1 million cases 
with an incidence of 1.78 million cases, and is responsible for approximately 517,000 deaths each 
year, globally. As discussed in more detail in the Literature review, chapter 1, section 1.3, the 
burden of GAS-disease remains poorly defined in Africa.  
 
The introduction of safe, effective and affordable vaccines to prevent GAS infections may be the 
most cost-effective method of primary prevention of severe GAS-related diseases. Potential 
vaccine coverage in different geographic regions, especially those with high rates of disease, 
requires a detailed understanding of the molecular epidemiology of GAS infections (Andrew C 
Steer et al., 2009). A sequence based method, emm typing, of the N-terminal region of the M protein, 
widely used in many regions of the world, is the preferred method to study and define the 
molecular epidemiology of GAS strains (Beall et al., 1996). Steer and colleagues, in an earlier 
systematic review, documented the global distribution of emm types of GAS to define prevalent 
strains and to assess the coverage and implications for  the experimental multivalent vaccine 
(Andrew C Steer et al., 2009). One of the main limitations were reported to be the small number 
of studies in regions such as Africa causing a potential bias in the results, and may not be 
generalizable to all countries in this region.  
 
We conducted a systematic review and meta-analysis to investigate the prevalence of GAS disease 
among children and adults in Africa. In addition, we also documented the frequency and 
distribution of emm types among isolates, thereby informing the development of putative vaccines.  
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4.2 Methods 
 
The protocol for this study has been published (Barth et al., 2015) and is registered on PROSPERO 
(International Prospective Register of systematic reviews, registration number CRD42014012900, 
http://www.crd.york.ac.uk/PROSPERO). The detailed methods for this systematic review can be 
found in Chapter 3, section 3.1.  
 
4.3 Results  
 
This systematic review is reported according to the Preferred Reporting Items for Systematic 
reviews and Meta-analysis (PRISMA) guidelines (Moher et al., 2009). The PRISMA checklist can 
be seen in Table 4.4.  
We retrieved 525 articles from searches in electronic databases (Figure 4.1). After screening the 
titles, we excluded 490 articles. We reviewed the abstracts of the remaining articles and further 
excluded articles not relevant to our study; thirty-five articles were identified to be eligible and 
included in the review. Twenty-five articles met inclusion criteria (Ringertz et al., 1993; Ibekwe & 
Okafor 1983; Fourati et al., 2009; Abd El-Ghany et al., 2015; Zegeye et al., 2016; Pius et al., 2016; 
Seale et al., 2016; Engel et al., 2017; Tesfaw et al., 2015a; A. Benouda et al., 2009; Boukadida et al., 
2003; Bassili et al., 2002; Steinhoff et al., 1997; Bélard et al., 2015; Gonsu et al., 2015; Rimoin et al., 
2011; SEDKI et al., 2010; Mezghani Maalej et al., 2010; Olivier & de Graad 1978; van Zyl et al., 
1981; Taplin & Lansdell 1973; Mzoughi et al., 2004; O’Meara et al., 2015; Tewodros et al., 1992; 
Milagritos D Tapia et al., 2015)(Table 4.1). Ten articles (El Kholy et al., 1980; Iroezindu et al., 2014; 
Beekmann et al., 2005; Hraoui, Boutiba-Ben Boubaker, A. Doloy, et al., 2011; A Benouda et al., 
2009; Rimoin et al., 2008; Liebowitz et al., 2003; Rimoin et al., 2010; Engel et al., 2014; Andrew C 
Steer et al., 2009) did not meet inclusion criteria and reasons for exclusion are listed in Table 4.2.   
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Figure 4.1: PRISMA flow diagram  
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4.3.1 Characteristics of included studies 
The included studies comprised twenty-five peer-reviewed journal articles published between 1973 
and 2016 and sample sizes ranging between 47 and 64,671 (Ringertz et al., 1993; Ibekwe & Okafor 
1983; Fourati et al., 2009; Abd El-Ghany et al., 2015; Zegeye et al., 2016; Pius et al., 2016; Engel et 
al., 2017; Tesfaw et al., 2015a; A. Benouda et al., 2009; Boukadida et al., 2003; Bassili et al., 2002; 
Steinhoff et al., 1997; Bélard et al., 2015; Gonsu et al., 2015; Rimoin et al., 2011; SEDKI et al., 2010; 
Mezghani Maalej et al., 2010; Olivier & de Graad 1978; van Zyl et al., 1981; Taplin & Lansdell 1973; 
Mzoughi et al., 2004; O’Meara et al., 2015; Tewodros et al., 1992; Milagritos D Tapia et al., 2015; 
Seale et al., 2016) (Table 4.1). Of these, 22 were cross-sectional study designs (n=73,311), while 3 
were longitudinal studies (n= 2,138). The age distribution aged from 1 day to 92 years. 
Microbiological culture was used to identify cases of GAS. Studies were conducted in 
clinics/outpatient departments, and in schools.  
 
All the studies were conducted across the African continent:  Southern Africa (3 studies, n= 1326 
(Olivier & de Graad 1978; Engel et al., 2017; van Zyl et al., 1981)), North Africa (10 studies, 5018 
(Abd El-Ghany et al., 2015; Boukadida et al., 2003; A. Benouda et al., 2009; Bassili et al., 2002; 
Fourati et al., 2009; Mezghani Maalej et al., 2010; Mzoughi et al., 2004; Rimoin et al., 2011; SEDKI 
et al., 2010; Steinhoff et al., 1997)),  East Africa  (7 studies, n=67,015 (Ringertz et al., 1993; O’Meara 
et al., 2015; Taplin & Lansdell 1973; Tesfaw et al., 2015a; Tewodros et al., 1992; Zegeye et al., 2016; 
Seale et al., 2016)), West Africa (3 studies, n=1931 (Ibekwe & Okafor 1983; Milagritos D Tapia et 
al., 2015; Pius et al., 2016)), Central Africa (2 studies, n=159 (Bélard et al., 2015; Gonsu et al., 2015). 
Studies were done in urban, rural and semi-urban areas.  
 
Among the studies included in this review, only 3 reported the molecular characterisation of GAS 
isolates (Engel et al., 2014; Milagritos D Tapia et al., 2015; Seale et al., 2016). All studies employed 
emm typing methods to determine the molecular epidemiology of GAS isolates.  
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A list of excluded studies and reasons for exclusion can be found in Table 4.2.  
 
4.3.2 Investigating Heterogeneity 
Given the notably large heterogeneity, I2= 96.3% (95% CI, 95% to 97%), we conducted a 
sensitivity analysis to assess the influence of various study characteristics such as quality of the 
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Table 4.1. Characteristics of included studies  
Study ID Region Countr
y 





Population description Inclusion criteria Selection 
Methods 





Egypt longitudinal Pediatric outpatient clinic in a 
Children’s Hospital, Cairo, 
Egypt 
Urban Children attending 
outpatient clinic 
Fever, sore throat and 
unequivocal erythema of the 





4 - 16 years 
Bassili 2002 Northern 
Africa 
Egypt cross-sectional Private health clinics (Higher 
SES) /Public Health Service 
(Lower SES) in Alexandria 
Urban Children attending private 
and public health services 
in Alexandria, Egypt  
Sore throat and or difficulty 
swallowing  
Systematic 
randon sampling  
Public and Private 
health clinics 
1 - 15 years 
Bassili 2002 Northern 
Africa 
Egypt cross-sectional Private health clinics (Higher 
SES) /Public Health Service 
(Lower SES) in Alexandria 
Periurban Children attending private 
and public health services 
in Alexandria, Egypt  
Sore throat and or difficulty 
swallowing  
Systematic 
randon sampling  
Public and Private 
health clinics 
1 - 15 years 
Bassili 2002 Northern 
Africa 
Egypt cross-sectional Private health clinics (Higher 
SES) /Public Health Service 
(Lower SES) in Alexandria 
Rural Children aged attending 
private and public health 
services in Alexandria, 
Egypt  




Public and Private 
health clinics 
1 - 15 years 
Bélard 2015 Central 
Africa 
Gabon cross-sectional Rural and urban areas within 
the province of Moyen-
Ogooué. 
Rural children and adults (pre-
school, school and adults) 
Sore throat; (1) provision of 
written informed consent and (2) 






sampling took place at 
the participants’  








cross-sectional Four primary health care in 
Rabat and 
Sale cities 
NS Children and adults 
presenting to primary 
health clinics 
Children and adults seen by a 
doctor who proposed treatment 
for a sore throat infection 
convenience 
sampling 





Tunisia cross-sectional Three primary health care 
centres in Sousse, Tunisia 
NS Anyone presenting to one 
of three clinics with a sore 
throat 
All children older than 3 years 












    
NS 




cross-sectional 3 community clinics in Langa 
and Bonteheuwel, Cape Town 
and South Africa. 
Urban children 3–15 years of age 
who presented with sore 
throat 
Sore throat convenience 
sampling 





Tunisia cross-sectional Emergency department and 
walk-in clinics - multicentre 
NS 
 
Children with pharyngitis convenience 
sampling 
Public Health Centres 3 - 17 years 




cross-sectional Paediatric Ear, Nose and 
Throat units of the University 
Teaching Hospital and the 
Central Hospital, Yaounde  
NS Cases presenting at a 
Paediatric Hospital 
3 to 72 years consulting for 






16 - 72 years 
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Study ID Region Countr
y 





Population description Inclusion criteria Selection 
Methods 
Site of recruitment Age(s) 
Maalej 2010 Northern 
Africa 
Tunisia cross-sectional Primary health care clinic NS Children attending a 
primary health care clinic in 
Tunisia. 
Sore throat convenience 
sampling 
Public health care 
clinic 





Tunisia cross-sectional Two paediatric outpatient 
clinics in Sousse (Lower SES) 
NS Children attending two 
paediatric outpatient clinics 
in Tunisia 
Sore throat convenience 
sampling 
Two paediatric 
outpatient clinics in 
Sousse (Lower SES) 





Kenya longitudinal rural village, 52% households 
fall below the poverty line 
(Lower SES) 
Rural  Children attending the 
outpatient department of 
Webuye District Hospital 
(WDH) 




1 - 12 years 




cross-sectional Outpatient clinic in 
Bloemfontein 
periurban Children with sore throat Sore throat convenience 
sampling 
Outpatient clinic 2 - 19 years 
Pius 2016 Northern 
Africa 
Nigeria cross-sectional Special care baby unit, 
hospital 
NS Neonates admitted to the 
SCBU who were at risk for 
sepsis or had presumptive 
diagnosis of NNS  
(1) preterm/ term neonates with 
clinical features suggestive of 
NNS, (2) presence of maternal 
perinatal risk factors for 
septicaemia, (3) history of 
unclean delivery and poor cord 
care and (4) consent. 
convenience 
sampling 
Special care baby unit, 
hospital 





Egypt longitudinal Pediatric outpatient clinic in 
Egypt (Lower SES) 
Urban children presenting to a 
pediatric outpatient clinic in 
Egypt 











cross-sectional Rural and Urban public health 




Sore throat convenience 
sampling 
Health care centres < 5 years 
Seale 2016 Northern 
Africa 
Kenya cross-sectional Rural Kilifi County Hospital 
in coastal Kenya (Lower SES) 
Rural cases of invasive GAS 
admitted to Kilifi County 
Hospital. 
Cases of invasive GAS infection convenience 
sampling 
Kilifi County Hospital 
in Kenya 
0 - 12 years 
Sedki 2010 Southern 
Africa 
Egypt cross-sectional Rural region of Eastern Cairo 
- Outpatient health centre and 
school dispensary room 
Rural Children with clinical 
diagnoses of non-treated 
acute pharyngitis 
1-Child presenting with acute 
pharyngo-tonsillitis. 





clinic of health centre 
or the school 
dispensary room) 





Egypt cross-sectional Urban Outpatient clinic of the 
Abu Reesh Children’s 
Hospital, University of Cairo 
Urban Children who presented 
with sore throats to the 
outpatient clinic of the Abu 
Reesh Children’s Hospital, 
University of Cairo 
 
 
history of sore throat; 
unequivocal erythema of the 
pharynx; and parental consent 





2- 13 years 
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Study ID Region Countr
y 





Population description Inclusion criteria Selection 
Methods 
Site of recruitment Age(s) 
Tapia 2015 Western 
Africa 
Mali cross-sectional Four public schools (Lower 
SES)  
Periurban Children attending one of 
four public schools in Mali.  




Four public schools 5 - 16 years  
Taplin 1973  Southern 
Africa 
Uganda cross-sectional not stated but assumed Rural 
setting 
NS Infants and school children 
(no further information 
given).  







cross-sectional Two Public health centres in 
Jimma 
Periurban children years with 
pharyngitis presenting at 
two Health Centers in 
Jimma town 
Sore throat convenience 
sampling 







cross-sectional three public elementary 
schools located near a 
paediatric teaching hospital, 
located in the centre of Addis 
Ababa. 
periurban Children attending three 
elementary schools 









Pretoria cross-sectional Outpatient hospital and two 
private practices  
Urban Children and adults with 
sore throat 
Sore throat convenience 
sampling 
Outpatient hospital 
and two private 
practices  







cross-sectional Pediatric Cardiac Clinic of 
TASH in Addis Ababa, 
Ethiopia 
Both Children on secondary 
prophylaxis for RHD 
participated in this study 
children who were on 
secondary prophylaxis for RHD 





as they came to the 
cardiac clinic for their 
follow up appointment 
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Table 4.2. List of excluded studies 
Author  Year Title  
 
Reason for exclusion 
Hraoui  2011 Epidemiological markers of Streptococcus pyogenes strains in Tunisia No Denominator/Not population-based 
Steer  2009 Global emm type distribution of group A streptococci: systematic review and implications for 
vaccine development. 
No denominator 
Liebowitz 2003 National surveillance programme on susceptibility patterns of respiratory pathogens in South 
Africa: moxifloxacin compared with eight other antimicrobial agents 
No denominator 
El Kholy  1980 A controlled study of penicillin therapy of group A streptococcal acquisitions in Egyptian 
families. 
Objective of study not applicable 
Iroezindo  2014 Sputum bacteriology and antibiotic sensitivity patterns of community-acquired pneumonia in 
hospitalized adult patients in Nigeria: a 5-year multicentre retrospective study. 
Denominator not representative of the 
population 
Beekmann 2005 Antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, Moraxella 
catarrhalis and group A -haemolytic streptococci in 2002–2003 
No denominator 
Rimoin  2008 Variation in Clinical Presentation of Childhood Group A Streptococcal Pharyngitis in Four 
Countries 
Duplicate study data. Chose later version 
Engel  2014 Group A Streptococcal emm Type Prevalence among Symptomatic Children in Cape Town and 
Potential Vaccine Coverage 
Duplicate study data. Chose later version 
Rimoin  2010 The utility of rapid antigen detection testing for the diagnosis of streptococcal pharyngitis in 
low-resource settings. 
Duplicate study data. Chose later version 
Benouda  2009 Antimicrobial Resistance of Respiratory Pathogens in North African Countries Duplicate study data. Chose later version 
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4.3.3 Assessment of risk bias in included studies  
Risk of bias was assessed using the Hoy criteria as modified by Werfalli and colleagues (Hoy et al., 
2012; Mahmoud Werfalli et al., 2014). Twelve studies had a low risk of bias (Bassili et al., 2002; 
Bélard et al., 2015; Boukadida et al., 2003; Mezghani Maalej et al., 2010; Milagritos D Tapia et al., 
2015; Tewodros et al., 1992; Steinhoff et al., 1997; SEDKI et al., 2010; Gonsu et al., 2015; van Zyl 
et al., 1981; Olivier & de Graad 1978; Engel et al., 2017), Twelve had a moderate risk of bias (A. 
Benouda et al., 2009; Abd El-Ghany et al., 2015; Mzoughi et al., 2004; O’Meara et al., 2015; Rimoin 
et al., 2011; Ringertz et al., 1993; Tesfaw et al., 2015; Pius et al., 2016; Zegeye et al., 2016; Milagritos 
D Tapia et al., 2015; Fourati et al., 2009; Seale et al., 2016)  and one study was deemed to have a 
high risk of bias (Ibekwe and Okafor, 1983)(Figure 4.2, Table 4.3).  
 
Figure 4.2. Risk of Bias Chart. 
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Table 4.3. Summary of risk of bias evaluation 





































Risk of bias 
Abd El-Ghany  2015 NCS NCS 0 1 1 1 1 1 1 1 7 Moderate 
Bassili 2002 1 1 1 1 1 1 1 1 1 1 10 Low 
Bélard 2015 1 1 0 1 1 1 1 1 1 1 9 Low 
Benouda 2009 NCS NCS 0 1 1 1 1 NCS 1 1 6 Moderate 
Boukadida 2003 1 1 0 1 1 1 1 1 1 1 9 Low 
Maalej 2010 1 1 0 1 1 1 1 1 1 1 9 Low 
Tapia 2015 1 1 0 1 1 1 1 1 1 1 9 Low 
Mzoughi 2004 NCS 1 0 1 1 1 1 1 1 0 7 Moderate 
O’Meara 2015 0 1 0 1 1 1 1 1 1 1 8 Moderate 
Rimoin 2011 0 0 0 1 1 1 1 1 1 1 7 Moderate 
Ringertz 1993 1 1 0 1 1 NCS 1 1 NCS 1 7 Moderate 
Steinhoff 1997 1 1 0 1 1 1 1 1 1 1 9 Low 
Tesfaw 2015 NCS NCS 0 1 1 1 1 1 1 1 7 Moderate 
Tewodros 1992 1 1 0 1 1 1 1 1 1 1 9 Low  
Zegeye 2016 0 1 0 1 1 1 1 1 1 1 8 Moderate 
Ebekwe 1983 NCS NCS 0 1 1 NCS NCS 1 NCS 1 4 High 
Pius 2016 0 1 0 1 1 1 1 1 1 1 8 Moderate 
Seale 2016 0 1 0 1 1 1 1 1 1 1 8 Moderate 
Gonsu 2015 1 1 0 1 1 1 1 1 1 1 9 Low 
Fourati 2009 NCS NCS 0 1 1 1 1 1 NCS 1 6 Moderate 
Sedki 2010 1 1 0 1 1 1 1 1 1 1 9 Low  
Taplin 1973 NCS NCS 0 1 1 1 1 1 NCS 1 6 Moderate 
Engel 2016 1 1 0 1 1 1 1 1 1 1 9 Low  
Olivier 1978 1 1 0 1 1 1 1 1 1 1 9 Low  
Van Zyl 1981 1 1 0 1 1 1 1 1 1 1 9 Low  
NCS. Not clearly stated 
Quality score: 0-5 high risk of bias; 6-8 moderate risk of bias; >8 Low risk of bias 
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4.3.4 Prevalence of included studies  
 
4.3.4.1 Overall  
The prevalence of GAS in 25 studies, (n=75,449) among patients aged between 2 months and 92 
years, presenting with pharyngitis, skin infection, fever, rheumatic fever and rheumatic heart 
disease living in Africa are shown below (Figure 4.3). One study comprised two groups of 




ES, effect size; CI, confidence interval; N, denominator; n, number  
Figure 4.3. Studies included in the systematic review 
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4.3.4.2 Invasive Disease 
Two studies (n=64,781) reported respective prevalence estimates of 5% and 0,6% (Pius et al., 2016; 
Seale et al., 2016) in GAS isolated from normally-sterile sites including blood, CSF and soft tissue.  
 
4.3.4.3 Non-invasive Disease 
 
Skin infections 
A single study reported on skin infections consisting of 86 participants with a prevalence of 74% 
(95% CI, 64% to 82%).  
 
Pharyngitis 
Twenty-two studies reported on the prevalence of GAS pharyngeal isolation and were considered 
for meta-analysis. All data synthesis in this review will be based on GAS pharyngitis.  
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4.3.5 Data synthesis: GAS Pharyngitis 
 
4.3.5.1 Overall  
The overall pooled prevalence estimate for GAS pharyngitis was 21% (95% CI, 17% to 26%; 22 
studies, n=10,520) for streptococcal pharyngitis among people within the age range of 2 months 




ES, effect size; CI, confidence interval; N, denominator; n, number  
Figure 4.4. Pooled estimate of GAS Pharyngitis prevalence in Africa 
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4.3.5.2 Regional Analysis 
The map below (Figure 4.5) shows the countries that contributed data to this systematic review.  
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4.3.5.3 Regional analysis: Pharyngitis  
The pooled prevalence estimates in North Africa were similar to a single study in West Africa, 
25% (95% CI, 19% to 31%) and 26% (95% CI, 24% to 26%) respectively. Southern regions had 
a pooled prevalence estimate of 32% (95% CI, 19% to 46%).  Central and East African regions 
had the lowest prevalence’s of 11% (95% CI, 7% to 17%) and 14% (95% CI, 6% to 23%; age 
range of 2 months - 92 years; I2= 95.40% (Figure 4.6).  
 
 
ES, effect size; CI, confidence interval; N, denominator; n, number  
Figure 4.6. Regional analysis: pharyngitis 
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4.3.5.4 Urban vs rural: Pharyngitis 
The pooled prevalence estimates by rural, peri-urban and urban geographical settings were 12% 
(95% CI, 2% to 29%), 29% (95% CI, 19% to 40%) and 32% (95% CI, 24% to 40%) respectively. 
Studies reporting prevalence estimates in both urban and rural geographical regions had a pooled 
prevalence estimate of 14% (95% CI, 12% to 16%); this difference was statistically significant, 
(P<0.0001). (Figure 4.7) 
 
ES, effect size; CI, confidence interval; N, denominator; n, number  
Figure 4.7. Setting: pharyngitis analysis 
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4.3.5.5 Age range: Pharyngitis 
Patients <18 years old had a pooled prevalence estimate of 22% (95% CI, 18% to 26%) and 
patients >18 years old had a pooled prevalence estimate of 21% (95% CI, 11% to 34%); this 




ES, effect size; CI, confidence interval; N, denominator; n, number  
Figure 4.8. Age analysis: pharyngitis 
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4.3.5 Sensitivity analysis 
 
4.3.6.1 Sample size: Pharyngitis 
Studies considered to be adequately powered had a prevalence estimate of 20% (95% CI, 15% to 
27%). In comparison, studies considered to be inadequately powered had a prevalence of 22% 




ES, effect size; CI, confidence interval; N, denominator; n, number  
Figure 4.9. Sample size analysis: pharyngitis 
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4.3.6.2 Quality: Pharyngitis  
When considering quality assessment among pharyngitis cases, studies considered having a low 
risk of bias studies (n=12) had a pooled prevalence of 27% (95% CI, 23% to 32%) and those who 
had a moderate risk of bias (n=10) had a pooled prevalence of 15% (95% CI, 10% to 22%); this 
difference was statistically significant (P<0.0001) (Figure 4.10). 
 
 
ES, effect size; CI, confidence interval; N, denominator; n, number  
Figure 4.10. Quality of the studies: pharyngitis 
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4.3.7 Molecular characterisation of symptomatic group A streptococcus isolates  
 
Two included studies reported on the molecular characterisation of GAS pharyngitis (Engel et al., 
2014; Tapia et al., 2015). The first study observed 26 different emm types; the most prevalent was 
emm48 which accounted for 15% of the total isolates. The most prevalent emm types were emm48, 
emm89, emm4, emm12, emm75, emm1, emm94, emm22, emm9 and accounted for 73% of isolates typed. 
These GAS isolates showed a 65% coverage with an additional 23% cross-reactivity compared 
with current 30-valent vaccine formulation. The second study observed 70 different emm types; 
most prevalent being emm65 which accounted for 5.6% of the total isolates typed. The most 
prevalent types were emm65 emm18 emm55 emm42 emm81 emm58 emm25 emm109 emm11 emm169 
emm89 emm77 emm75 emm64, representing 49% of the total isolates. These GAS isolates showed a 
31% vaccine coverage and 44.1% emm cross-reactivity. One study reported on the molecular 
characterisation of invasive GAS disease (Seale et al., 2016), observing 88 different emm types in 
the study population. No emm type represented >5% of the total isolates and showed a 28% 
coverage and 29% emm cross-reactivity.  
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4.4 Discussion 
 
This systematic review is the first comprehensive synthesis of the prevalence of group A 
streptococcus infection, particularly GAS pharyngitis, among people living in Africa.  
 
There are three important findings: (1) There is a high prevalence of GAS pharyngitis among 
people living in Africa, (2) There are regional differences with Central Africa having a significantly 
lower prevalence of GAS compared with the North, Southern and West African regions, (3) There 
are geographical differences; urban settings have a significantly higher prevalence rate compared 
with rural settings.  
 
 The pooled prevalence of GAS pharyngitis in Africa was determined to be 21% (95% CI, 13% to 
30%). A single study reported on the prevalence of GAS skin infections with a prevalence of 74% 
(95% CI, 64% to 82%). Two studies, reporting on the molecular characterisation of GAS 
pharyngitis, showed a vaccine coverage and cross-reactivity of 75% and 88% respectively, with 
reference to a 30-valent vaccine currently under development. A single study reporting on the 
molecular characterisation of invasive GAS (iGAS) indicated a low coverage (28%), and cross-
reactivity (29%), together providing a potential coverage of 57%. In addition, given the paucity of 
iGAS studies highlighted in this review, we conducted a prospective surveillance study to collect 
information on iGAS infection (Chapter 5).  
 
Shaikh and colleagues, in an earlier systematic review, reported pooled prevalence estimates of 
37% (95% CI, 32% to 43%) and 24% (95% CI, 21% to 26%) in children among all ages and those 
younger than 5 years respectively, presenting with pharyngitis and residing in low, middle and high 
income countries (Shaikh et al., 2010). A single study in this review from Egypt, reported a higher 
prevalence estimate of 27% (95% CI, 25% to 30%). Our pooled estimate of 21% (95% CI, 17% 
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to 26%) for GAS pharyngitis, indicates that the prevalence of GAS infection remains high among 
African people.  
In a review by Steer et al, the emm types included in the reformulated vaccine covered less than 
65% of all isolates in four regions; Middle East, Asia, Pacific region and with particularly poor 
coverage in Africa (Andrew C Steer et al., 2009).  
 
Central Africa had the lowest pooled prevalence of 11% (95% CI, 7% to 17%) and contrasted 
significantly with pooled prevalence rates in the North (25%), Southern (32%), and West African 
(26%) regions. Of interest, compared with pooled prevalence estimates of GAS carriage, West 
African regions had a significantly lower prevalence compared with other regions (Moloi, 2015).  
 
We considered the impact of geographical setting on the overall prevalence estimates of GAS in 
Africa. Urban and peri-urban settings had a similar prevalence of 32% and 29% respectively. As 
expected, a pooled prevalence estimate of 12% (95% CI, 2% to 29%) in rural settings, were lower 
than urban settings, and may be explained by the socioeconomic factors which influence infection 
such as overcrowding and the lack of suitable housing etc. (Factor et al., 2003).  
 
We also considered the effect of age on prevalence estimates and found no significant difference 
between older and younger people living in Africa. This finding was unexpected given that GAS 
pharyngitis is thought to be most commonly observed in younger children between the ages 5 - 
15 years old ( Carapetis, Steer, et al., 2005; Shulman et al., 2012; Steer et al., 2009).  
 
Our study results were robust when considering the impact of sample size on pooled prevalence 
estimates using n=796 as a cut-off as recommended by Daniel W (Daniel, 1999). Studies 
considered to be adequately powered had a slightly lower pooled prevalence estimate of 20% (95% 
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CI, 15% to 27%), compared with those considered not adequately powered, 22% (95% CI, 16% 
to 28%).  
We also considered the impact of quality of included studies for GAS Pharyngitis. Studies with a 
moderate risk of bias had significantly lower prevalence estimate of 15% (95% CI, 10% to 22%) 
compared with those of low risk of bias, 27% (95% CI, 23% to 32%). This finding suggests our 
overall pooled results may underestimate the prevalence of GAS pharyngitis in Africa. 
 
This systematic review provides further evidence for the high burden of disease caused by GAS 
infection in Africa, thus providing support for a vaccine. The direct and indirect costs of GAS 
disease in the US alone in 2005 were in excess of 2 billion dollars per year (A. L. Bisno et al., 2002). 
A GAS vaccine would undoubtedly be a cost effective primary level intervention to prevent GAS 
infections. Currently, a 30-valent vaccine (reformulated from a 26-valent vaccine) based on the 
variable N-terminal regions of the surface M protein of GAS is being developed  (Dale et al., 2011).  
 
One of the main strengths of this review is attributed to multiple databases searched, using an 
African search filter and a robust approach to the meta-analysis of the data. We systematically and 
purposefully assessed all the data available with no language exclusions, using the most recently 
published standard quality assessment tools for prevalence studies. A limitation to the results of 
our systematic review is the significant heterogeneity in the prevalence estimates produced in the 
meta-analysis, however, this is expected when pooling prevalence studies. We made use of the 
Freeman-Tukey double arc-sine transformation to stabilise the variance of primary studies before 
pooling, thus limiting the impact of studies with either small or large prevalence on the overall 
pooled estimates, as well as across major subgroups (Nyaga et al., 2014).  
 
Attempts to fully explain the heterogeneity was unsuccessful in terms of subgroup analyses. Given 
the variance of standardised epidemiological and laboratory efforts used in various studies, 
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comparisons between populations, and conclusions about the differences in prevalence rates 
should be made with caution. We also intended to perform sub-analysis of GAS colonization risk 
factors including crowding, gender and seasonality; however, due to data limitations, these could 
not be performed. 
 
Our results, which we believe are an underestimate of the true prevalence of GAS pharyngitis, 
confirm the high prevalence of GAS infections in Africa, warranting the need for new and 
improved prevention strategies which include well-functioning disease registries such as 
AFROStrep (Barth et al., 2016) to collect robust clinical, microbiological and molecular data. 
Improved rapid diagnostic tools and the need for training health care professionals with updated 
clinical prediction rules is vital to reduce the prevalence of pharyngitis due to missed diagnoses. 
Regional data were scarce on differences and associated risk factors, and thus studies are needed 
to provide these missing figures. Our findings support the call for the development of a vaccine 
as a primary preventative measure in attempt to reduce the burden of GAS diseases in Africa and 
around the globe ( Dale et al., 2011; Steer et al., 2009).  
 
Chapter 4: Prevalence of group A streptococcal disease in Africa: Systematic review 
PhD Thesis: Dylan D Barth 106 
Table 4.4. PRISMA checklist 
Section/topic  # Checklist item  Reported on page #  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  80 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and 
interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic 
review registration number.  
81 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  62 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and 
study design (PICOS).  
63 
METHODS   
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration 
information including registration number.  
63 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication 
status) used as criteria for eligibility, giving rationale.  
65 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in 
the search and date last searched.  
64 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.  64 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-
analysis).  
66 
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and 
confirming data from investigators.  
66 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.  64 
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Risk of bias in individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or 
outcome level), and how this information is to be used in any data synthesis.  
67 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  68 




Page 1 of 2  
Section/topic  # Checklist item  Reported on page #  
Risk of bias across studies  15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within 
studies).  
67 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-
specified.  
69 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally 
with a flow diagram.  
83 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the 
citations.  
86 – 88 
Risk of bias within studies  19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).  91 
Results of individual 
studies  
20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) 
effect estimates and confidence intervals, ideally with a forest plot.  
92 – 98 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.  92 – 98 
Risk of bias across studies  22 Present results of any assessment of risk of bias across studies (see Item 15).  90 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).  99 – 100 
DISCUSSION   
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., 
healthcare providers, users, and policy makers).  
102 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, 
reporting bias).  
104 
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Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future research.  105 
FUNDING   




From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. 
doi:10.1371/journal.pmed1000097  
For more information, visit: www.prisma-statement.org.  
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5. CHAPTER FIVE: 
STUDY 2:  INVASIVE AND NON-INVASIVE GROUP A Β-
HAEMOLYTIC STREPTOCOCCAL INFECTIONS IN PATIENTS 
ATTENDING PUBLIC SECTOR FACILITIES IN SOUTH 
AFRICA: 2003 - 2015 
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5.1 Introduction 
 
Increases in the annual number of cases for invasive GAS (iGAS) and non-invasive GAS (non-
iGAS) diseases have been observed globally since the 1980s. In the United Kingdom, a report 
from routine surveillance data indicate a significant increase of invasive GAS isolates from 
December 2008 (n=143) compared to the same period in 2007 (n=86) (Lamagni et al., 2009). The 
reasons for these observations are not clearly understood and have subsequently caused many 
countries to commence active surveillance systems for invasive GAS to document the 
epidemiology of the disease. However, data from the Centers for Disease Control and Prevention 
surveillance programme reported stable incidence rates for invasive GAS disease from 1996 – 
1999, and from 2002 – 2009 (O’Loughlin et al., 2007; Stockmann et al., 2012). 
 
The incidence and prevalence of both invasive and non-invasive GAS infections in developing 
countries are largely unknown (Carapetis et al., 2005). The aim of this study was to describe the 
epidemiology of iGAS and non-iGAS infection and associated clinical characteristics in the public 
sector of South Africa, over a recent 13-year period (2003 – 2015).  
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5.2 Methods 
 
The detailed methods for this study are described in Chapter 3, section 3.2. Briefly, we performed 
a retrospective analysis of iGAS and non-iGAS cultured at the National Health Laboratory Service 




Clinical characteristics  
The clinical characteristics of patients with iGAS infection and non-iGAS are presented in Table 
5.1. For the period between 2003 and 2015, 10,091 GAS isolates were recovered from South 
African patients. Sources of isolates included blood, CSF, abscesses, joint aspirates, pleural fluid, 
burn swabs, ear, eye and pus swabs (Table 5.2). Blood and aspirates were common sources of 




When considering the GAS data at a provincial level, a number of anomalous data collection trends 
were highlighted. The Northern Cape Province represented 0.4% of the total GAS infections in 
South Africa over the study period; data were missing for years 2005, 2008-2009, 2011-2013), 
(Figure 5.1.)  In the Western Cape, low reporting rates were seen for the first 11 years of the study 
period, followed by major peaks in reporting rates in 2014 and 2015, (Figure 5.1.)  In Gauteng, the 
overall number of GAS reported over the study period was low considering it has the largest 
population compared to other provinces in South Africa. The very low number of cases in 2013 
and 2015 is also notable, (Figure 5.1). The Free State province showed low reporting of GAS in 
2005, 2008 – 2011, (Figure 5.1). 
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The provinces of Limpopo and the North West show similar patterns of reporting with many 
cases reported in the beginning of the study period followed by a decline after 2006 and almost no 
data reported after 2011, (Figure 5.1). The Mpumalanga province also showed inconsistent 
reporting with a peak in 2011 followed by almost no data thereafter. Kwazulu-Natal recorded the 
least number cases of GAS in South Africa (n=34) despite it being home to the second largest 
population, after Gauteng. It must be noted that the Kwazulu-Natal province was the last to be 
integrated into the NHLS electronic system, with reporting only commencing in the later years. 
The Eastern Cape province accounted for 52% of the total GAS cases throughout the country 
(Figure 5.1).  
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Figure 5.1. GAS isolation by Province 
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GAS Disease incidence in South Africa 
The provincial level data revealed a low ascertainment and inconsistent reporting practices of GAS 
infections throughout the study period and we were unable to determine any variation in IRs of 
GAS over the study period across the provinces. The Eastern Cape was the only province with 
complete data for each of the years within the study period, thus making it possible to evaluate 
incidence rates and describe trends of GAS infection over the study period.   
 
GAS Disease incidence in Eastern Cape only 
The mean annual IR for GAS infection was 6.00 cases per 105 py. The annual IR decreased 
significantly from 2003 to 2015 from 12.04/105 py to 0.45/105 py (rate difference (RD), 11.59/105; 
95% (CI, 10.73/105; 12.45/105) (Figure 5.2). Twenty-eight percent of isolates (n=1,474) were from 
patients younger than 18 years of age, 58% from patients (n=3,014) aged 18 – 64 years and, 14% 
(n=722) from those older than 64 years. The mean age was 30 years; Range, 2 days – 102 years). 
The mean age-specific IRs were as follows:  <18 years, 3.62/105 py; 18-64 years, 7.29/105 py; ≥65 
years, 14.06/105 py. The increase in IRs with age was apparent in both the iGAS, and non-iGAS 
sub-sets of patients (Table 5.1).  
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Figure 5.2. Annual GAS incidence rates among 5, 256 patients with invasive and non-
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Table 5.1. Year of isolation, age and sex of the 10,091 cases with invasive and 
non-invasive group A streptococcal infection, South Africa, 2003-2015 
Year of isolation N (%) 
2003 1079 (10.7) 
2004 915 (9.1) 
2005 931 (9.2) 
2006 959 (9.5) 
2007 640 (6.3) 
2008 301 (3.0) 
2009 571 (5.7) 
2010 628 (6.2) 
2011 683 (6.8) 







Patient age, years  
< 18 






Male 5080 (51.4) 
Female  4809 (48.6) 
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Table 5.2. Source of isolates taken from the 10,091 patients with invasive and  
non-invasive group A streptococcal infection, South Africa, 2003-2015 
  
Source of Isolate N (%) 
  
Invasive GAS * 1,646 (16) 
Blood culture 
Other aspirates 
Pleural fluid            





Joint aspirate  41 (0.4) 
Intra-abdominal fluid  
Biopsy 












Burn swab          474 (4.7) 
Ear swab 366 (3.6) 
Wound swab 147 (1.5) 
Sputum 142 (1.4) 





Other sites (≤5 cases) 123 (1.2) 
* data shown for sites where number of isolates > 5 per site.  
N, number; GAS, Group A Streptococcus 
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Four hundred and twenty-eight cases of iGAS isolates (8% of total GAS cases in the Eastern Cape) 
were documented in the NHLS database. A multi-modal curve was observed over the study period 
(Figure 5.3), with a mean annual IR of 0.48 cases per 105 py (mean age, 27 years; Range, 2 days – 
84 years).  
Over the study period, there was a decrease in the annual IR, RD, 0.23/105 py; 95% CI, 0.02 - 0.44 
/105 py. Breakdown by age-specific categories was 36% among those <18 years of age, 51%, 18 – 
64 years, and 13%, ≥ 65 years. The mean age-specific IRs for iGAS were as follows:  < 18 years, 
0.38/105 py; 18-64 years, 0.52/105 py; >65 years, 1.03/ 105 py. The IRs remained stable between 
2003 and 2012, with slight increases and decreases. The IR for iGAS peaked in 2014 followed by 




Four thousand eight hundred and twenty-eight cases making up 92% of the dataset met with the 
case definition for non-iGAS. The mean age was 31 years (Range, 2 days – 102 years); GAS 
isolation for age-specific categories were 28%, <18 years of age, 58%, 18 – 64 years and 14%, ≥ 
65 years (Table 5.3).  
Mean annual incidence rates for non-iGAS were 5.48 cases per 105 py. Over the complete study 
period, there was a decrease in the rate of infections, RD, 11.36/105 py; 95% CI, 10.53 - 12.19/105 
py. The mean age-specific IRs for non-iGAS were as follows (Table 5.3): <18 years, 3.24/105 py; 
18-64 years, 6.77/105 py; >65 years, 13.03/105 py.   A multi-modal shaped curve for incidence was 
observed; GAS IRs declined steadily from the beginning of the study period to 2008. This was 
followed by a slight increase before steadily declining to the end of the study period. There was a 
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marked decline in the numbers of GAS organisms isolated in 2008 and 2013 (Figure 5.3). The 
Mann-Kendall test and the Theil-Sen estimator showed a significant decreasing trend in the 
incidence of non-iGAS infection over the study period (P=0.002) (Table 5.4).  
 
Table 5.3. Mean age-specific incidence rates of GAS, Eastern Cape, 2003-2015 
 
Age Category (yr) Total 
<18 18 – 64 ≥ 65 
 
Mean IR 
All GAS n (%) 1474 (28) 3014 (58) 722 (14) 
 
5210 (100) 
IR (per 105 py) 3.62 7.29 14.06 
 
6.00 
Invasive GAS n (%) 153 (36) 214 (51) 53 (13)  420 (100) 
IR (per 105 py) 0.38 0.52 1.03  0.48 
Non-invasive GAS n 
(%) 
1321 (28) 2800 (58) 669 (14)  4790 (100) 
IR (per 105 py) 3.24 6.77 13.03  5.48 
yr, years;  n, number;  IR, Incidence rate;  py, person-years 
Age data were not available for n=31 (0.99%)  
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Figure 5.3. Annual Incidence rates of invasive and non-invasive group A streptococcal (GAS) 
infection. Eastern Cape, South Africa, 2003-2015  
 
 




Table 5.4:  Mann-Kendall trend test and Sen slope estimation for GAS infection in the 

































































































Annual invasive & non-invasive GAS incidence rates in Eastern Cape
NON-INVASIVE GAS INVASIVE GAS
GAS infection Mann-Kendall Sen estimation (median change (95% CI)) 
Invasive GAS P = 0.2 -0.01 (-0.03 to 0.01) 
Non-invasive GAS P = 0.002 -0.65 (-0.82 to -0.50) 
CI, confidence interval 
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5.4 Discussion 
 
We sought to determine the incidence of GAS infection in all the provinces of South Africa. 
However, incomplete data were pervasive, with the Eastern Cape province being the only one with 
information for all the years under review, and accounted for 52% of the isolates collected in this 
study. Therefore, the incidence study was confined to the Eastern Cape. 
 
The incidence rates (IR) of laboratory-confirmed iGAS and non-iGAS infection reported in the 
Eastern Cape Province of the South African public sector appears to have declined over the last 
13 years. Specimens were retrieved from a variety of sources, the bulk of which were pus swabs, 
blood and urine samples. Of interest, the age-specific IRs increased with increasing age category, 
with those older than 65 years having the highest IR of 14.06 per 105 person-years. Non-iGAS 
infections showed a statistically significant decrease over the study period. 
The laboratory data, retrieved from the National Health Laboratory Service database of South 
Africa, represent the public health sector serving 84% of the total South African population 
(Mayosi & Benatar, 2014).  
 
In the Eastern Cape, the public health sector serves a slightly higher proportion (89%) of the 
population in the province than other provinces (ECDOH, 2015). To our knowledge, only two 
studies have reported incidence data on iGAS in Africa (Seale et al., 2016; Berkley et al., 2005). In 
a study conducted among children in rural Kenya, the IRs per 105 py for all (definite and probable) 
iGAS were as follows: children <5 years, 35, (95% CI, 30 - 40); and children <1 year was 101, 
(95% CI, 83 - 121) (Seale et al., 2016). The second study reported iGAS and non-iGAS IRs per 105 
py: children <5 years, 29 and children <1 year was 96 (Berkley et al., 2005). These figures are among 
the highest reported compared with studies done in other resource limited settings and contrasts 
noticeably with our low mean IR of 3.62 /105 py amongst children < 18 years of age.  The high 
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IR reported in Kenya was thought to be due to the presence of a number of risk factors including 
severe acute malnutrition, malaria and HIV infection which confirm reports from an earlier study 
conducted in Kenya, where iGAS was associated with malnutrition and HIV infection (Berkley et 
al., 2005). Unfortunately, for our study, data regarding these putative risk factors were unavailable. 
Elsewhere, in Fiji, high IRs per 105 py were also reported; among those <5 years, IRs were 26 
(95% CI, 19 - 34), and > 65 years, IRs were 85 (95% CI,  61 - 116) (Steer et al., 2008; Andrew C. 
Steer et al., 2009), while in New Caledonia, the all-ages (definite and probable) iGAS IR was 43/105 
py (95% CI, 35 - 52) (Baroux et al., 2014). It is possible that the low incidence of GAS infection in 
our study is due to infrequent submission of specimens for microbiological culture by health 
practitioners in the Eastern Cape Province, particularly in more remote areas of the province. 
 
The slight decrease in iGAS incidence in our data is in contrast with those reported elsewhere in 
the world since the 1980s (Efstratiou, 2000). In a surveillance study in Utah, USA, the overall 
incidence of iGAS disease increased significantly from 2002 to 2010 (Stockmann et al., 2012). 
Ireland also experienced an increase in IRs with the highest annual IR observed in 2013 since 
iGAS became notifiable in 2004 (Meehan et al., 2013). Similar increases have been observed 
elsewhere in Europe (Darenberg et al., 2013; Report 2014). Slightly more males were affected 
compared with females; and the increase in incidence of iGAS and non-iGAS disease with age is 
in keeping with  trends seen in studies published in New Caledonia and Fiji ( Baroux et al., 2014; 
Steer et al., 2009). 
 
The fluctuations in the IRs, observed over the study period for both iGAS and non-iGAS 
infection, followed a marked decrease observed in 2008 and 2013 in both iGAS and non-iGAS 
infection and are not clearly understood. We acknowledge that the variations in the incidence rates 
may be due to one of two, or both of the following reasons:  (1) it may represent a reflection of 
the true variance in incidence, or (2) it may be a reflection in the number of samples submitted for 
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processing by NHLS laboratories which may be attributed to the rate of the reporting of cases at 
any given point in time and/or laboratory budget restrictions. The implications for these would 
thus be, in the case of the former, an indication that non-iGAS-related diseases are indeed on the 
decline in the South African setting. However, should the latter be the case with lower numbers 
of sample submitted to the laboratory, these data would nevertheless, represent the minimum 
incidence rates for GAS-related diseases. Also, the higher number of GAS cases reported from 
the Eastern Cape provinces may be due to close proximity of laboratories to academic hospitals 
and specimen-taking practices which may vary between the different institutions of the country, 
rather than a higher prevalence of GAS-related diseases in these provinces. It should also be noted 
that specimen collection practices may differ among provinces. Also, provinces such as Kwazulu-
Natal only joined the digital system in the latter years. Thus, these findings emphasize the need for 
further research to allow for a more accurate estimation of the extent of GAS-related conditions. 
 
The collection of epidemiological data in many developing countries is poor. A 2005 WHO report 
on iGAS disease showed that GAS is an important cause of mortality and morbidity on the global 
scale and in Africa (Carapetis et al., 2005);  thus, valid estimates of GAS infection in South Africa 
and Africa are needed to inform the revision of current prevention and control strategies and the 
development of new primary prevention strategies including the development of a universal GAS 
vaccine to reduce the burden of iGAS disease and their consequences (Dale et al., 2013).  
 
The main strength of this study is the large sample size of GAS isolates (>10,000) that were 
collected from the NHLS database over a 13-year period from all provinces of South Africa and 
representing 84% of the population. It is to be noted that IRs were calculated based on data from 
the Eastern Cape Province only (>5,000), where NHLS serves 89% of the population. This study, 
however, has several limitations including the retrospective design and source of data, and the lack 
of detailed clinical information in the NHLS database. Moreover, this study may underestimate 
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the incidence of non-iGAS infection, specifically for pharyngitis, given that microbiological throat 
swabs are not done routinely as standard clinical practice in South Africa. Similarly, for iGAS, our 
data are likely to underestimate the true incidence given widespread empiric use of antibiotics 
without culture in clinical practice.  
 
Public health surveillance systems provide valid and reliable scientific information essential to 
inform appropriate decision making for the best possible action and intervention (Nsubuga et al., 
2006). In response to the need for an enhanced surveillance system, to collect high quality data, 
the AFROStrep registry has been established to collect prospective and comprehensive information 
on iGAS and non-iGAS infection in Africa as an initial attempt to address the dearth of 
information on iGAS disease on the continent (Barth et al., 2016). 
 
In conclusion, the decrease in IRs among non-iGAS infection and persistent IRs for iGAS 
infection in the Eastern Cape, emphasizes the need to remain vigilant in diagnosing iGAS correctly 
and for systematically collecting data so as to ensure an efficient and functioning disease-control 
programme (Nsubuga et al., 2006). Moreover, our data are almost certainly an under-estimate of 
the true burden of GAS disease which needs to be documented appropriately in a prospective 
surveillance study proposed by the AFROStrep registry.  
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6. CHAPTER SIX: 
STUDY 3: THE MOLECULAR TYPING OF NON-INVASIVE 
AND INVASIVE GROUP A STREPTOCOCCAL INFECTION 
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6.1 Introduction 
 
The World Health Organization (WHO) ranked group A β-haemolytic streptococcus (GAS) (also 
known as Streptococcus pyogenes)  as the ninth leading cause of human mortality, with the majority of 
deaths attributable to invasive group A streptococcal (iGAS) diseases (World Health Organisation, 
2005). The majority of cases occur in developing countries (Carapetis et al., 2005). It is believed 
that >600,000 cases of iGAS infection occur annually, with >160,000 deaths. Despite these 
alarming numbers, data on GAS infection are scant in developing countries (Carapetis et al., 2005).  
 
GAS is responsible for a wide range of invasive and non-invasive group A streptococcal (non-
iGAS and iGAS) diseases (Bailie et al., 2005; Steer et al., 2007). These diseases range from mild 
infections such as impetigo and pharyngitis to serious diseases such as streptococcal toxic shock 
syndrome, and necrotising fasciitis. Moreover, GAS may trigger autoimmune diseases following 
repeated episodes of infection, such as acute rheumatic fever (RF)/rheumatic heart disease (RHD) 
and acute post-streptococcal glomerulonephritis (APSGN) (Carapetis et al., 2005).   
 
There is a dearth of emm type data in sub-Saharan Africa; three studies (Engel et al., 2014; Tapia et 
al., 2015; Tewodros & Kronvall 2005) have reported on the molecular typing of non-iGAS and a 
single study (Seale et al., 2016) reported on the molecular epidemiology of iGAS.  
 
The African GAS infection registry (the AFROStrep Study) was established to collect 
epidemiological data on GAS in Africa, where surveillance information is largely lacking. Launched 
in 2016 with a pilot project in South Africa, it aimed to provide an understanding of GAS disease 
in Africa (Barth et al., 2016).  
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Primary prevention of GAS has been focused on the development of a vaccine; the most advanced 
being a 30-valent vaccine formulation (Dale et al., 2011). The M serotypes of GAS included in the 
current vaccine formulation were based on data from the developed world with cross coverage of 
certain emm types being observed. Information about the emm types causing iGAS disease is 
crucially important to assess potential vaccine coverage, especially in regions such as sub-Saharan 
Africa, where the burden of iGAS disease are among the highest (Carapetis et al., 2005). By means 
of a one-year prospective laboratory study, under the auspices of AFROStrep, we determined the 
clinical characteristics and molecular types of non-iGAS and iGAS infection among patients 
attending Groote Schuur Hospital, a tertiary institution in Cape Town, so as to inform the 
development of M protein-based vaccines. Specifically, we aimed to describe the molecular 
characteristics of iGAS isolates, particularly with respect to how they compare and contrast with 




6.2.1 Study design and participants  
In order to determine the extent of GAS infections and the serotypes that cause disease in Cape 
Town, we conducted a prospective laboratory surveillance study among samples from February 
2016 – March 2017 submitted to the National Health Laboratory Service (NHLS) from inpatients 
and outpatients attending Groote Schuur Hospital (GSH) in Cape Town. GSH is a tertiary level 
hospital serving a catchment population of approximately one and a half million people (Myer et 
al., 2013) and forms part of a network of clinics and hospitals that are affiliated to the University 
of Cape Town. GSH provides care to more than five-hundred and sixty thousand referrals and 
inpatient admissions every year of adults (>12 years) and neonates (Groote Schuur Hospital, no 
date). 
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We documented demographic data, clinical presentation, laboratory data and emm types that cause 
non-invasive group A streptococcal (non-iGAS) and invasive group A streptococcal (iGAS) 
infections. The study was approved by the Human Research Ethics Committee at the University 
of Cape Town (HREC/REF: R006/2015). 
 
6.2.2 Clinical Surveillance and Case Definitions 
At the time of a laboratory-confirmed GAS diagnosis, a standardized case report form was 
completed by the study microbiologist. Clinical information was obtained by accessing the 
patient’s medical record. Isolates were collected and stored at -80 degrees Celsius until transfer to 
the AFROStrep laboratory.  
iGAS was defined as GAS isolated from a sterile site such as blood, cerebrospinal fluid and pleural 
fluid (Invasive Group A streptococcus Sub-Committee 2006; Sharkawy et al., 2002), or isolated 
from a wound culture with a clinical diagnosis of necrotising fasciitis or streptococcal toxic shock 
syndrome (Nelson et al., 2016). GAS culture from deep tissue (e.g. abscess) or a biopsy sample 
following surgery were also considered to be invasive infection (Steer et al., 2009). GAS isolated 
from a non-sterile site such as the skin and throat was considered to be non-invasive (Su et al., 
2009).  
 
6.2.3 Molecular assays  
Emm typing has been discussed in chapter 3, section 3.4.  Briefly, GAS isolates were stored in the 
AFROStrep laboratory at -80°C in cryopreservative microbeads until DNA extraction. These 
isolates were sub-cultured on 5% sheep’s blood agar media by isolation, streaking and the plate 
was incubated for 24 to 48 hours at a temperature of 37°C. DNA was extracted using the Wizard 
Genomic DNA Purification Kit and the DNA quality and quantity were determined using the 
NanoDrop 1000 spectrophotometer (Thermo Scientific, Wilmington, DE, USA) technique. The 
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amplified DNA product was sent to Stellenbosch University for sequencing according to 
guidelines by the Centres for Disease Control and Prevention (CDC) 
(https://www.cdc.gov/streplab/protocol-emm-type.html). The BLAST programme 
(https://www2a.cdc.gov/ncidod/biotech/strepblast.asp) was used to compare the DNA 
sequences with published sequences in the CDC databases.  
 
 
6.2.4 Statistics  
We evaluated the association between emm type and clinical symptoms using Chi-Square or Fishers 
Exact tests. A p value of <0.05 was considered to be statistical significant. All statistical analysis 
was performed using Stata® (version 13.1; StataCorp, College Station, TX).  
The sample size was calculated using a prevalence of 21% for GAS pharyngitis as reported in a 
previous study conducted in Cape Town (Engel et al., 2017). The minimum reliable sample size 
was n=255 to be able to detect possible differences between non-iGAS and iGAS infection groups. 
The confidence level was set at 95% and the margin of error was set at 5%. More information on 
the methods for this study can be found in Chapter 3, section 3.3. 
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6.3 Results 
 
From February 2016 to March 2017, 488 laboratory-confirmed GAS cases were identified at the 
NHLS based at GSH in Cape Town. The median age was 31 years (IQR, 21 – 45 years). GAS was 
more commonly isolated from males (63%). iGAS accounted for 46% of GAS cases. Patients with 
iGAS infection were older, with a median age of 36 years (IQR, 22 – 53 years) compared with 
patients who had non-iGAS infection with a median age of 29 years (IQR, 20 – 40 years). The 
proportion of iGAS infections were more common among newborns and patients ≥65 years old 
compared with non-iGAS infections. Characteristics of patients with non-iGAS and iGAS 
infection are listed in Table 6.1.  
 
Clinical information was available for 460 (94%) isolates (Table 6.2).   Among non-iGAS, the most 
common clinical manifestations were wound infections (34%), abscesses (11%) and hand sepsis 
(11%). For iGAS infections, the most common clinical presentations were bacteraemia (33%), 
septic arthritis (18%), and abscesses (7%). Emm 80 was significantly associated with patients 
presenting with non-iGAS abscesses (P=0.007).  
 
Information on the site of sampling was available for 475 isolates (97%); data were recorded as 
detailed on the laboratory requisition form. In addition to those listed in Table 6.3, bone, nasal 
swabs and tissue samples were contained under “other”. Thirteen isolates had no site of isolation 
information; however, classification into non-iGAS and iGAS infections were based on clinical 
data and additional information recorded in the notes section of the CRF.  
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Non-iGAS, non-invasive group A streptococcus; iGAS, invasive group A streptococcus; n, number; 











female 100 (38%) 76 (34%) 176 (36%) 
male 162 (62%) 143 (63%) 305 (63%) 
NS  7 (3%) 7 (1%) 
≤12 months 4 (2%) 10 (4%) 14 (3%) 
 >1 – 5 years 20 (8%) 12 (5%) 32 (7%) 
>5 - 12 years 25 (10%) 11 (5%) 36 (7%) 
>12 - 18 years 12 (5%) 6 (3%) 18 (4%) 
>18 - 64 years 192 (72%) 140 (62%) 332 (68%) 
≥65 years 9 (3%) 26 (12%) 45 (9%) 
unknown age  21 (9%) 21 (2%) 
Table 6.1. Gender and age distribution of cases with non-invasive 
and invasive group A streptococcal infection in Cape Town 
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Table 6.2. Clinical manifestations of non-invasive and invasive GAS infection by age category 
 
 




1 - 5 
Years 
6 - 12   
Years 
13 – 18 
Years 
19 – 64 
Years 
≥65 
Years Total N (%) 
 
Non-invasive GAS infection (n=262) 
   
 
 
Wound infection 1 6 11 5 63 3 89 (34%) 
Abscess 1 4 2 2 19 1 29 (11%) 
Hand sepsis* 0 2 4 2 20 0 28 (11%) 
Hand infection 0 0 1 1 15 0 18 (6%) 
Lower limb infection 0 1 0 0 15 2 18 (7%) 
Other 2 6 6 0 42 2 58 (26%) 
NS       22 (8%) 
Invasive GAS infection (n=226) 
 
   
 
 
Bacteraemia 7 5 2 1 41 18 74 (33%) 
Septic Arthritis 0 3 3 1 29 5 41 (18%) 
Abscess 2 0 1 0 13 0 16 (7%) 
Necrotizing Fasciitis 0 0 0 1 10 1 12 (5%) 
Wound infection 0 0 0 0 7 1 8 (4%) 
Cellulitis 0 1 0 0 4 0 5 (2%) 
Osteomyelitis 0 0 1 0 4 0 5 (2%) 
Erysipelas 0 0 1 0 3 0 4 (2%) 
Other† 1 2 3 2 25 1 34 (15%) 
NS       6 (3%) 
Missing age data       21 (9%) 
 
 
    
 
  
GAS, group A streptococcus; NS, not stated; N, number of cases with clinical manifestations. 
† Symptoms occurring in <5 patients included osteitis, osteomyelitis, empyema and meningitis amongst others. 
* Hand sepsis is considered non-invasive because infection was inoculated through the skin. 
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Sample  N (%) 
Pus swab 258 (53%) 
Blood 90 (18%) 





CSF 5 (1%) 
Other 8 (2%) 
NS 13 (3%) 
Total 488 (100%) 
Table 6.3. Sample types submitted for processing 
CSF, cerebrospinal fluid; NS, not stated; N, number 
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Figure 6.1. Distribution of emm-types identified by non-invasive and invasive GAS isolates 
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Distribution of M types 
 
Molecular evaluation was conducted on 238/488 isolates; reasons included contaminated agar plates 
(following sub-culture of GAS isolates), failed PCR reactions, and remaining isolates are pending 
sequencing. Five isolates failed to report emm types with results reading as “no hits found”.  Forty-
six emm types were identified in 233 non-iGAS and iGAS isolates (Figure 6.1). The 10 most prevalent 
emm types accounted for >67% of the isolates; these were, in descending order, M76 (16%), M81 
(10%), M80 (6%), M43.7 (6%), M183.2 (6%), M44 (5%), M53 (5%), M92 (5%), M184 (4%), and 
M116(3.0%). Twenty different emm types accounted for 86% of GAS isolates. STG1750.0 was a 
newly characterized emm type identified in one isolate. Twenty emm types were represented only once.  
 
Vaccine coverage 
We assessed the proportion of emm types that were included in the 30-valent GAS vaccine currently 
being developed (Dale et al., 2011). Fifteen emm types amongst our cohort are included in the vaccine 
are represented by 54 GAS isolates (23%) (Figure 6.2). Fifteen non-vaccine emm types represented 
100 isolates (43%) have shown cross protection, demonstrating >50% bactericidal killing in the 
presence of rabbit antisera generated after vaccination with the 30-valent vaccine (Dale et al., 2011). 
Our most commonly isolated emm type (M76) is not included in the 30-valent vaccine but is among 
the emm types that evoked bactericidal antibodies.   
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Of 233 GAS isolates, 54 were vaccine types (VT) and 100 were non-vaccine types indicating cross 
coverage (NVT-K). Forty (17%) isolates had no information regarding potential vaccine coverage 















VT, vaccine type, NVT-K, nonvaccine type-killed, NVT-NK, nonvaccine type-not killed 
Figure 6.2. Frequency of non-invasive and invasive emm types observed: VT (vaccine types), NVT-K 
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Non-iGAS 
A total of 32 emm types were identified in 126 non-iGAS isolates (Figure 6.3). Of these, the most 
prevalent emm types, with a frequency of >3% in the population were M76 (15%), M81 (12%), M80 
(8%), M43.7 (6%), M184 (6%), M183.2 (6%), M44 (5%), M53 (5%), M92 (5%), and M49 (3%). The 
10 most prevalent emm types accounted for 71% of the isolates; 20 different emm types accounted 
for 90% of non-iGAS isolates. No new emm types were observed.  Twelve emm types were presented 
only once. 
 
The proportion of non-iGAS emm types included in the 30-valent vaccine was 29 (23%), representing 
11 different emm types. An additional 47 non-iGAS isolates (37%) representing 7 emm types were 
included among cross-protection isolates. The most commonly isolated emm type for non-iGAS 
infection, (M76) was not included in the 30-valent vaccine. The potential coverage for non-iGAS 
infection in our setting is 60%. Twenty-eight (22%) isolates had no information regarding potential 
vaccine coverage (No killing data).  
Figure 6.3. Frequency of non-invasive emm types observed: VT (vaccine types), NVT-K (non vaccine 
type coverage), NVT-NT (non-vaccine types not covered) and no killing data. 
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iGAS 
 
Thirty-five emm types were identified in 107 iGAS isolates (Figure 6.4). Among these isolates, the 
most prevalent emm types, with a frequency of >3% in the population were M76 (17%), M81 (8%), 
M183.2 (7%), M43.7 (6%), M44 (6%), M53 (6%), M92 (6%), M80 (5%), M116.1 (4%), M33 (4%), 
and M8 (3%). The 10 most prevalent emm types accounted for 66% of the isolates; 20 different emm 
types accounted for 84% of the GAS cases isolated. STG1750.0 was identified in 1 isolate as a newly 
characterized emm type. Seventeen emm types were only represented once.  
 
The proportion of iGAS emm types included in the 30-valent vaccine was 24 (22%), representing 11 
different emm types. An additional 39 iGAS isolates (36%) representing 9 more emm types were 
included among the cross-protection isolates. The most commonly isolated emm type for iGAS 
infection (M76) was not included in the 30-valent vaccine. The potential coverage for iGAS infection 
in our setting is 59%. Twenty-seven (25%) had no information regarding potential vaccine coverage 
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Figure 6.4. Frequency of non-invasive emm types observed: VT (vaccine types), NVT-K (non vaccine 
type coverage), NVT-NT (non-vaccine types not covered) and no killing data.  
VT, vaccine type, NVT-K, nonvaccine type-killed, NVT-NK, nonvaccine type-not killed  
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Clusters 
 
Of the 233 GAS isolates, we were able to assign an emm cluster designation to 231 isolates (Table 
6.4) according to the cluster classification method (Baroux et al., 2014). Ten emm type clusters were 
observed among the GAS isolates (Table 6.4). Five emm-clusters namely D4, E2, E3, E6 and E4 
comprised 90% of the emm types.  
 
 
Cluster Freq. Percent Cum % 
   
 
D4 59 25.54  
E2 54 23.37 48.91 
E3 41 17.74 66.65 
E6 34 14.71 81.36 
E4 20 8.65 90.01 
NS 9 3.89 93.09 
stG6.6 9 3.89 97.79 
Clade Y 2 0.86 98.65 
D2 1 0.43 90.08 
E1 1 0.43 99.51 
Formerly st3211.0 1 0.43 100.00 
   
 
Total 231 100.00  
 
  
Table 6.4: Emm Cluster types  
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Seasonal variation 
 
There was an association between the type of GAS infection across the seasons, however, this did 
not reach statistical significance (Chi-square for trend, P=0.06). Non-iGAS infections showed a peak 
in the winter months. iGAS infections troughed in the winter months and peaked in summers 
months (Figure 6.5). Furthermore, a higher proportion of iGAS infections were observed during the 
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6.4 Discussion 
 
This is the first prospective study to describe the molecular types of both non-invasive and invasive 
GAS infections in South Africa. The most prevalent emm types were almost evenly distributed 
between non-iGAS and iGAS isolates; few emm types accounted for the majority of non-iGAS (90%) 
and iGAS (84%) cases. The proportion of iGAS cases was remarkably high, accounting for almost 
half (46%) of GAS infections in our surveillance study.  
 
Compared with the 30-valent vaccine, only one-third of the 46 emm types in our study (15/46), were 
included translating to a vaccine coverage (vaccine type and nonvaccine type-killing) for non-iGAS 
and iGAS infection of 60% and 59%, respectively. Notably, our most prevalent strains, in both non-
iGAS and iGAS groups, were not included in the 30-valent vaccine. Interestingly, a new emm type, 
STG1750.0 not yet assigned an emm type in the CDC database, was obtained from one patient 
presenting with bacteraemia.  
 
We showed a lower diversity of emm types, a result similar to others found in high-income countries 
(Steer et al., 2009). In our study, 20 emm types represented 86% of GAS isolates, which is lower than 
studies conducted in Africa which reported 25 emm types representing 70% of 70 emm types (Tapia 
et al., 2015), 26 emm types representing 63% of 91 emm types ( Steer et al., 2009) for GAS pharyngitis, 
and 48 emm types representing 62% of 78 emm types for GAS skin and pharyngeal infections 
(Tewodros and Kronvall, 2005). Another study of  iGAS isolates, conducted in Kenya  reported 88 
different emm types (Seale et al., 2016);  74% of our  strains were common in their study. Of interest, 
our study findings were similar to a surveillance study conducted in Tunisia (Hraoui et al., 2011). 
Their twenty most prevalent emm types represented 82% of the total emm types and the proportion 
of iGAS cases was 46%, compared with our surveillance study of 49%. Furthermore, the most 
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common emm types (M1, M12, M28, M3, and M4) isolated in high-income countries were not 
represented in our study.  
 
Epidemiological studies have shown significant associations between emm type and GAS disease 
manifestations. Emm types 1, 3, 5, 6, 12, 14, 17, 44, and 61 have been associated with superficial GAS 
disease (Cunningham 2000; Johnson et al., 1992; Shea et al., 2011) and emm types 1, 3 and 28 associated 
with iGAS diseases (Olsen and Musser, 2010). In addition, emm types have also been associated with 
clinical manifestations which include APSGN (emm types 1, 4, 12, 49, 55, 57, and 60)(Shulman and 
Tanz, 2010), and ARF (emm types 1, 3, 5, 6, 11, 12, 14, 17, 18, 19, 24, 27, 29, 30, 32, and 41)(Shulman 
and Bisno, 2014)(Shulman and Tanz, 2010).  Our study represents emm types that have been 
previously shown to be associated with pharyngitis, impetigo, ARF, and PSGN.   
 
Seasonal variation in the frequency of GAS cases have been observed in studies conducted in the 
United States of America. GAS Infection have been shown to peak in the winter and early spring 
months, and trough in the summer and autumn months (Nelson et al., 2016). Similar seasonal 
variations have also been observed in Europe (Darenberg et al., 2013a; Lamagni et al., 2008). Non-
iGAS infections in our study are in keeping with this observation, however, for iGAS infection, a 
higher number of cases were observed in the summer months.   
 
A new emm cluster typing system classifies >200 emm-types into 48 emm clusters containing closely 
related M proteins that share structural and binding properties (Sanderson-Smith et al., 2014). This 
system predicts the M protein vaccine antigen content and serves as a framework to investigate the 
cross-protection phenomenon and provide complementary hypothesis for the many variants from 
low-middle income countries (Sanderson-Smith et al., 2014). Five emm clusters were responsible for 
90% of the disease burden. It is thus conceivable, that the emm cluster typing system could be an 
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important typing tool to identify vaccine antigen candidates that may prove to be effective at 
preventing a larger proportion of GAS infections, especially in South Africa (Sanderson-Smith et al., 
2014). 
 
Our study had a number of limitations: 
1. We were unable to assess the variation in the distribution of emm types over time, as reported 
in other studies (Meehan et al., 2013; Nelson et al., 2016), since our data collection was over a 
one-year period. 
2. This was a hospital-based study and therefore could not calculate population-based incidence 
rates over the study period. 
3. GSH is mainly an adult hospital hence the low number of cases in young patients, therefore, 
caution must be applied when generalising these findings to the lower age category.   
4. Emm data were not available for all GAS isolated over the study period. We compared the 
isolates that were typed with those not typed and found no significant difference with regard 
to gender (Chi-Square, P=0.92) and non-iGAS and iGAS groups (Chi-Square, P=0.87). We 
also considered age group analysis and found no difference among patients between the ages 
of 13 – 18 (Z test for proportions, P= 0.84), 19 – 64 years (Z test, P=0.79) and those older 
than 64 years (Z test, P=0.90). There was a difference in the younger population, among the 
newborns (Z test, P= 0.02) and 6 - 12 years, (Z test, P=0.02). This difference could be due to 
the small sample size in these age categories.    
 
Our results have implications for current vaccine development initiatives. The current 30-valent 
vaccine formulation is informed by high-income countries accounting for 90% of strains causing 
disease in those regions. By comparison, vaccine coverage in our study was considerably lower than 
the coverage in high-income countries. Even though our five most prevalent emm types (M76, M81, 
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M80, M183 and M43), accounting for 45% of our cases, were not included in the current 30-valent 
vaccine formulation, there is evidence of cross-protection based on bactericidal antibodies that 
recognize shared epitopes in the N-terminal region of the emm types (Dale et al., 2011; Dale et al., 
2013). Few emm types are responsible for the majority of GAS cases in our setting, thus, an effective 
vaccine will not require diverse emm serotypes. Furthermore, an important finding in our study is 
that bactericidal activity against 33% of the non-vaccine emm types in our study could translate to 
additional protective coverage of 43%.   
 
The same emm types caused both iGAS and non-iGAS infections in our study, thus suggesting that 
host immune factors have a role to play in determining the severity and outcome of GAS infections 
in different individuals (Davies et al., 1996). Patients with serious GAS infections who present with 
severe clinical manifestations are inclined to produce elevated levels of proinflammatory cytokines 
in response to GAS products (Norrby-Teglund et al., 2000). 
 
Although we were unable to calculate incidence rates, the proportion of iGAS infection at GSH was 
high, however, this is to be expected given that GSH is a tertiary level hospital where patients with 
severe disease are referred for care. In contrast, at a community health centre, we would expect to 
see less iGAS infections and more non-iGAS infections e.g. GAS pharyngitis.  
 
iGAS infection is responsible for a substantial burden of disease and its clinical manifestations are 
associated with important causes of premature mortality and morbidity. Following the first 
comprehensive review, published more than a decade ago, there remains a challenge in quantifying 
the burden of GAS disease around the world. Although more data are slowly becoming available, 
more work needs to be done especially in resource limited areas such as sub-Saharan Africa. 
Understanding the epidemiology and true burden of GAS diseases will help target efforts and settings 
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in which the vaccine and other trials could be conducted. While vaccine development, targeting areas 
other than emm-protein are underway, it must be noted that the emm-protein vaccine is currently at 
the most-advanced stage of development, thus warranting documenting the variation thereof. 
Furthermore, the reporting of iGAS through passive surveillance provides a platform to evaluate 
trends, identify new strains causing disease and in so doing, inform the development of vaccine 
efforts.     
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SUMMARY AND CONCLUSIONS 
IMPLICATIONS FOR POLICY, PRACTICE AND FUTURE RESEARCH 
 
This thesis details the establishment of the AFROStrep registry as a platform for GAS-related 
research with three studies of GAS infection in South Africa providing insights into the burden of 
GAS-related disease. The synopsis below presents the unique contributions made by these studies. 
The implications for policy and practice, as well as recommendations for future research are also 
represented.  
 
7.1 Originality / Novel Insight 
 
The primary purpose of this thesis was to determine the epidemiology for GAS infection in Africa. 
To provide context, I endeavoured to identify and summarise all studies reporting on the prevalence 
and molecular epidemiology of GAS isolates in Africa. In South Africa specifically, I sought to (1) 
describe from national laboratory data, the incidence of invasive and non-invasive GAS isolates, 
2003 – 2015, (2) to establish the AFROStrep biorepository and clinical database composed of South 
African patients with invasive and non-invasive GAS infection, (3) to conduct a prospective, 
surveillance study in order to determine the burden of invasive disease associated with GAS in South 
Africa over a 12-month period and, finally, (4) describe the molecular emm types of invasive GAS 
isolates in South Africa, particularly with respect to how they compare and contrast with emm types 
of non-invasive isolates. 
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There are three principal findings from this series of studies: 
 
Study one:  This systematic review provided the first comprehensive estimates on the prevalence of 
GAS infection in Africa and provides strong justification for improved prevention strategies and 
efforts to support the development of vaccine initiatives, given the high prevalence of GAS infection 
in African people. In addition, this work highlights the dearth of molecular type data of GAS-related 
diseases in Africa and emphasises the need for further research to address this need. In addition, this 
work emphasises the need for healthcare workers to be vigilant, ensuring accurate diagnosis and 
treatment of GAS infections.  
 
Study two: This study suggests that laboratory-confirmed non-invasive GAS infection in the South 
African public sector appears to have declined over the last 13 years. There is the possibility that the 
lower incidence of invasive and non-invasive GAS infection found in our study is due to infrequent 
submission of specimens for microbiological culture by health practitioners; thus, our findings may 
be an underestimate of the true burden of disease in South Africa. Interestingly, this study showed 
an increase in incidence with age in our cohort, consistent with findings reported previously. This 
work further highlights the need for accurate and comprehensive surveillance of GAS in South 
Africa. 
 
Study three:  This is the first prospective study to describe the molecular types of both non-invasive 
and invasive GAS infections in South Africa. The most prevalent emm types were almost evenly 
distributed between non-iGAS and iGAS isolates; few emm types accounted for the majority of non-
iGAS (90%) and iGAS (84%) cases. The proportion of iGAS cases was remarkably high, accounting 
for almost half (46%) of the total cohort. Our most prevalent emm types causing the majority of 
invasive and non-invasive GAS disease were not included in the 30-valent vaccine currently under 
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development. Finally, this research showed a low potential vaccine coverage in our setting (60% and 
59% for non-iGAS and iGAS respectively) and thus emphasises the need for revised primary 
prevention efforts and a vaccine formulation with improved coverage in areas where the burden of 
disease is high.  
 
This thesis highlights the need for comprehensive public health surveillance systems to record 
complete and accurate information on the epidemiology of GAS in South Africa and Africa, as an 
essential step to reduce the burden of GAS-related diseases in Africa. Thus, surveillance, we believe 
will allow us to be confident in our disease estimates and disease characteristics so as to better inform 
prevention strategies including the development of an effective vaccine.  
 
7.2 Implications for policy and practice 
 
The findings of this thesis provide important baseline information for clinicians, health care workers 
and policy makers regarding the burden of GAS in South Africa. The pooled prevalence estimate of 
32% (95% CI, 19% to 46%) in Southern Africa, provides support to the need to remain vigilant in 
accurately diagnosing GAS pharyngitis infections.     
While some developed countries have invasive GAS infections listed as a notifiable disease so as to 
monitor outbreaks and new strains, more African data is needed to allow for a similar directive, 
especially given resource and personnel constraints. 
 
7.3 Implications for future research 
 
This work highlights the need for more studies on the molecular epidemiology of invasive GAS 
infections so as to have a better understanding of the epidemiology of GAS in areas where the 
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burden of GAS disease is high e.g. South Africa and sub-Saharan Africa. Longitudinal, population-
based surveillance studies are essential to determine trends in the incidence of GAS, changes in the 
distribution of prevalent and new emm types circulating in our setting, and to be confident in our 
disease estimates so as to better inform public health prevention strategies.  
 
This thesis provides important information with regard to a 30-valent GAS vaccine currently under 
development. Our findings suggest that an effective vaccine formulation with good coverage does 
not require a diverse group of serotypes since few emm types caused the majority of GAS disease in 
our setting. 
 
This work further alludes to the need for an alternative approach to the vaccine development, 
perhaps such as the emm cluster tool to supplement the emm type distribution data, given the diversity 
and change in emm types over time, especially in sub-Saharan Africa.  
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Appendix 9.2: Systematic review data extraction form 
 
 
Review Title: The Prevalence of Group A Beta Haemolytic Streptococci in Africa: 
























Publication type (e.g. 
full report, abstract) 
 
Bibliography hand 
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Study Eligibility  
Study Characteristics  
 
Eligibility criteria Eligibility criteria met? 
 
Types of study Observational study reporting 
on Prevalence.  
 
Yes    No     Unclear  
Participants  Including children of ages 5-15 
years 
 
Yes    No     Unclear  
 Have throat swab/RADT 
 
Yes    No     Unclear  
Setting Study took place in an African 
country 
 
Yes    No     Unclear  
Types of Outcome 
measure  
Primary outcome:  
Prevalence of Beta haemolytic 
Group A streptococcus 
 
Yes    No     Unclear  
 Secondary outcomes: 
Distribution of Beta haemolytic 
Group A streptococcus, M-
Protein gene types. 
Yes    No     Unclear  
Results Prevalence Yes    No     Unclear  
 










DO NOT PROCEED IF STUDY EXCLUDED FROM REVIEW 
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Characteristics of the Study 
 Descriptions as stated in report/paper 
Aim of study   
Study Design  
Start date  
End date  
Seasons of participation    
Diagnosis criteria 
(RADT, Throat swab) 
 
No of Diagnosis/tests on individual 
child 
Informed consent obtained  Yes              No          Unclear  
Ethical approval needed/ obtained 
for study 
 
Yes    No           Unclear  
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Participants  
 Descriptions as stated in report/paper 
Country   
Population description  




Inclusion criteria   
Exclusion criteria  
Method of recruitment 




Site of recruitment of 
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Outcome  















No of symptomatic 


























No of symptomatic 














Stratified Prevalence  
Factors adjusted 
for in this study. 
Total sample 
size analysed 
per factor  
 
No of symptomatic 
GAS cases analysed 









   
Gender  
 
   
Household Number  
 
 
   





   
Antibiotics   
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 Descriptions as stated in report/paper 
Key conclusions of study 
authors 
 










 Other Information 
Study funding sources 
(Including role of funders) 
  
 
Possible conflicts of interest 
(For study authors) 
 
Missing data  
Correspondence required for 
further study information 
(from whom, what and when) 
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Risk of Bias for Prevalence Studies  
1. Was the study's target population a close 
representation of the national population in 
relation to relevant variables? 




2. Was the sampling frame a true or close 
representation of the target population? 




3. Was some form of random selection used to 
select the sample, OR was a census undertaken? 




4. Was the likelihood of nonresponse bias 
minimal? 




5. Were data collected directly from the subjects 
(as opposed to a proxy)? 




6. Was an acceptable case definition used in the 
study? 
 




7. Was the study instrument that measured the 
parameter of interest shown to have validity and 
reliability? 
Yes         No         Unclear  
 
Explain:   
 
8. Was the same mode of data collection used for 
all subjects? 




9. Was the length of the shortest prevalence 
period for the parameter of interest appropriate? 




10. Were the numerator(s) and denominator(s) for 
the parameter of interest appropriate? 




11. Authors’ reported limitations of study’s 
methods/results  
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Quality of the study 
After considering items 1-11, rate the overall quality of the study as “Good,” “Fair,” or “Poor” 




Good: Few of the items are rated “No” and none of the limitations are thought to 
decrease the validity of the conclusion. If items 3,4,7,or 8 are rated “no”, then 
the study id likely to have major flaws. 
 
 
Fair: Enough items are rated “No”, with at least some important limitation. Thus 
introduce some uncertainty about the validity of the conclusions. 
 
 
Poor: Several items are rated “No”, introducing serious uncertainty about the 
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Appendix 9.3: AFROStrep Case Record Form 
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Appendix 9.4: Lab SOP: Culture procedure 
 
SOP TITLE: Culture Procedure SOP#  S###-01 





LINKED DOCS  
 
APPROVED BY:  EFFECTIVE DATE 01 Mar 2017 
 
1. Purpose:   To describe the procedures for sub-culture of GAS isolates from 
AFROStrep sites to the Reference Laboratory    
2. Applies to: All sites participating in the AFROStrep research project 
3. Responsibilities: Principal Investigator or designee 
 
4. Procedure: 
o Sub-culture the GAS isolates on 5% blood agar.  
o Incubate overnight at 37oC in 5% CO2. 




















Wasas AD, Huebner RE, De Blanche M, Klugman KP. Long-term survival of Streptococcus pneumoniae 
at room temperature on Dorset egg medium. J Clin Microbiol 1998;36:1139-40. 
 
 
For questions regarding collection, please email Dr Mark Engel  mark.engel@uct.ac.za or 
contact the AFROStrep Coordinating Office by phone (+27214045735) or fax (+27214486815)  
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Appendix 9.5: Lab SOP: DNA Extraction 
 
SOP TITLE: DNA Extraction SOP#  S###-01 





LINKED DOCS  
 
APPROVED BY:  EFFECTIVE DATE 01 Mar 2017 
 
1. Purpose:   To describe the procedures for DNA extraction of GAS isolates from 
AFROStrep sites to the Reference Laboratory    
2. Applies to: All sites participating in the AFROStrep research project 
3. Responsibilities: Principal Investigator or designee 
 
4. Materials 
- 2% blood agar plates 
- sterile loops 




1. Collect samples from -80C  
2. Samples are placed on lab bench until they defrost 
3. Record the sample id and date on the agar plates 
4. Ensure sample has defrosted & use a sterile loop to sub culture the GAS (from 
cryovials) 
5. Leave agar plates on bench for 10-15 mins (upright) 
6. Incubate at 37 C in presence of 5% CO2 
 
DNA Extraction (Wizard Genomic DNA Purification Kit,500) 
 
1. Heat the waterbath to 37 C  
2. Heat the waterbath to 80 C 
 
Materials to Be Supplied by the User 
 
• 1.5ml microcentrifuge tubes 
• water bath, 80ÅãC 
• water bath, 37ÅãC 
• isopropanol, room temperature 
• 70% ethanol, room temperature 
• water bath, 65ÅãC (optional; for rapid DNA rehydration) 
• 50mM EDTA (pH 8.0) (for gram positive bacteria) 
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• 10mg/ml lysozyme (Sigma Cat.# L7651) (for gram positive bacteria) 
• 10mg/ml lysostaphin (Sigma Cat.# L7386) (for gram positive bacteria) 
 
 
1. Add 1ml of an overnight culture to a 1.5ml microcentrifuge tube. 
2. Centrifuge at 13,000–16,000 Å~ g for 2 minutes to pellet the cells. Remove the supernatant. For 
Gram Positive Bacteria, proceed to Step 3. For Gram Negative Bacteria go directly to Step 6. 
3. Resuspend the cells thoroughly in 480μl of 50mM EDTA. 
4. Add the appropriate lytic enzyme(s) to the resuspended cell pellet in a total volume of 120μl, and 
gently pipet to mix. The purpose of this pretreatment is to weaken the cell wall so that efficient 
cell lysis can take place. Note: For certain Staphylococcus species, a mixture of 60μl of 10mg/ml 
lysozyme and 60μl of 10mg/ml lysostaphin is required for efficient lysis. However, many Gram 
Positive Bacterial Strains (e.g., Bacillus subtilis, Micrococcus luteus, Nocardia otitidiscaviarum, 
Rhodococcus rhodochrous, and Brevibacterium albidium) lyse efficiently using lysozyme alone. 
5. Incubate the sample at 37ÅãC for 30–60 minutes. Centrifuge for 2 minutes at 13,000–16,000 Å~ 
g and remove the supernatant. 
6. Add 600μl of Nuclei Lysis Solution. Gently pipet until the cells are resuspended. 
7. Incubate at 80ÅãC for 5 minutes to lyse the cells; then cool to room temperature. 
8. Add 3μl of RNase Solution to the cell lysate. Invert the tube 2–5 times to mix. 
9. Incubate at 37ÅãC for 15–60 minutes. Cool the sample to room temperature. 
10. Add 200μl of Protein Precipitation Solution to the RNase-treated cell lysate. Vortex vigorously at 
high speed for 20 seconds to mix the Protein Precipitation Solution with the cell lysate. 
11. Incubate the sample on ice for 5 minutes. 
12. Centrifuge at 13,000–16,000 Å~ g for 3 minutes. 
13. Transfer the supernatant containing the DNA to a clean 1.5ml microcentrifuge tube containing 
600μl of room temperature isopropanol. Note: Some supernatant may remain in the original tube 
containing the protein pellet. Leave this residual liquid in the tube to avoid contaminating the DNA 
solution with the precipitated protein. 
14. Gently mix by inversion until the thread-like strands of DNA form a visible mass. 
15. Centrifuge at 13,000–16,000 Å~ g for 2 minutes. 
16. Carefully pour off the supernatant and drain the tube on clean absorbent paper. Add 600μl of 
room temperature 70% ethanol and gently invert the tube several times to wash the DNA pellet. 
17. Centrifuge at 13,000–16,000 Å~ g for 2 minutes. Carefully aspirate the ethanol. 
18. Drain the tube on clean absorbent paper and allow the pellet to air-dry for 10–15 minutes. 
19. Add 100μl (concentration changed to 60μl) of DNA Rehydration Solution to the tube and rehydrate 
the DNA by incubating at 65ÅãC for 1 hour. Periodically mix the solution by gently tapping the 
tube. Alternatively, rehydrate the DNA by incubating the solution overnight at room temperature 
or at 4ÅãC. 
20. Store the DNA at 2–8ÅãC. 
 
Reference 
Wasas AD, Huebner RE, De Blanche M, Klugman KP. Long-term survival of Streptococcus pneumoniae 
at room temperature on Dorset egg medium. J Clin Microbiol 1998;36:1139-40. 
 
https://www.promega.com/-/media/files/resources/protocols/technical-manuals/0/wizard-genomic-dna-
purification-kit-protocol.pdf Wizard Genomic DNA Purification Kit,500 protocol 
 
For questions regarding collection, please email Dr Mark Engel  mark.engel@uct.ac.za or 
contact the AFROStrep Coordinating Office by phone (+27214045735) or fax (+27214486815) 
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Appendix 9.6: Lab SOP: Polymerase Chain Reaction  
 
As per the cdc website:  
 
https://www.cdc.gov/streplab/protocol-emm-type.html#modalIdString_CDCTable_2  
1. Spin down lysate at full speed for 1 min. 
2. For each sample, aliquot 24 µL master mix in PCR tubes/plate. 
3. Add no more than 1.0 µL lysate supernatant – vortex gently – centrifuge for few seconds to 
collect reaction mix at the bottom of the PCR tube/plate. 
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Appendix 9.8: AFROStrep Standard operating procedure   
 
 
A REGISTRY  
FOR GROUP A STREPTOCOCCAL INFECTION  






















Dylan D Barth 
Mark E Engel 
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The AFROStrep Study: A registry for group A streptococcal (GAS) infection in Africa 
Group A β-haemolytic Streptococcus (GAS), a gram-positive bacterium also known as Streptococcus 
pyogenes, results in skin conditions, such as pyoderma and mucosal diseases such as pharyngitis. 
Repeated GAS infections may lead to severe GAS-related illnesses which include acute post-
streptococcal glomerulonephritis, acute rheumatic fever (ARF) and rheumatic heart disease (RHD). RHD 
is associated with significant morbidity and mortality in children and young adults living in developing 
countries. Increases in the number of cases for invasive and non-invasive GAS diseases have been 
observed globally since the 1980s. The reasons for these observations are not clearly understood and 
have subsequently caused many countries to commence active surveillance systems for invasive GAS to 
closely document the epidemiology of the disease. Prevalence and incidence data on GAS infections 
from Africa are largely lacking especially given that GAS infections are not notifiable.  
The AFROStrep project is a proposed multi-centre study with the objective to collect comprehensive 
data on GAS disease in Africa. The study comprises two approaches:  (1) an active community-based 
surveillance of (non-invasive) GAS pharyngitis at sentinel sites and, (2) passive data collection of invasive 
GAS disease diagnosed at laboratories across South Africa. Currently, the existing database and 
repository contains data and isolates of >230 participants obtained from a community-based pilot 
Demonstration Site in Cape Town. Isolates are to be subjected to DNA isolation to allow for 
characterization by molecular methods and cryo-preservation for long-term storage. It is anticipated 
that AFROStrep will allow for the evaluation of a number of entities including rates of severe GAS 
infection, sequence typing of the emm gene, etc.  
 
The objectives of the AFROStrep Registry: 
1. To collect demographic and clinical information from patients with non-invasive and invasive 
laboratory-confirmed GAS infection.  
2. To establish a bio repository of isolates so as to allow for studies to determine the molecular 
epidemiology on non-invasive and invasive GAS infection.  
3. To conduct studies that contribute to the growing body of knowledge informing vaccine 
development  
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1. GLOSSARY 
GAS group A streptococcus  
CRF Case Report Form 
GCP Good Clinical Practice 
MOP Manual of Operations 
SOP Standard Operating Procedures 
PCO Project Coordinating Office 
PI Principal Investigator 
ERF Event Record Form 
 
2. STUDY OVERVIEW 
TITLE THE AFROSTREP STUDY:  
A SURVEILLANCE SYSTEM FOR GROUP A STREPTOCOCCAL INFECTION IN AFRICA 
STUDY SIZE OPEN-ENDED 
STUDY DESIGN ITERNATIONAL MULTI-CENTRE CROSS-SECTIONAL DESIGN 
OBJECTIVES • TO COLLECT DEMOGRAPHIC AND CLINICAL INFORMATION FROM PATIENTS 
WITH NON-INVASIVE AND INVASIVE LABORATORY-CONFIRMED GAS 
INFECTION IN AFRICA 
• TO ESTABLISH THE AFROSTREP BIOREPOSITORY AND CLINICAL DATABASE 
COMPOSED OF AFRICAN PATIENTS WITH A GAS-RELATED DIAGNOSIS.  
• TO CONDUCT A PROSPECTIVE, SURVEILLANCE STUDY IN ORDER TO 
DETERMINE THE BURDEN AND REGIONAL DISTRIBUTION OF INVASIVE 
DISEASE ASSOCIATED WITH GAS AT COLLABORATING SITES IN AFRICA 
OVER A 12-MONTH PERIOD 
• TO DESCRIBE THE MOLECULAR EPIDEMIOLOGY OF INVASIVE GAS ISOLATES 
IN AFRICA, PARTICLUARLY WITH RESPECT TO HOW THEY COMPARE AND 




INCLUSION INTO AFROSTREP IS SUBJECT TO: 
• ANYONE PRESENTING WITH A SORE THROAT 
• MICROBIOLOGICAL LABORATORY CONFIRMATION OF GAS 
• INFORMED CONSENT  
• AVAILABILITY OF CLINICAL DATA 
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EXCLUSION 
CRITERIA 
PATIENTS WILL BE EXCLUDED IF NO INFORMED CONSENT WAS OBTAINED 
PROJECT  
COORDINATING  
OFFICE: AFRICA  
(PCO) 
DR MARK ENGEL (PI) 
 
MR DYLAN BARTH (CO-PI) 
DEPARTMENT OF MEDICINE, J 46.47 OLD MAIN BUILDING, GROOTE SCHUUR 
HOSPITAL 
UNIVERSITY OF CAPE TOWN, OBSERVATORY  7925 
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2.1 AFROSTREP PROCESS FLOW CHART 
 
Comprehensive information of cases obtained from both components will be captured into the 
AFROStrep registry database and specimens will be stored in a bio repository.  
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2.2 COLLABORATING AFRICAN SITES (CURRENT) 
 
Coordinating centres: Ethiopia, Jimma University; Mali, Centre pour le Développement des Vaccins; Nigeria, 
University of Benin;  South Africa, University of Cape Town;  Sudan, University of Khartoum. 
 
The map above displays the current collaborating sites in the AFROStrep Registry. Geographical 
Information Systems (GIS) flowing out of recent work (Barth et al, 2015) will be used for spatial analyses 
including clustering of cases, prevalence maps, etc.  
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3. PATIENT ELIGIBILITY 
 
* Please maintain a SCREENING LOG of all patients screening for enrolment in the AFROStrep 
registry .  
 
3.1 INCLUSION AND EXCLUSION CRITERIA 
I. Inclusion Criteria [ALL criteria must be present for eligibility to be confirmed] 




One of the following  
• Anyone presenting with a sore throat 
• Microbiological laboratory confirmation of GAS 
 
II. Exclusion Criteria [none of the criteria must apply for the patient to be eligible] 
• Inability to provide informed consent/assent 
 
3.2 INFORMED CONSENT  
Written Informed consent must be obtained prior to enrolling patients in the study.  
If the patient or person providing the informed consent cannot sign the Informed Consent Form, a 
thumbprint will suffice. 
For future reference, please record in the patient’s file: 
• The date and time of consent. 
• The name of the person obtaining consent. 
• The informed consent form. 
*Refer to appendices for consent forms 
A template Informed Consent Form is included in appendices. This should be adapted and translated 
for use in each site. A copy of the consent form must be provided to the participant. 
ASSENT:    
Children who are 8 years and older will be required to sign an assent form in addition to the consent 
form for inclusion into the study. 
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*Refer to appendices for assent forms 
 
 
3.3 PATIENT CONFIDENTIALITY 
All patients will be identified by a unique number assigned at enrollment. The number consists 
currently of a combination of the center number plus the order in which the patient was enrolled. 
For example: A patient at center 100 (Clinic 01 - Cape Town), who was the 4th patient enrolled, will 
be identified by Patient Identification Number 100-04.  
All Case Report Forms and all other study documentation, including source documents and 
correspondence regarding the patient, must document the center and subject number. Please ensure 
this number is placed on ALL documents. Patient confidentiality must be upheld in all study 
documentation. The registration form with contact details must be kept separately from the study 
documentation to maintain confidentiality as regards data. 
 
 
3.4 CENTRE NUMBERS AS AT 1 JULY 2015 
 
100 Cape Town: Clinic 1 
101 Cape Town: Clinic 2 
102 Cape Town: Hospital 1 
110 Pretoria: Clinic 1 
111  Polokwane: Clinic 1 
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4. CASE REPORT FORM  
 
To complete the case report form: 
• Ensure that the participant has signed the consent form. 
• Ensure that the participant meets all of the inclusion criteria. 
• Ensure that all exclusion criteria are assessed and none apply. 
• Confirm that participant  meets the eligibility criteria  
• Please complete Centre and Participant number on each page. 
• Please answer each question by marking an X in one box on each line OR writing numbers in 
the spaces provided OR writing neatly and legibly on the lines provided. 
 
General Instructions: 
• When completing forms please use black pen only. Never use pencil or red pen. 
• For questions where a number is required for a response and there is more than one 
box provided, please fill the boxes from right to left and zero fill all empty boxes. For 
example, a response of 16 years of age would be recorded as below. 
0 1 6 
 
• If it is necessary to make a correction, please draw a single line through the incorrect 
value and write the correct value nearby. Please initial and date each correction. Never 
use Liquid Paper/Tippex/correction fluid. 
 




To complete the contact information sheet, please record patient information including: 
• Name, initials, home address and phone number(s) of the patient. Include the GPS 
coordinates if available and hospital number. 
• Contact information of at least two contacts including family members, friends or 
neighbours. 
• The contact information of the local clinic. 
 
M E  24/03/2015 
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5. DATA MANAGEMENT 
 
 
 PROCEDURE:  
1. The data manager will receive complete, quality assured, and corrected CRFs 
 
2. All CRFs will be captured within 2 weeks of the study visit utilizing the OpenClinica database 
program. The standard operating procedure for data entry using OpenClinica is attached as an 
appendix.  
 
3. All data entry will be double-checked for accuracy using the following methods:  
(a) Visual proofing of the CRF with the computer screen post scanning/data entry. 
(b) Cross-referencing with source documents as appropriate. 
 
4. All CRFs captured into the OpenClinica database program will be initialed and dated in a 
designated location on the CRF.  
 
5. Data entry will take place on a designated internet based password protected computer.  
 
6. All completed and verified CRFs will be filed in its appropriate CRF folder.  
 
* Refer to the OpenClinica SOP attached as an appendix 
 
6. STUDY ORGANISATION AND RESPONSIBILITIES 
6.1 ORGANISATION AND GOVERNANCE 
 
Coordinators:  
Dylan Barth, Mark Engel 
Responsibilities include:  
• Day-to-day running of the registry under the supervision of the Steering Committee  
• Keeping and disseminating the minutes of the Steering Committee. 
• Preparation of the trial protocol, a master copy of the study materials and aids, development 
of the case record forms, study database, data internal consistency checks and data analysis. 
• Preparation of the interim reports for the independent data safety and monitoring board  
• Applications for research grants to fund the study. 
Operations Committee: Mark Engel (Chair), Dylan Barth, Andrew Whitelaw, Bongani Mayosi 
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• It is responsible for monitoring the Registry’s function on a short–term basis and for 
implementing decisions of the Steering Committee.  
• The Operations Committee will meet every three months and its decisions and minutes will 
be circulated to all participants by means of a newsletter. 
The Steering Committee: 
• The Steering Committee consists of the members of the Operations Committee and Site 
Principal Investigators. Mark Engel (Chair).  
• It is proposed that at least one member of the Steering Committee should be from each of 
the countries actively recruiting.  
• The Steering Committee is responsible for the overall policy of the Registry and for supervising 
its successful conclusion. Publication policy and sub-study policy are decided by the Steering 
Committee. Decisions of the Steering Committee will be communicated to all active 
participants by dissemination of its minutes through the regular newsletter. 
• The Steering Committee will attempt to meet annually (dependent on finance). It is 
recognized that many meetings will be “opportunistic” and will be held at the time of national 
meetings which most members will attend. If this is not possible in any one year an 
international tele-conference will be held in its place. 
 
6.2 PUBLICATION POLICY 
• Publication policy and authorship will be co-ordinated through the Publications Committee 
that reports directly to the Steering Committee of which it is a sub-committee. Guidelines for 
the Publications Committee are as follows:  
• Mark Engel will chair the Publications Committee and will be responsible for selecting, 
through a process of consultation with members of the Steering Committee. 
• The overall purpose of the Publications Committee is to: 
o Ensure the timely writing and publication of high quality manuscripts from Registry 
data;  
o Solicit, review and prioritise analysis plans and manuscripts from the Registry database;  
o Prioritise authorship of manuscripts / abstracts / posters arising from the Registry 
database in a fair and just manner;  
o Review manuscripts / abstracts / posters arising from the Registry database. 
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6.3 AUTHORSHIP GUIDELINES 
• Primary Publications: it is anticipated that at least two primary publications should result if 
the registry is successful. The first (methods) will describe the rationale, design and 
methodology of the registry. The second (results) will describe the outcome of the registry. 
Authorship of the primary publications will be in the name of the AFROStrep registry – pilot 
study. All actively recruiting centres will be listed in an appendix under the name of the 
principal investigator and his / her organisational affiliation. 
• Secondary Publications: These may arise from sub-studies or from suggestions from 
participants who wish to analyse the Registry database in areas of personal interest. In such 
instances the Publications Committee will be responsible for ensuring that first and last 
authors are the people that have developed the project idea and done the writing and also 
for ensuring that all listed authors meet conventionally accepted authorship credit guidelines. 




• Actively recruiting centres and investigators are encouraged to propose sub-studies and sub-
analyses of the data in the Registry database.  
• A Sub-study Committee (Chair: Mark Engel), which reports to the Steering Committee, will 
review all such proposals to ensure that they are feasible and do not compromise the integrity 
of the database and primary publications.  
• Proposed sub-studies:  
– Rapi-Strep Trial 
– Laboratory investigations using molecular techniques 
 
6.5 MEMORANDUM OF AGREEMENT 
• Signed after ethics approval has been obtained 
• Outline site specific deliverables 
• Confirm the arrangement and details for the transfer of funds to the site 
 
6.6 PROJECT COORDINATING OFFICE: 
 Department of Medicine, Groote Schuur Hospital, University of Cape Town, South Africa. 
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Responsibilities include: 
• Ensuring good collaboration with the study sites.  
• Assisting sites in obtaining ethical & regulatory approvals 
• Preparation and distribution of study materials and study aids. 
• Receiving CRFs and other relevant material from study sites.  
• Data entry, data validation and quality control checks. 
• Organisation of Investigator’s meetings  
• Communication help lines 
• Monitoring of study sites 
• Preparation and distribution of study updates 
• Assisting sites with smooth running of the study 
• Training site teams on study procedures 
 
6.7 INVESTIGATING SITES 
RESPONSIBILITIES INCLUDE: 
• Forming the ASAP AFROStrep team and raise awareness among all medical and nursing staff 
involved in the study. 
• Obtaining ethics and other regulatory approvals. 
• Ensuring that all patients admitted with a diagnosis of group A streptococcal infection are 
considered for screening, making sure that all eligible consenting patients are enrolled. 
• Completing all necessary Case Report Forms and sent to the designated data capturer for data 
entry.  
• Responding promptly to all inquiries from the Project Coordinating Office regarding patient 
CRFs, lab forms etc. or other important study matters.  
• Participating in monitoring visits by responding to all queries raised. 
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6.8 MAINTENANCE OF RECORDS 
The Principal Investigator must: 
• Maintain a Screening Log of all patients with a sore throat considered for enrolment.  
• Make sure that all patients folders and related all documents are kept in an office in a securely 
locked cabinet , and accessible to study staff. 
• Obtain a correctly completed Patient Informed Consent Form for each patient enrolled into 
the study. 
• Maintain a list of Patient ID and corresponding patient names to enable records to be found 
at a later date (this should be kept in a locked cabinet away from CRFs to maintain 
confidentiality).  
• Retain all records, including the signed Informed Consent Forms and the Patient Identification 
List for at least 2 years after the official study closeout. 




The first line of contact for study related questions would be the Project Coordinating Office.  
Contacts 
 
PROJECT COORDINATING OFFICE  
Department of Medicine 
H47, Old Main Building 
Groote Schuur Hospital 
University of Cape Town 
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7. THROAT CULTURE - SOP 
 
The throat culture is an important procedure to identify pathogens that cause pharyngitis or that 
colonize the throat. It must be performed with care and in an identical fashion from subject to subject. 
When performed incorrectly, the sensitivity of the culture falls; in other words, some subjects who 
have a pathogen in their pharynx will not be identified. The most commonly identified bacterial 
organism that causes pharyngitis is Streptococcus pyogenes, or Group A Strep (GrAS). This Standard 
Operating Procedure (SOP) describes the procedure for obtaining and plating a throat culture. 
 
Culture Procedure: 
1. Verify the identity of the subject and label a sterile culture swab and, when used at the point of 
contact, the back of an agar plate, with the information requested by the protocol (typically 2 
patient identifiers, the date, and an identifier for the person plating the organism). 
2. Put on gloves. These gloves need not be sterile. 
3. Hold a bright flashlight or penlight in one hand or have the subject face a bright fixed source of 
light. 
4. Remove the swab from its sterile container taking care to keep the cotton tip end sterile. Do 
not use swabs found in packages in which the sterile packaging has been violated. 
5. Ask the subject to open the mouth widely and protrude the tongue and say, “aghhh” or pant. If 
the tonsils or tonsillar fossae and the posterior pharynx are easily seen, the culture may be done 
without a tongue depressor. If not, then use a tongue depressor, placed about ½ to ¾ of the 
way to the posterior edge of the tongue and firmly push the tongue inferiorly. Do not put the 
tongue depressor so far posteriorly as to gag the subject. 
6. Rub the swab on one tonsil, the posterior pharynx, and the other tonsil. Do not touch the tongue 
or oral cavity, if possible. 
7. If the protocol calls for it, place the swab back in its cap and crush the ampoule that holds the 
transport media in the tip. On the other hand, if the protocol allows for it, one may swab the 
specimen directly onto an appropriate agar plate or other solid media, most commonly 5% 
sheep blood agar. 
8. Transport the labellled swab or the inoculated agar plate to the laboratory as directed in the 
individual protocol. 
9. If GrAS is to be identified, an antibiotic disk containing 0.04 
U of bacitracin (an “A” disk) should be placed on the agar 
in an area of expected heavy growth. It is placed firmly on 
the agar using forceps or other sterile means. 
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Appendix 9.9: AFROStrep Assent form   
 
Assent Form for children 8 years and older 
The AFROStrep REGISTRY: A surveillance system for group A streptococcal 
(GAS) infection in South Africa 
 
Principal Investigator: Prof Bongani M. Mayosi, D.Phil.  
   Groote Schuur Hospital and University of Cape Town 
   Tel:  27-21-406-6200 
   Email: bongani.mayosi@uct.ac.za  
 
 
We are doctors and nurses from the University of Cape Town and Groote Schuur Hospital and we are 
doing a study of sore throat in children. Sore throat can be caused by many kinds of germs. 
 
We would like to ask you and your parent / legal guardian a few questions about your sore 
throat. After that, the nurse will ask to look inside your mouth at your throat and feel your neck for 
swollen glands. 
 
To find out if you have a germ in your throat, we will use a long soft stick (like an earbud) and lightly 
touch the back of your throat. This will not hurt at all and is very quick, but may be a little 
uncomfortable. This stick will then be sent away to test for a germ that causes sore throat. If you allow 
us to examine you, you will be helping doctors understand sore throat better.  
 
Your information will help doctors and nurses to learn how to treat sore throat in children. You are 
allowed to say that you don’t want to be in the study. Nobody will be angry with you if you say no. The 
clinic nurses will still treat your sore throat if you don’t want to be in the study. Before you decide, you 
can ask us questions. If you want to be in the study, you must write your name on this sheet of paper. 






Printed name     Signature      Date 
 
Study doctor or research nurse: 
 
________________________________________________________________________ 
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Appendix 9.10: AFROStrep consent form and patient information sheet 
 
 
The AFROStrep REGISTRY:  
A surveillance system for group A streptococcal infection in South Africa 
 
 
Information Sheet:  Sore Throat Study 
 
 
Principal Investigators: Mark Engel, BSc (Hons), MPH (Epid/Bios), PhD 
Groote Schuur Hospital and University of Cape Town 
   Tel:  27-21-404-7676 
   Email: mark.engel@uct.ac.za  
 
Co-Investigators:  Dylan Barth, BTech (Env. Epid), MPH 
Groote Schuur Hospital and University of Cape Town 
 
     Bongani M. Mayosi, D.Phil.  
   Groote Schuur Hospital and University of Cape Town 
    
 
Andrew Whitelaw, M.B., Ch.B. 





Your child has been asked to participate in the AFROStrep registry because he/she has a sore throat. A 
research registry is a collection of information about patients who have a particular disease or condition, 
or who receive a particular treatment to be used for future research studies. The collection of data is 
essential for a functioning disease-control programme and allows researchers to conducts studies 
directed at increasing our knowledge on diseases. This information sheet provides you with information 
that you should know and understand before agreeing to be included in the AFROStrep registry.  
 
After reading this information sheet, please feel free to ask any questions or voice concerns that you 
may have. You may keep a copy of this consent form and patient information sheet for your records 
and referral. 
 
An unlimited number of participants will be enrolled in the AFROStrep registry. Your child’s 
participation in this registry will not involve any visits in addition to routine care and he/she may 
withdraw from participating in the AFROStrep Registry at any point.  
 
 
WHY IS THIS REGISTRY BEING ESTABLISHED? 
 
The purpose of the AFROStrep registry is to collect comprehensive demographic, clinical, 
microbiological and epidemiological data from patients with group A streptococcal (GAS) infection. 
Information in this registry may be used to enable a wide range of future genomic and genetic studies, 
biologic and immunologic research, epidemiological, clinical, and health services research.   
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Future research studies emanating from the AFROStrep registry will only use the information in this 
registry and will not require additional informed consent from participants in the registry. The 
information in this registry may also be used to identify patients who may be eligible to participate in 
certain future research studies conducted by the University of Cape Town that relate to their particular 
disease, condition, or treatment and for which information is needed that is not in the registry. If your 
child is identified (based on information about you in the registry) as being potentially eligible for a 
future research study that relates to a particular disease, condition, or treatment, you may be contacted 
to find out if he/she would be interested in participating in the research study. If you are interested at 
that point, the research study would be fully explained to you, and informed consent will be required 
before participating.  
 
 
WHY ARE WE DOING THIS STUDY? 
 
There are many causes of sore throat. Most often a sore throat is caused by a virus. A virus is a germ 
which can cause illnesses, for example colds and flu. Antibiotics do not work against viruses. 
Antibiotics should only be used when a doctor or clinical nurse believes that a patient’s illness is caused 
by a bacterium, which is a different kind of germ which can be killed by antibiotics. 
 
If antibiotics are used too often and incorrectly, bacteria become resistant to the antibiotics. This means 
that antibiotics no longer work against them and so in future, we may be unable to treat infections 
caused by these bacteria.   
 
A particular type of bacterium called Streptococcus pyogenes can cause sore throat. As a complication 
of this type of sore throat, a small percentage of patients can later develop disease of the heart valves 
(Rheumatic heart disease) or kidney disease. Antibiotics can prevent these complications from 
developing. 
 
There are many different genetic types of Streptococcus pyogenes and it is not known which types of 
this bacterium are most common in your area. In the study, we will take throat swabs. Bacteria isolated 
from these swabs will be sent to a laboratory in Cape Town to examine the genetic structure of the 
bacteria. The genes of the bacteria, and not those of yourself, will be investigated. 
 
It is hoped that if we know which genetic types are most common, it will help researchers to produce 
an effective vaccine against Streptococcus pyogenes. A vaccine is a substance that is used to protect a 
healthy person from developing an infection. 
 
 
IF YOUR CHILD PARTICIPATES, WHAT WILL BE EXPECTED OF HIM/HER?  
 
If you agree to participate in the study, the study nurse or doctor will ask you questions about your 
child’s illness. After a brief examination, a throat swab will then be performed. Using a long plastic 
stick with cotton wool at the end (much like an earbud) a sample of the mucous or pus from the back 
of the throat will be taken. This sample will be tested immediately using a rapid strep test, thereafter 
being sent to a laboratory where we will look for the presence of Streptococcus pyogenes.   
 
Following the swab being taken, the clinic doctor or nurse will examine and treat your child as usual. 
 
 
WHAT WILL HAPPEN TO THE THROAT SWAB AT THE END OF THE STUDY?  
 
Throat swabs collected from your child during this study will be labelled with a unique code. It will not 
be possible to determine your child’s identity from this information. Should your child’s swab contain 
bacteria, the sample will be stored. We will conduct further molecular investigations on the bacteria 
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later on. You will not be informed of any results of these studies, nor benefit financially from any 
medicines or vaccines which are produced by these studies.  
 
Any future research with your child’s samples will be reviewed by the University of Cape Town’s 
Institutional Review Board before the research can begin. Your permission is required for these later 
studies.  If you do not agree to the storage and later investigations of the bacteria, you can still be 
involved in the rest of the study procedures.  
 
 
WHAT ARE THE RISKS OF BEING INVOLVED IN THE STUDY? 
 
Taking the throat swab can be uncomfortable, especially for younger children. Touching the back of 
the throat may make your child feel nauseous for a little while. We will try to make the procedure as 
quick and comfortable as possible. 
 
 
WHAT ARE THE BENEFITS OF TAKING PART IN THIS STUDY? 
 
The results of the laboratory diagnosis of your child’s swab will be made available to the clinic staff to 
be added to his/her folder. Your child’s participation in this research will enable researchers to better 
understand the prevalent Streptococcal pyogenes strains in South Africa and will assist researchers to 
develop a vaccine that is effective in our setting and which may one day help in the prevention of the 
complications of sore throat. 
 
 
HAS THIS STUDY BEEN APPROVED? 
 
This study is being performed by investigators from the Department of Medicine and the Department 
of Medical Microbiology at Tygerberg Hospital.   
 
The study has been approved by the Human Research Ethics Committee of the University of Cape 
Town. If you have any problem with this study, please contact this committee at 021 406 6338. 
 
 
YOUR RIGHTS AS A PARTICIPANT IN THIS STUDY 
 
You have the right to refuse to participate in this trial. Your child will still be treated in the same way 





All information collected during the course of this study will be kept securely and confidentially. 
Reports about the study and results that may be published in scientific journals will not include any 
information which identifies the participant personally.  
 
If the investigators have any further questions about your child’s medical information which may be 
important for this study, we may need to find the clinic folder to gather such information. This 
information will be treated as confidential. 
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INFORMED CONSENT: The AFROStrep REGISTRY: A  surveillance system for group A 
streptococcal (GAS) infection in South Africa 
 
 
• I hereby confirm that I have been informed about the purpose, benefits and risks of 
my child’s participation in this study. 
 
• I am aware that some information regarding my child’s health will be used 
anonymously by the investigators and researchers. 
 
• I have been informed that participation is voluntary. 
 
• I have had an opportunity to ask questions and these have been answered 
 
• I have read and understood the contents of this document.  
 
 
I agree to the storage and later investigations of bacterial specimens obtained from my child’s throat.             
 







Printed name                                      Signature                                                    Date 
 
 
Study Doctor or Research Nurse: 
 
 






Printed Name                                     Signature                                                     Date  
 
 
 
 
	
 
 
 
 
 
 
 
